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Abstract 
Colorectal cancer (CRC) is the fourth most common cancer in the United Kingdom. Up to half 
of patients with CRC will develop liver metastases. For selected patients with liver metastases, 
liver resection can offer a chance of long-term cure. The aim of this thesis was to investigate 
the management and outcomes associated with the surgical treatment of patients with CRC 
liver metastases in England in an attempt to identify areas where care may be improved. 
 
Four separate studies were performed describing i) the impact of centralisation of 
hepatobiliary surgical services on liver resections rates for patients with CRC liver metastases 
and patient survival, ii) the effect of socioeconomic deprivation on rates of liver resection in 
patients with CRC liver metastases ,and the impact on survival, iii) the timing of liver resection 
in relation to CRC resection in patients with synchronous CRC liver metastases and iv) the 
impact of advancing age on outcomes following liver resection. These studies were conducted 
by linking three national databases: the National Bowel Cancer Audit, Hospital Episode 
Statistics data and Office for National Statistics mortality data.  
 
The results of these studies highlight that firstly, amongst patients with synchronous CRC 
liver metastases, those diagnosed at hospital sites with no on-site hepatobiliary services and 
those of higher socioeconomic deprivation have poorer survival than would be expected. This 
appears to relate to inequalities in provision of liver resection. Secondly, there is wide inter-
hospital variation in the timing of liver resection in relation to CRC resection in England. 
Thirdly, although elderly patients are at increased risk of post-operative mortality following 
liver resection, cancer-specific and overall survival in patients between 65 and 74 years are 
comparable to younger patients. This thesis also discusses methodological issues associated 
with using national routine data for the analyses in this patient cohort.  
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1.1 Chapter overview 
Colorectal cancer (CRC) is a common diagnosis in the Western world and is the fourth most 
common cancer in the United Kingdom (UK) (Cancer Research UK, 2014). Up to 20% of 
CRC patients have liver metastases at presentation and a further 30% of patients will be 
diagnosed with liver metastases as part of follow-up (Manfredi et al., 2006).  Patients with 
CRC liver metastases may be classified into three groups: those with clearly resectable liver 
metastases, those with marginally resectable liver metastases and those with clearly 
unresectable liver metastases. The mainstay of treatment for patients in the second and third 
groups is systemic chemotherapy. This thesis is centered around the surgical management of 
patients, and therefore will focus on patients in the first group.  
 
In many forms of cancer, a diagnosis of metastatic disease equates to a non-curative 
management strategy with the focus of care on extending life, maintaining quality of life and 
reducing symptoms. Isolated CRC liver metastases, however, can be considered quite unique 
among presentations of common malignant disease in this regard. In CRC patients with 
metastatic disease who undergo complete surgical resection, cure rates superior to those 
observed in non-metastatic primary cancer of other solid organs may be achieved 
(Lyratzopoulos et al., 2007). This depends on the identification of such patients and 
subsequent referral to specialist teams. These teams must, in conjunction with the patient and 
the referring team, decide if the patient is to be treated with curative intent, usually consisting 
of one or more surgical procedures.  
 
The management of patients with CRC liver metastases has become increasingly complex and 
relies upon these systems working smoothly to ensure patients have timely access to services. 
It is deficiencies in the treatment of patients with metastatic disease which is cited as one of 
the potential reasons that the UK is lagging behind much of Europe in the survival of patients 
with CRC (Angelis et al., 2014). The aim of this thesis was to investigate the management 
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and outcomes associated with the surgical treatment of patients with CRC liver metastases in 
England in an attempt to identify areas where care may be improved in the future.  
 
This introductory chapter will provide an overview of the incidence of CRC liver metastases, 
outline the current treatment options and describe the provision of services for these patients 
in England. This chapter will conclude by identifying a number of current evidence gaps in 
the literature and describe how the research presented in this thesis will address these.  
 
1.2 Colorectal cancer 
CRC accounts for 11% of new cancer diagnoses in the UK and it is the second most common 
cause of cancer-related deaths. Over 40,000 new cases of CRC are diagnosed in the UK per 
annum with 72 new cancer cases for every 100,000 males and 56 for every 100,000 females. 
(Cancer Research UK, 2014). When a patient is diagnosed with CRC, the extent of local 
disease and any metastatic spread must be determined to allow treatment planning.  
 
The pathologist Cuthbert Dukes (1932) proposed a classification designed to represent a step-
wise progression of locoregional invasion by rectal cancers, and later adapted it to include 
colon cancer. Many refinements of the original classification have now been reported in the 
surgical literature. The American Joint Committee on Cancer (AJCC) (2017) in an attempt to 
provide a uniform classification for CRC, proposed a staging system based on the TNM 
classification system (Table 1.1) (Sobin and Fleming, 1997). This assesses the extent of the 
primary tumour (T), the status of regional lymph nodes (N), and the presence or absence of 
distant metastases (M) and allows patients to be assigned to one of 4 stages (Table 1.2) 
(American Joint Committee on Cancer, 2017).  
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Table 1.1 The Tumour Node Metastases (TNM) classification system (Sobin and Fleming, 
1997) 
Primary tumour 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1 Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades through the muscularis propria into the pericolorectal tissues 
T4a Tumour penetrates to the surface of the visceral peritoneum 
T4b Tumour directly invades or is adherent to other organs or structures 
Regional lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-3 regional lymph nodes 
N1a Metastasis in 1 regional lymph node 
N1b Metastasis in 2-3 regional lymph nodes 
N1c 
Tumour deposit(s) in the subserosa, mesentery, or nonperitonealised pericolic or perirectal tissues 
without regional nodal metastasis 
N2 Metastasis in 4 or more lymph nodes 
N2a Metastasis in 4-6 regional lymph nodes 
N2b Metastasis in 7 or more regional lymph nodes 
Distant metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Metastasis confined to 1 organ or site 
M1b Metastases in more than 1 organ/site or the peritoneum 
 
Table 1.2 The American Joint Committee on Cancer staging system (2017) 
Stage TNM 
Stage I T1 N0 M0 
Stage I T2 N0 M0 
Stage II-A T3 N0 M0 
Stage II-B T4 N0 M0 
Stage III-A T1-2 N1 M0 
Stage III-B T3-4 N1 M0 
Stage III-C any T, N2 M0 
Stage IV any T, any N, M1 
 
Establishing the stage of disease is essential to formulate a treatment plan and inform 
prognosis. The presence of distant metastases at diagnosis, stage IV disease, has a significant 
impact, not only on the treatment plan, but also patient survival. 
 
In CRC patients treated with curative intent, surgical excision is the mainstay of treatment and 
around two thirds of patients with CRC in England undergo a major resection (nboca.org.uk, 
2016). Surgical excision of a colonic tumour along with the appropriate vascular pedicle and 
accompanying lymphatic drainage is the gold standard for colonic tumours (Nelson et al., 
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2001). Total mesorectal excision (TME) is the optimal treatment strategy for patients with low 
or mid-rectal cancer (Heald and Ryall, 1986).  
 
1.3 Colorectal cancer liver metastases 
Metastasis (meta (μετά) = after, next and stasis (στάση) = arrest) is a word of Greek origin, 
describing the development of secondary malignant growths at a distance from the primary 
cancer site (Paschos et al., 2014, National Cancer Institute, 2017). Metastases are the main 
cause of cancer-related mortality in CRC due to associated organ failure (Van Cutsem et al., 
2016). The presence of metastatic disease at the time of diagnosis of CRC is relatively 
common. The National Bowel Cancer Audit (NBOCA) reports 19% of patients in England 
and Wales have metastatic disease at diagnosis (nboca.org.uk, 2016). Around 50% of patients 
without metastases at presentation develop distant metastases within 3 years of diagnosis 
(McArdle, 2000).  
 
The liver is one of the most frequent sites of organ-specific metastasis for many cancers. The 
preferential spread of CRC to the liver is thought to be partially attributable to circulation 
patterns with blood draining from the large bowel through the portal system to the liver 
(Nguyen et al., 2009). In approximately 50- 80% of patients with CRC metastases, the liver is 
the only site of metastatic disease (Sjovall et al., 2004, Manfredi et al., 2006). 
 
 Current terminology  
Liver metastases may be detected either at the time of diagnosis or at a later date. Although 
some experts are of the opinion that all metastases are synchronous and it is just our ability to 
detect them that renders their diagnosis metachronous (Adam et al., 2015), in clinical practice 
synchronicity refers to those evident at the time of clinical presentation, and metachronous to 
those detected at a later time point (Siriwardena et al., 2014).  
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In practical terms there are a variety of definitions of synchronous, and therefore 
metachronous disease. Synchronous metastases have been defined as those detected at pre-
operative staging or during the primary tumour resection (Manfredi et al., 2006, Adam et al., 
2015, van der Pool et al., 2010) or within 3 months (Ng et al., 2009), 6 months (Wang et al., 
2007) or 1 year (Bockhorn et al., 2008) of primary diagnosis. An international consensus 
group recently recommended synchronous disease should be termed, ‘synchronously detected 
metastases’ and defined as metastases detected at or before diagnosis of the primary tumour 
(Adam et al., 2015). They recommend that early metachronous disease should be considered 
as that detected within 12 months of diagnosis or surgery to the primary tumour, and late 
metachronous disease, that detected at 12 months or more.  
 
 Incidence of liver metastases 
The incidence of synchronous liver metastases is not fully known. Due to recruitment bias and 
differences in referral practices, the reported incidence in single centre studies tends to be 
over-estimated (Leporrier et al., 2006). In addition, cancer registries such as the NBOCA tend 
to report overall rate of metastases and not specifically liver metastases (nboca.org.uk, 2016). 
 
The EUROCARE study reported 23% of patients to have synchronous liver metastases at 
diagnosis in 1990 (Gatta et al., 2000). A more recent study performed in a German population 
diagnosed with CRC from 2002 to 2007 reported the rate of synchronous liver metastases as 
18% (Hackl et al., 2014). Other population-based studies have reported the rate to be lower. 
The incidence in two separate studies of French populations were described as 14.5% and 14.7% 
(Manfredi et al., 2006, Mantke et al., 2012). Similarly, results from a population based 
Swedish study reported the rate to be 15% (Sjovall et al., 2004).  
 
The majority of patients with no detectable metastatic disease at diagnosis who do develop 
liver metastases will do so within 3 years of diagnosis of primary CRC  (Manfredi et al., 2006). 
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Again, the proportion of CRC patients reported to have metachronous disease varies, and 
comparisons must be made with caution due to differing follow up times and surveillance 
schedules. Amongst 3,655 patients undergoing a curative major CRC resection in a French 
population over a 25 year period, 13% developed metachronous liver metastases in the 5 years 
following diagnosis. The overall actuarial cumulative rate was 4% at 1 year, 12% at 3 years 
and 17% at 5 years (Manfredi et al., 2006). However, over a follow-up period of 10 years in 
a more recent German population the rate of metachronous liver metastases was much lower 
at 7% (Hackl et al., 2014).  
 
 Risk factors for liver metastases 
Stage of the primary tumour at diagnosis has been shown to be the greatest predictor of the 
development of both synchronous and metachronous liver metastases (van Gestel et al., 2014, 
Landreau et al., 2015). Manfredi et al. (2006) reported an almost 8-fold increase in the relative 
risk of liver metastases for patients with stage III CRC when compared to those with stage I 
disease at diagnosis. Patients who are diagnosed with synchronous metastases, compared to 
those with metachronous disease, tend to have more locally advanced primary CRC as well as 
a greater burden of liver metastases (Mantke et al., 2012).   
 
Liver metastases appear to be more common in men than in women (Manfredi et al., 2006, 
Mantke et al., 2012, van Gestel et al., 2014). Studies have also reported that younger patients 
are more likely to be diagnosed with liver metastases (Manfredi et al., 2006, Mantke et al., 
2012). This may relate to younger patients more commonly having a later stage of disease at 
diagnosis, or undergoing more thorough staging investigations as they may be treated more 
aggressively than older patients.  
 
Data regarding the propensity of patients to develop liver metastases based on the site of the 
primary tumour within the bowel is conflicting. Some studies report a higher rate of liver 
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metastases in patients with a colonic primary when compared to those with a rectal primary 
(Mantke et al., 2012, Qiu et al., 2015), whereas other studies have found no association 
between location of the primary and the development of liver metastases (van Gestel et al., 
2014, Landreau et al., 2015).  
 
 Diagnosis of liver metastases 
 Imaging 
Adequate pre-treatment imaging is critical for patients with suspected CRC liver metastases 
for diagnosis, staging and treatment planning (Charnsangavej et al., 2006).  Computed 
tomography (CT) is widely used as the first cross-sectional imaging assessment in patients 
with CRC. The National Institute of Health and Clinical Excellence (NICE) (2014) 
recommends all patients should undergo a contrast-enhanced CT of the chest, abdomen and 
pelvis at diagnosis.  In addition, patients who have undergone CRC resection with curative 
intent should undergo regular surveillance with a minimum of two CTs of the chest, abdomen 
and pelvis in the first 3 years after resection (National Institute for Health and Care Excellence, 
2014). 
 
When patients are suspected to have liver metastases, imaging should be undertaken to define 
the number and segmental/lobar distribution, determine surgical resectability and identify any 
extra-hepatic disease. As well as CT, further imaging options include ultrasound, magnetic 
resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-
PET). The use of these modalities in clinical practice varies according to local availability,  
expertise, and clinical indication. 
 
MRI is the most accurate imaging technique for detection and characterisation of liver masses 
(Adams et al., 2013), and can help in distinguishing malignant from benign lesions, and in 
establishing a road map of the anatomical distribution of lesions (Siriwardena et al., 2014). 
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MRI is particularly sensitive in the detection of metastases in patients with steatosis or changes 
to the liver parenchyma secondary to pre-operative chemotherapy 
 
FDG-PET, used with concurrent CT, has a high sensitivity and specificity for the detection of 
liver metastases (Bipat et al., 2005). FDG-PET is particularly efficacious in the detection of 
extra-hepatic disease, which can have important implications for patient management. FDG-
PET is currently recommended by the Royal College of Radiologists (2016) for use in staging 
of CRC patients with synchronous metastases at presentation or to detect recurrence in patients 
in whom there is clinical suspicion.  
 
 Carcinoembryonic antigen 
Serum levels of the complex glycoprotein carcinoembryonic antigen (CEA) are widely used 
in post-resection surveillance. In the Follow-up After Colorectal Surgery (FACS) trial 
investigating follow-up methods for CRC patients who had undergone a curative resection, 
1202 participants were randomised to one of four groups, CEA screening, CT screening, CEA 
and CT screening, or minimum (symptomatic) follow up (Primrose et al., 2014b).  Among 
these patients, either CT or CEA screening each provided an increased rate of surgical 
treatment of recurrence with curative intent compared with minimal follow-up; there was no 
advantage in combining CEA and CT.  It is therefore recommended that CRC patients have 
CEA tests at least every 6 months in the first 3 years following resection (National Institute 
for Health and Care Excellence, 2014). An increase in the serum CEA level has a reported 
sensitivity of 84% and specificity of 96% in the diagnosis of liver metastases (Arnaud et al., 
1980).  
 
 Patient survival with liver metastases 
Untreated, the median survival time for patients with CRC liver metastases is around 5 months, 
with less than 30% of patients alive at 1 year (Bengtsson et al., 1981, Erlichman et al., 1988).  
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Patients with unilobar liver disease and those with a limited number of metastases have a better 
prognosis then those with more advanced disease (Stangl et al., 1994). However even in 
patients with less disease burden, without treatment very few would be expected to be alive at 
5 years. The median survival for patients with less than one quarter of their liver volume 
replaced by tumour without treatment is reportedly 11 months (Stangl et al., 1994). 
 
With the advent of modern chemotherapy regimens, the overall survival in patients with 
unresected metastatic disease who receive systemic treatment has improved over the past two 
decades. Median survival for these patients is now of the order of around 24 months (Cutsem 
et al., 2011).  
 
Wherever possible, treatment should be aimed toward complete excision of disease (Garden 
et al., 2006). Liver resection is commonly regarded as the only curative treatment modality 
for patients with liver-limited disease. Survival following resection of CRC liver metastases 
can be widely variable and is dependent on clinical, tumour and molecular factors. In addition, 
selection criteria for liver resection is not usually consistent between centres; staging 
algorithms vary, and there is a great deal of heterogeneity between treatment protocols. In a 
meta-analysis of outcomes after liver resection for CRC liver metastases based on 60 studies, 
5-year survival ranged from 16% to 74% with a median of 38%, and 10-year survival ranged 
from 9% to 69% with a median of 26% (Vigano et al., 2008). Many of the included studies 
were from single institutions and could not account for referral or selection bias. Population-
based studies may be better placed to describe survival outcomes following liver resection, 
and recent publications using registry data from English and Swedish cohorts report 5-year 
survival rates of 44% and 45% respectively (Morris et al., 2010, Norén et al., 2016).  
 
The comparison of survival in synchronous and metachronous disease is again limited by the 
lack of standardised definitions, however synchronicity is generally thought of to be a sign of 
poor prognosis, regardless of treatment (Manfredi et al., 2006, Adam et al., 2015). These 
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patients have a cancer biology which is less favourable and therefore a reduced chance of 
long-term survival (Fong et al., 1999). The natural history of patients with metachronous liver 
metastases is less well documented. The reporting of outcomes in this cohort is complicated 
by the fact it is generally accepted that a proportion of patients presenting with metachronous 
disease most likely had this at initial presentation. Similar to synchronous disease, however, 
liver resection is the most effective therapy with associated 5-year survival rates ranging from 
28% to 58% (Mann et al., 2007). 
 
1.4 Treatment of colorectal cancer liver metastases 
 Surgical anatomy of the liver 
Liver surgery is largely based on the contributions of two surgeon-anatomists, Couinaud (1957) 
and Healey (1953),  to the understanding of liver anatomy. In their work on hepatic division, 
Couinaud used the portal and hepatic veins as the basis of division, while Healey used the 
hepatic arteries and bile ducts. The classification according to Couinaud, which has gained the 
widest acceptance, divides the liver into eight functional segments, each with its own blood 
supply, and venous and biliary drainage (Figure 1.1). Segment II, III and IV collectively form 
the functional left lobe of the liver, with the functional right lobe consisting of segments V, 
VI, VII and VIII. The caudate lobe, segment I, is located posteriorly.   
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Figure 1.1 The segments of the liver and the current surgical nomenclature. Image reproduced 
from Siriwardena et al. (2014). 
 
 
 
 Liver resection 
There are no randomised controlled trials comparing surgical resection of liver metastases 
versus systemic treatment alone (Van Cutsem et al., 2016). However, even in the absence of 
such, surgery is considered the gold-standard treatment for patients with CRC liver metastases. 
 
Traditionally, liver resection was associated with high rates of morbidity and mortality, such 
that it was considered a challenging and high-risk procedure. The liver hosts the most complex 
vascular anatomy of any human organ, and consequently it has been control of haemorrhage, 
both in the past and present, which has posed the major challenge in liver surgery. The first 
successful hepatectomy was carried out by the German surgeon Carl Johann August 
Langenbeck (1888), who removed a left lobe lesion in 1888. Subsequent advances in blood 
transfusion services in the 20th century allowed the field of liver surgery to grow. Catell (1940) 
performed the first successful surgical excision of a CRC liver metastases in 1940, with the 
first left hepatectomy performed in 1941 and right hepatectomy in 1952 (Felekouras et al., 
2010).  
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Despite the anatomical discoveries of the 1950s, it was several decades until liver surgery 
gained momentum. This mainly relates to advances in techniques for the control and 
modulation of hepatic blood flow. In modern liver surgery, tumours that are positioned deep 
within liver parenchyma or close to critical vascular or biliary structures, may be resected with 
precision due to the use of specific tools such as the ultrasonic dissector, argon gas diathermy, 
magnifying loupes and intraoperative ultrasound, allowing precise delineation of the proper 
transection plane (Mentha et al., 2007, Aragon and Solomon, 2012). In addition, both the 
Pringle manoeuvre and the maintenance of low central venous pressure remain important 
adjunctive techniques in reducing blood loss during liver transection (Pringle, 1908). 
 
 Types of liver resection 
1.4.2.1.1 Anatomical resection 
Anatomic liver resections are largely based on our understanding of the liver segments as 
described by Couinaud. In an attempt to standardise definitions of anatomical liver resection, 
the Brisbane 2000 system was developed (Terminology Committee of the International 
Hepato-Pancreato-Biliary Association, 2000). This is a unified nomenclature for the 
classification of liver resection (as shown in Table 1.3), and has become generally accepted 
as a standardised reporting system.    
 
Table 1.3 Nomenclature for hepatic anatomy and resections according to the Brisbane 2000 
system  (Terminology Committee of the International Hepato-Pancreato-Biliary Association, 
2000) 
 
Term for surgical resection Couinaud segments 
Right hepatectomy/ right hemihepatectomy V, VI, VII, VIII 
Left hepatectomy/ left hemihepatectomy II, III, IV 
Right anterior sectionectomy V, VIII 
Right posterior sectionectomy VI, VII 
Left median sectionectomy VI 
Left lateral sectionectomy II, III 
Segmentectomy Any one of I - IX 
Bisegmentectomy Any two of I - IX in continuity  
Right trisectionectomy/ extended hepatectomy/ extended hemihepatectomy IV, V, VI, VII, VIII ± I 
Left trisectionectomy/ extended hepatectomy/ extended hemihepatectomy II, III, IV, V, VIII ± I 
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Many of the potential risks of liver resection relate to the volume of the remnant liver 
remaining. However, this measurement is inconsistent and is not reported in most resection 
series. The extent of resection is therefore used as a surrogate. Anatomical liver resections 
may be considered as ‘major’ or ‘minor’. Risk stratification by extent of resection has been 
used to analyse post-operative morbidity and mortality across multiple case series, with 
patients undergoing major liver resection at the highest risk of adverse outcomes (Aloia et al., 
2009). There is, however, a lack of consensus on the definitions of such terms with major liver 
resection being defined as the resection of two, three, four or five segments. Reddy et al. 
(2011) reported that the resection of four or more segments was independently associated with 
risk of post-operative morbidity and mortality. There were no significant differences in any 
post-operative outcome after resection of three, or two or fewer, segments.  They therefore 
advocate that major hepatectomy should be defined as resection of four or more liver 
segments. Despite this, many recent reports continue to define major hepatectomy as resection 
of three or more segments. The 2014 recommendations from the Second International 
Consensus Conference on laparoscopic liver resection suggest the ‘classical definition’ for 
extent of liver resection should be used where a minor resection is the resection of two or 
fewer Couinaud segments, and major resection the resection of three or more (Wakabayashi, 
2014).  
 
1.4.2.1.2 Non-anatomical resection 
Non-anatomic resection, also termed parenchymal-sparing hepatectomy, involves resection of 
the lesion along with a margin of uninvolved tissue (Alvarez et al., 2016). This has the 
advantage of both preserving parenchyma and thus minimising the risk of post-operative 
hepatic insufficiency, and enabling a repeat hepatectomy at a later date if disease was to recur. 
Previously, this approach had raised concern for increased rates of local recurrence due to 
closer margins. This has not, however, been substantiated and in a recent study comparing 
outcomes of 156 CRC patients with a parenchyma-sparing approach to 144 patients 
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undergoing an anatomical resection, the parenchyma sparing approach was not associated with 
recurrence in the liver remnant and in fact, improved 5-year survival in cases of recurrence 
(Mise et al., 2016).  
 
1.4.2.1.3 Laparoscopic liver resection 
The use of laparoscopic techniques for liver resection has been relatively slow in comparison 
to other gastrointestinal surgical procedures where laparoscopy has been established as the 
standard of care (Wakabayashi et al., 2015a). Initial difficulties in laparoscopic liver resection 
related to the challenge of achieving haemostasis at the transection plane and controlling 
haemorrhage from intra-hepatic vessels. However, with advances in instrument technology 
and surgical technique, minimally invasive approaches for liver resection are now gaining 
momentum.  
 
At the Second International Consensus Conference on laparoscopic liver resections held in 
2014, the panel acknowledged that a minor liver resection performed laparoscopically has a 
sufficient safety and benefit record to achieve ‘standard practice’ level, whereas laparoscopic 
major resections were still to be considered innovative procedures with continued caution 
recommended for their introduction (Wakabayashi, 2014).  
 
A recent meta-analysis of over 9000 cases showed a laparoscopic approach offered reduced 
overall rate of complications, blood loss, rate of transfusion, and hospital stay following minor 
resection, and reduced overall rate of complications, blood loss, and hospital stay following 
major resection (Ciria et al., 2016). There were no observed differences in resection margins. 
There are several randomised controlled trials currently underway to evaluate the safety and 
the long-term oncological outcomes of laparoscopic liver resection in comparison to open 
surgery (Fretland et al., 2015). 
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 Complications associated with liver resection 
Techniques to reduce blood loss and better understanding of hepatic anatomy have greatly 
improved the safety of liver resection. Post-operative mortality has gradually dropped from 
rates of 50% in 1963, to 20% in the 1990s (Thompson et al., 1983, Fan et al., 1995), to recent 
reports of up to zero mortality even for complex procedures (Imamura et al., 2003, Vauthey 
et al., 2004).   
 
However, literature-based data on mortality may be misleading, as poor outcomes are less 
likely to be published. In an analysis of national mortality data following major hepatic 
resection in the United States (US) the mortality rate reported in the literature was found to be 
3.6% compared to 5.6% in the National Inpatient Sample dataset (Asiyanbola et al., 2008). 
This suggests that actual population-based mortality rates may be higher than those reported 
in the literature.  A recently published series of 4,152 patients undergoing liver resection 
reported a 90-day mortality of 5% before 1999, 2.3% from 2000 to 2006, continuing to 
decrease to 1.6% from 2007 to 2012 (Kingham et al., 2015). In modern clinical practice, a 
patient undergoing liver resection would usually be advised of an associated 90-day mortality 
of 1-2%, with the exact figure depending on factors such as the extent of the liver resection, 
patient age and fitness, and the condition of the liver due to chemotherapy and cirrhosis 
(Dokmak et al., 2013).  
 
Despite the drop in mortality following liver resection, there remains significant associated 
morbidity, with large series reporting complications occurring in 24-56% of patients (Mullen 
et al., 2007, Dokmak et al., 2013, Kingham et al., 2015). This may partly reflect the increased 
complexity of modern liver surgery. Significant complications now more commonly relate to 
post-operative liver failure rather than bleeding. In a large recent series of patients undergoing 
liver resection, 23% of the 546 patients with CRC liver metastases experienced a serious 
complication (Clavien–Dindo class 3 or 4) (Dokmak et al., 2013). Pulmonary complications 
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were noted in 18% of patients, ascites in 18%, biliary fistula in 4%, liver failure in 2% and re-
operation in 4%.  
 
 Criteria for resectability 
Ultimately, eligibility for surgery is determined by taking into account three aspects: the 
operative risk to the patient, the technical resectability and the oncological benefit. The 
presence of four or more metastases within the liver, extra-hepatic disease, large size of 
hepatic metastases and the inability to achieve a cancer free resection margin (R0) were 
previously considered contraindications to resection (Ekberg et al., 1986).  However, over the 
past 10 years the criteria for defining resectability in patients with CRC liver metastases has 
been expanded (Pawlik et al., 2008). Advances in systemic chemotherapy, and adjunctive 
techniques such as thermal ablation and portal vein embolisation have resulted in a paradigm 
shift in resectability.  Now resectability is determined by whether complete resection of the 
disease may be performed and if an adequate liver remnant will remain following surgery.  
 
Pawlik et al. (2008) suggest four main criteria that determine resectability: 
1) Macroscopic and microscopic complete resection of the liver disease and any extra-
hepatic metastases must be achievable 
2) Two or more segments of the liver should be spared 
3) Vascular inflow and outflow and biliary drainage must be preserved 
4) The future liver remnant (FLR) (i.e. the volume of liver remaining after resection) 
must be adequate. This usually means at least 20% of the total estimated liver volume 
for normal parenchyma and between 30% and 60% if the liver has been injured by 
chemotherapy.  
 
18 
 
A multidisciplinary panel of experts meeting in 2012 proposed a new system, as shown in 
Table 1.4, for determining eligibility in a bid to simplify treatment decisions and standardise 
care across centres and reporting in clinical trials (Adam et al., 2012).  
 
Table 1.4 Contraindications to hepatic resection in patients with CRC liver metastases. Any 
patient should be categorised as A1 or A2/B1, B2, or B3. Adapted from Adam et al (2012). 
Category Contraindication 
Technical (A) 
1. Absolute Impossibility of R0 resection with 25%–30% liver remnant 
Presence of unresectable extrahepatic disease 
2.  Relative R0 resection possible only with complex procedure (portal vein embolisation, two-stage 
hepatectomy, hepatectomy combined with ablation (includes all methods, including 
radiofrequency ablation) 
Oncological (B) 
1.          Concomitant extrahepatic disease (resectable) 
2.          Number of lesions ≥5 
3.          Tumour progression 
 
With regard to patient risk, medical fitness for general anaesthesia and major abdominal 
surgery should be carefully evaluated pre-operatively. Obese patients and those who have 
undergone previous chemotherapy, should be considered at increased risk and the volume of 
the predicted FLR should be appropriately adjusted (Tucker and Heaton, 2005).  
 
 Metachronous liver metastases 
The management of patients with metachronous liver metastases is often considered more 
straightforward than in those with synchronous disease. Resectability will be assessed 
according to the criteria discussed above and a treatment plan will be formulated through 
discussion with a hepatobiliary multidisciplinary team (MDT) meeting. Metachronous liver 
metastases tend to be more commonly unilobar, and present in smaller numbers (Tsai et al., 
2007). This may relate to the fact that metachronous lesions are diagnosed when they are less 
advanced due to the regularity of post-operative follow up. The resection of liver metastases 
is performed more frequently in patients with metachronous than synchronous disease, (17% 
vs. 6%) (Manfredi et al., 2006). 
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 Synchronous liver metastases 
The optimal management of patients diagnosed with CRC and synchronous liver-limited 
metastases is complex. There are multiple factors which must be considered, such as the 
presence of symptoms, the location and extent of the CRC primary and the liver metastases, 
and the patient’s underlying fitness. Patients should be offered multimodal treatment as 
appropriate, comprising surgery, chemotherapy and, if the patient has rectal cancer, 
radiotherapy.  
 
 The timing of liver resection 
Advances in radiological and surgical techniques, systemic chemotherapy and anaesthesia, 
over the last decade have allowed more possibilities in the management of CRC patients with 
synchronous liver metastases (Siriwardena et al., 2014). Now, it is not only enough to decide 
if liver metastases are potentially amenable to surgical resection, but how the liver resection 
will be timed in relation to resection of the primary tumour must also be considered.   
 
1.4.4.1.1 Bowel-first 
The traditional management of CRC with synchronous liver-limited metastases involves the 
resection of the primary CRC followed by resection of the secondary liver metastases at a later 
date (Lambert et al., 2000). This approach is termed the ‘bowel-first’, or the ‘classical’ 
approach. The rationale for this strategy is that the primary neoplasm should be managed first 
as the patient will have symptoms, such as partial obstruction, bleeding, lethargy and 
diarrhoea, therefore necessitating a timely bowel resection. Some studies have reported the 
rate of complications related to the primary CRC if resection is delayed, as high as 20% 
(McCahill et al., 2012).  
 
Within the bowel-first strategy, two approaches may be undertaken. The first involves 
resection of the primary tumour followed by a period of recovery and then a liver resection. 
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No systemic treatment is given between the surgical procedures. This is mainly undertaken 
when technical considerations, such as a CRC resection involving pelvic dissection, or the 
necessity to perform a major liver resection, preclude a simultaneous resection. The second 
approach, the delayed approach, involves administration of chemotherapy between the two 
operations. Scheele et al. (1995) advocate a ‘test of time’ strategy, where 3 to 6 months is 
waited following primary resection before liver resection, acting as a means of natural 
selection for operable disease.  
 
A commonly cited disadvantage of the bowel-first approach, particularly with a delay, is the 
potential for progression of the liver metastases beyond resectability whilst dealing with the 
primary tumour. This may not be the case however, as a study of 318 patients with CRC liver 
metastases, 73 of whom had resectable disease, did not show any patients undergoing delayed 
resection of synchronous liver metastases to become unresectable due to the growth of initial 
metastases (Lambert et al., 2000). This may be more of a concern however in patients who 
have a delay in systemic chemotherapy owing to morbidity associated with the CRC resection.  
 
1.4.4.1.2 Simultaneous resection 
The ‘simultaneous’ approach involves the resection of the liver metastases and CRC in the 
same procedure and may provide several advantages to both patients and healthcare providers. 
This strategy involves only one anaesthetic and post-operative recovery period, reduced 
overall hospital stay  and possible reduction of healthcare resources (Martin et al., 2003, 
Reddy et al., 2007, Slesser et al., 2013). A simultaneous approach can be adopted with or 
without neoadjuvant treatment.  
 
Even when a margin free liver resection appears technically achievable at the time of surgery 
for the primary CRC, the patient will not benefit from surgical resection if occult extrahepatic 
disease is present (Alberts and Poston, 2011). Proponents of a staged approach argue that 
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delaying the resection of synchronous disease may allow such disease to become clinically 
overt (Lambert et al., 2000). In this approach patients in whom disease becomes irresectable 
in this interval may be spared from undergoing an operation, with its associated risks, which 
would not provide a survival benefit. A simultaneous resection also increases the complexity 
of the surgical procedure as well as the operative time. This approach can increase the risk of 
infected haematoma due to contamination from translocation of intestinal bacteria (Klein et 
al., 2012). In addition, the Pringle manoeuvre causes an increase in portal hypertension thus 
resulting in intestinal oedema, potentially compromising the colonic anastomosis (Nakajima 
et al., 2012).  
 
1.4.4.1.3 Liver-first 
Recently there has been increasing interest in the ‘liver-first’, or ‘reverse’ approach as first 
described by Mentha et al. (2006). This is where liver metastases are resected, usually after a 
period of down-staging chemotherapy, before resection of the primary. 
 
Whether further disease progression is driven by the primary CRC or by the liver metastases 
is an important consideration in the adoption of the liver-first approach. This strategy is based 
on a belief that it is the metastatic disease, and not the primary CRC, which results in further 
systemic metastases  and thus determining the patient’s survival (de Jong et al., 2011). It is 
postulated that the primary tumour produces anti-angiogenic molecules and with resection this 
inhibition is lost thus resulting in proliferation of metastases (Peeters et al., 2006). The 
evidence to support this concept is limited however, and there is counter-evidence to suggest 
the presence of the primary tumour drives an angiogenic environment in the liver, perpetuating 
metastatic tumour growth (van der Wal et al., 2012). 
 
A more accurate description of the liver-first approach would in fact be the ‘chemotherapy-
first approach’. Preoperative systemic chemotherapy will treat both the CRC primary and the 
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liver metastases. The liver-first strategy particularly lends itself to a rectal cancer primary as 
the post-radiation waiting period provides a window of opportunity for a liver resection 
procedure (Jegatheeswaran et al., 2013).  The increasing use of colonic stenting also facilitates 
the use of the liver-first strategy. Stents can palliate symptoms of partial obstruction without 
the need for surgery therefore allowing patients to be candidates for systemic chemotherapy 
at an early stage in their treatment pathway (Karoui et al., 2007). Patients with non-obstructive 
colonic cancer with extensive liver disease that necessitates down-staging to achieve negative 
margins may also benefit from this approach as it could provide a narrow window of 
resectability (De Rosa et al., 2013). 
 
 Decisions regarding strategy 
NICE recommends that the decision on whether a patient has a synchronous or staged 
approach to resecting their CRC and liver metastases should be made by the site-specialist 
MDTs in consultation with the patient (National Institute for Health and Care Excellence, 
2014). Due to the differences in patient and disease characteristics in those typically 
considered eligible for a liver-first or simultaneous approach, very few patients would be a 
candidate for all three strategies. In most clinical circumstances the choice of strategy for an 
individual patient is between the bowel-first approach and the liver-first approach, or the 
bowel-first approach and the simultaneous approach. The optimal timing of resection of liver 
metastases from CRC has been identified as a research priority in a modified Delphi approach 
by the Association of Coloproctology of Great Britain and Ireland (ACPGBI) (Tiernan et al., 
2014).  
 
 Outcomes according to surgical strategy   
When considering the surgical approach for patients with synchronous CRC liver metastases 
the associated post-operative and oncological outcomes should be considered. Early reports 
comparing the bowel-first and the synchronous approach predate the use of neoadjuvant 
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chemotherapy and more sophisticated imaging modalities such as PET-CT, and therefore the 
findings are no longer generally applicable. For example, Norlinger et al. (1996) compared 
outcomes in 115 patients undergoing a simultaneous approach to 893 patients with a bowel-
first approach. The 90-day mortality reported in the simultaneous group was significantly 
higher at 7% compared to 2% in the bowel-first group. 
 
Ten years later, Reddy et al. (2007) published one of the largest studies to date comparing the 
post-operative outcomes from 135 simultaneous and 475 staged patients undergoing liver 
resection across three hepatobiliary institutions. Rates of 90-day mortality were similar 
following simultaneous CRC resection and minor liver resection compared to minor liver 
resection alone (1% vs. 0.5%), whereas for major liver resection, simultaneous CRC resection 
significantly increased mortality (8.3% vs. 1.4%). Conversely Capussotti et al. (2007) 
compared outcomes in 31 patients undergoing simultaneous major hepatectomy and primary 
CRC resection, and 48 who underwent delayed major hepatectomy. They reported no 
difference in mortality between the groups, with 0% mortality in the 9 patients undergoing 
major hepatectomy concurrently with anterior rectal resection. Thelen et al. (2007) reported 
outcomes in 219 patients, 40 of whom underwent simultaneous resection and 179 bowel-first 
approach. They found the mortality to be significantly higher (10% vs. 1%) in patients 
undergoing simultaneous approach, with all patients who died in this group undergoing a 
major resection. These authors also reported 5-year survival of 53% in the simultaneous group 
and 39% in the bowel-first group, but this was not a statistically significant difference. 
 
Similar studies published in more recent years have described no difference between 90-day 
mortality across surgical strategies, even when including major liver resection in the 
simultaneous group (Martin et al., 2009). To control for the often wide differences in patient 
characteristics in patients undergoing a simultaneous or bowel-first approach, Moug et al. 
(2010) performed a case-matched analysis of 32 patients undergoing a simultaneous approach 
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to bowel-first patients, demonstrating no difference in 90-day mortality and comparable 
median survival (39 months in the synchronous group vs. 42 months in the bowel-first group).  
 
Several recent studies have also reported the outcomes of patients undergoing a liver-first 
approach. These demonstrate a wide range of reported long-term survival, but appear to 
show similar long-term outcomes when compared to patients undergoing a bowel-first 
approach. Andres et al. (2012), using data from the LiverMetSurvey, a prospective 
international registry of patients undergoing surgery for CRC liver metastases, compared 
patients with two or more liver metastases diagnosed from 2000 to 2010, including 729 in 
the bowel-first group, and 58 in the liver-first group. Overall survival and disease-free 
survival were reportedly similar in the liver-first and bowel-first group (48% vs. 46% and 
30% vs. 26% at 5 years respectively). Two systematic reviews reporting the outcomes of 
patients treated with the liver-first approach showed 5-year overall survival rates to range 
widely from 31% to 89% despite apparently similar protocols (Lam et al., 2010, 
Jegatheeswaran et al., 2013). Welsh et al. (2016) in a propensity score-matched analysis of 
outcomes of the liver-first approach, reported that after matching according to the 
Basingstoke Predictive Index, there was no difference in long-term outcomes between the 
liver-first and bowel-first approach. 
 
There are only three studies published to date comparing the outcomes of the three strategies. 
Brouquet et al. (2010) compared the post-operative mortality and 5-year survival in 156 
consecutive patients. In this cohort, 73 patients underwent a bowel-first approach, 43 a 
simultaneous resection and 27 a liver-first approach. There was no significant difference in 
90-day mortality (5%, 3% and 1% respectively). The authors grouped patients undergoing 
either a bowel or liver resection into a single ‘staged’ group for the analysis of long-term 
outcomes. There was similarly no difference in 5-year survival between the staged and 
simultaneous group with reported rates of 48% and 55% respectively. In the same year, van 
der Pool et al. (2010) published an analysis of the outcomes of rectal cancer patients, in whom 
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29 patients had a bowel-first approach, 8 a simultaneous approach and 20 patients a liver-first 
approach. The authors reported no in-hospital mortality associated with any strategy and 5-
year survival rates of 28% (bowel-first) 73% (simultaneous) and 67% (liver-first). In the 
largest study to date comparing the use of the three strategies, Mayo et al. (2013) analysed 
1,004 patients with synchronous CRC liver metastases undergoing surgical management 
across 4 institutions. Of the 647 patients who had a bowel-first approach, 28 liver-first and 
329 simultaneous resection, there was no significant difference in 90-day mortality (3%, 0% 
and 3% respectively). There was also no difference in 5-year survival in patients managed 
with simultaneous or staged approach (42% vs. 44%) (Mayo et al., 2013).  
 
Although there appears to be evidential equipoise around the three surgical treatment options, 
these previous studies are largely single institution, include patients diagnosed over a long 
time period and have very small numbers in the liver-first or simultaneous group, or they group 
the liver-first and bowel-first patients together as a ‘staged’ cohort. The limited studies 
previously comparing survival between the three strategies are also hampered by direct 
comparison of strategies without accounting for selection bias. 
 
 Current recommendations 
As with many aspects of modern hepatic surgery, there are no randomised control trials 
guiding clinicians in the selection of surgical strategy (Alberts and Poston, 2011). It is 
generally accepted that a practical approach should be taken to these decisions based on the 
nature of the surgery required (Pathak et al., 2010). Patient fitness and the anatomical location 
and extent of liver metastases and primary CRC largely govern which of the alternative 
strategies is a possible treatment option. However, there are certain clinical situations in which 
it is generally agreed a staged approach would be indicated. When a patient is found to have 
synchronous liver metastases at the time of emergency CRC resection it would not be 
considered appropriate to resect liver metastases in a simultaneous procedure. These patients 
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have a high likelihood of extra-hepatic and peritoneal disease, and, due to their emergency 
presentation, may have not have undergone thorough pre-operative staging. In addition, in 
patients in whom there is a higher risk of post-operative hepatic failure, such as those with 
cirrhosis, it would be inadvisable to perform a synchronous bowel and liver resection.  
 
The European Society for Medical Oncology published a suggested treatment algorithm in 
2012 for patients with synchronous liver metastases (Schmoll et al., 2012). A modified version 
by Siriwardena et al. (2014) is shown in Figure 1.2. In summary, this suggests that patients 
with clearly R0 resectable metastases who have a single metastatic lesion less than 2cm which 
is favourably located and an easily resectable tumour of the colon, should be considered for 
synchronous resection followed by adjuvant chemotherapy. Patients with a greater burden of 
liver disease, even if resectable are suggested to undergo neoadjuvant systemic chemotherapy 
followed by a staged resection.  
 
Figure 1.2 A flowchart of recommended management of patients with CRC and liver-limited 
metastases from Siriwardena et al. (2014)  
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More recently consensus recommendations formulated using a modified Delphi by a 
multidisciplinary expert panel for the management of patients with CRC and synchronous 
liver metastases were published (Adam et al., 2015). This group suggested that a simultaneous 
approach would not be advocated for patients with resectable liver metastases and an 
asymptomatic CRC requiring complex surgery, in high-risk patients, or for those when 
hepatectomy would be major. They advise that simultaneous resections may be considered in 
selected patients requiring limited hepatectomy. No guidelines exist regarding the use of the 
liver-first approach.  
 
 Strategies to improve resectability 
It is estimated that only around 10-30% of patients presenting with CRC liver metastases are 
candidates for curative resection (Adam and Vinet, 2004, Simmonds et al., 2006). A 
multimodal approach which includes chemotherapy and aggressive surgical techniques may 
improve resectability rates by 10-50% in patients with bilobar metastases who would 
otherwise not be candidates for a curative approach (Karoui et al., 2010).  
 
 Conversion chemotherapy  
Patients with initially unresectable CRC liver metastases who sufficiently respond to 
chemotherapy to allow surgical resection have superior long-term survival to patients treated 
with chemotherapy alone (Nordlinger et al., 2007). Therefore systemic chemotherapy, given 
with the aim of converting unresectable liver metastases to resectable, may be given to patients 
with liver-limited disease who would otherwise be a candidate for curative treatment (Van 
Cutsem et al., 2016). Adam et al. (2004) reported that 138 out of 1,104 patients (12.5%) with 
initially unresectable disease managed at a single centre over an 11-year period, underwent 
liver resection after treatment with either FOLFOX (folinic acid (leucovorin), fluorouracil (5-
FU), oxaliplatin) or FOLFIRI (folinic acid, 5-FU, irinotecan). The authors reported 5- and 10- 
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year survival rates of 33% and 23 % respectively in these patients, only slightly lower than 
that in patients with initially resectable disease.   
 
 Portal vein embolisation 
Many patients with extensive liver metastases may not be candidates for surgical resection at 
initial presentation due to insufficient FLR volume; a strong, independent predictor of post-
operative hepatic dysfunction (Shoup et al., 2003). As outlined in the criteria for resectability 
described above, an adequate FLR volume, usually at least 20% of the total estimated liver 
volume for normal parenchyma, must remain following liver resection. Portal vein 
embolisation (PVE) is an image guided procedure used in patients with marginal FLR. The 
procedure uses embolisation to induce atrophy of the lobe of the liver to be resected and thus 
resulting in hypertrophy of the non-embolised lobe. The use of PVE may allow major 
hepatectomy in patients with previously technically unresectable disease due to small FLR, as 
well as lowering the risk of liver insufficiently post-operatively due to borderline FLR (Adam 
et al., 2015). PVE is usually performed under conscious sedation by interventional 
radiologists, with resection typically occurring 3-6 weeks following embolisation. The overall 
technical and clinical success rate of PVE are reportedly close to 100%  with 85% of patients 
proceeding to liver resection (van Lienden et al., 2013).  
 
 Two stage hepatectomy 
A two-stage hepatectomy can accomplish complete resection of liver metastases previously 
deemed unresectable because the remnant liver volume would be too small (Adam et al., 
2000). The first-stage is resection of all metastases from the part of the liver which will 
constitute the FLR in the form of minor metastasectomy with or without locally destructive 
techniques. In patients with synchronous disease this first stage may be combined with bowel 
resection. This may be followed by PVE to induce primary hypertrophy of the future liver, 
thus allowing the second-stage resection to be completed with minimal risk of post-operative 
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hepatic insufficiency. The second stage is completed in 76-87% of patients undergoing stage 
one. For patients who complete the second stage, long-term survival is equivalent to patients 
with more limited disease treated with a conventional single-stage strategy (Brouquet et al., 
2011).  
 
 Loco-regional therapies 
Loco-regional, also known as liver-directed, therapies may be used in patients with 
unresectable liver metastases to prolong survival, and also as adjuncts to surgical resection to 
aid local control in patients with resectable disease. The most common loco-regional 
therapies: ablation and intra-arterial therapy are discussed below.  
 
 Ablative therapies 
Ablative therapy involves the delivery of localised destructive treatment to a tumour. The 
precise role of ablative techniques is not clearly defined but common consensus is that its use 
should be limited to an adjunct to surgery in patients with widespread disease or a means of 
achieving local control in patients with unresectable disease either due to wide-spread liver 
metastases or extra-hepatic disease (Pathak et al., 2011). While radiofrequency ablation (RFA) 
and microwave ablation (MWA) are the most commonly used ablative therapies, there are a 
range of additional techniques, including high intensity focused ultrasound (HIFU), 
irreversible electroporation therapy (IRE) (Nanoknife), focussed radiotherapy (Cyberknife), 
cryoablation and laser ablation.  
 
RFA is the most widely used tumour ablation technique. It involves applying localised high 
frequency alternating current to the tumour to produce heat, resulting in coagulative necrosis 
(Guenette and Dupuy, 2010). Ten-year follow-up results of the randomised phase II European 
Organisation for Research and Treatment of Cancer (EORTC) 40004 CLOCC study 
demonstrated a promising role for ablation in patients who are ineligible for resection. Patients 
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with unresectable CRC liver metastases were randomly assigned to systemic treatment alone 
(standard arm) or systemic treatment plus local treatment by RFA with or without additional 
resection (experimental arm). Progression-free survival was improved in the experimental arm 
at 16.8 months, compared to 9.9 months in the standard arm (Ruers et al., 2010).  
 
Due to concerns regarding a high rate of local recurrence (local recurrence rates of 47% 
following ablation have been demonstrated compared to 13% after surgery (Nishiwada et al., 
2014)), RFA is not currently used as an alternative to surgical resection in patients with 
potentially operable disease (Lee et al., 2015).  
  
There is evidence to suggest that RFA is associated with lower complication rates and an 
improved health-related quality of life than surgery (Loveman et al., 2014). It has therefore 
been proposed that ablation may be a feasible alternative to surgery in high-risk patients who 
would currently be considered for liver resection but are likely to have poorer short- and long-
term outcomes after surgery. The LAVA (Liver Resection Surgery Versus Thermal Ablation 
for Colorectal LiVer MetAstases) trial  is currently seeking to address this (ISRCTN registry, 
2017).  
 
MWA uses heat generated by microwaves for localised destruction of the tumour (Petre and 
Sofocleous, 2017).  MWA has been reported to have lower rates of local recurrence and major 
complications than RFA but a higher rate of minor complications (Pathak et al., 2011).  There 
is a single randomised controlled trial  comparing MWA to liver resection, which suggested 
MWA to be equally effective in the treatment of CRC liver metastases (Shibata et al., 2000). 
These findings are limited however, as the trial did not describe allocation concealment or 
blinding, and excluded 25% of participants from analysis after random assignment (Bala et 
al., 2013).  
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 Intra-arterial therapy 
The concept of intra-arterial therapy is based on the knowledge that the blood supply to hepatic 
tumours originates predominantly from the hepatic artery, in contrast to normal healthy liver 
tissue which is supplied by the portal vein (Ackerman, 1974).  
 
Hepatic artery infusion (HAI) therapy involves directed chemotherapy (either 5-FU or 
leucovorin) via a pump attached to a catheter which gets implanted through the gastroduodenal 
artery. The administration of therapy via the hepatic arterial system may enhance drug delivery 
to the tumour and reduce the occurrence of systemic side-effects. A Cochrane review of 
randomised trials reported that despite an improved tumour response rate in patients treated 
with HAI when compared to systemic chemotherapy, HAI does not provide a survival 
advantage over systemic chemotherapy in patients with unresectable CRC liver metastases 
(Mocellin et al., 2009). HAI has therefore not gained widespread acceptance.  
 
Transarterial chemoembolisation (TACE) involves selective administration of chemotherapy, 
usually combined with embolisation of the hepatic artery, resulting in ischemic and 
chemotherapeutic effects on liver metastases, leaving normal parenchyma virtually 
unaffected. Fiorentini et al. (2012) randomly assigned 74 patients with CRC liver metastases 
to either receive TACE in the form of irinotecan loaded drug-eluting beads (DEBIRI) or 
systemic chemotherapy. At 50 months, overall survival was significantly longer for patients 
treated with DEBIRI than for those treated with systemic chemotherapy. No trials have yet 
compared liver resection with TACE.  
 
Selective internal radiation therapy (SIRT) is a form of brachytherapy in which the radiation 
source yttrium-90 is coupled with an embolic particle, termed a microsphere. This allows the 
delivery of the therapeutic dose of radiotherapy to the tumour to induce cytotoxicity with 
minimal damage to the uninvolved tissues. At present, patients are not eligible to receive SIRT 
funded by the National Health Service (NHS). A randomised trial of 74 patients with non-
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resectable CRC liver metastases by Gray et al. (2001) demonstrated that those randomised to 
HAI with floxuridine with the addition of SIRT had significantly improved response rate and 
time to progression of disease within the liver than those undergoing HAI with no SIRT. There 
was, however, no improvement in overall survival.   
 
 Hepatic transplant 
A small number of patients with unresectable CRC liver metastases have undergone liver 
transplantation. Transplantation in this cohort has been the subject of a recent systematic 
review  which pooled the results of 11 studies including 66 patients (Moris et al., 2017). The 
largest study, conducted by Muhlbacher et al. (1991) which included 25 patients, reported 1-
, 3- and 5-year post-transplant survival of 76%, 32% and 12% respectively (Muhlbacher et al., 
1991). A more recent study of 21 patients by Hagness et al. (2013) reported superior survival 
with 1-, 3- and 5-year post-transplant survival of 95%, 68% and 60% respectively (Hagness 
et al., 2013). Recurrence, however, across all studies was high at 67%, with time to recurrence 
being less than a year in most cases. The most common site of recurrence was the lung. As 
there are only a small number of patients who have undergone transplantation for CRC liver 
metastases, a lack of comparative studies and a shortage of donor organs, liver transplantation 
is not currently supported in patients with unresectable CRC liver metastases. 
 
 Systemic chemotherapy in patients with resectable liver metastases 
Although treatment decisions regarding liver resection must be made with consideration of 
the role of systemic chemotherapy, optimal practice remains undefined. The EPOC (EORTC 
40983) trial compared oxaliplatin/5FU given both prior to and after surgery, to surgery alone 
in patients with liver-limited CRC liver metastases, and reported a marginal improvement in 
progression free survival in the chemotherapy group (Nordlinger et al., 2008). The new EPOC 
trial which compared patients with resectable liver metastases all of whom received peri-
operative chemotherapy either with or without the addition of the biological agent cetuximab, 
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closed early after revealing a worse disease free survival in the cetuximab group (Primrose et 
al., 2014a).  
 
The detailed use of systemic chemotherapy in patients with liver metastases is outside the 
remit of this thesis. However, in brief, European Society for Medical Oncology (ESMO) 
guidelines recommend decisions regarding the use of peri-operative chemotherapy should be 
based on prognostic and surgical considerations, as shown in Figure 1.3  (Van Cutsem et al., 
2016). Prognostic considerations relate to the FONG score (Fong et al., 1999), as discussed 
below, with surgical criteria based on the technical difficultly of resection.  Patients with easily 
resectable liver metastases with an excellent prognosis often proceed directly to liver resection 
with no pre-operative therapy.  
 
Figure 1.3 Categorisation of patients according to technical and oncological criteria. 
FOLFOX (5-fluorouracil, leucovorin, oxaliplatin). Adapted from Van Cutsem et al. (2016).  
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 Recurrence  
Although a proportion of patients following liver resection will achieve long-term cure, 
disease will recur in 50-70% of patients, with the majority in the first 2 years (Galjart et al., 
2016). The mechanism of recurrence includes involved resection margins, missed or 
undetected lesions at the first resection, or natural progression of micrometastases from the 
primary colorectal tumour (Lintoiu-Ursut et al., 2015).  
 
Despite a patient having technically resectable disease, the concern remains that not all 
patients with technically resectable disease will actually benefit from surgical resection. Fong 
et al. (1999) developed a clinical score to predict recurrence after hepatic resection identifying 
seven factors with a significant impact on survival. Positive margin and the presence of 
extrahepatic disease, both increased risk of death by 1.7 times, and thus were suggested to be 
a relative contraindication to resection. The five factors contributing to the overall score were 
lymph node positive primary, <12 months disease-free interval from primary to metastases, 
number of hepatic tumours >1, size of hepatic tumour >5cm and CEA >200ng/ml. A scoring 
system assigning 1 point for each of the five factors was devised with patients scoring 0 points 
having a 5-year survival of 60% vs. 14% in patients with 5 points. Although this score is not 
routinely used in decisions regarding patient selection for resection, it may highlight patients 
in whom neoadjuvant chemotherapy is a better option than upfront surgery. 
 
The overall strategy for managing patients with disease recurrence is the same as that for the 
first presentation of metachronous liver metastases and involves full staging followed by 
discussion at an MDT meeting. Surgical resection is the treatment of choice and up to 40% of 
patients with disease recurrence will be candidates for re-resection (Viganò et al., 2014).  
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1.5 Care provision in England 
 Colorectal cancer multidisciplinary team 
In the mid-1990s two documents were published that had a significant impact on the structure 
and provision of cancer care within the NHS. The Calman-Hine report from the Department 
of Health (1995) and the Guidance on Commissioning Cancer Services from NHS Executive 
(1997) were strategic frameworks for creating a network of cancer care in England and Wales. 
They led to significant changes in the way that care was provided, from being predominantly 
organised and delivered by individual surgeons, to a MDT based approach.  
 
It is now expected that the management of all patients with CRC should be the responsibility 
of a CRC MDT (National Institute for Health and Care Excellence, 2004). The MDT model 
is a patient-centred approach in which relevant specialists will work together to identify the 
appropriate tests and treatment options available. Important benefits to patients with CRC 
from effective MDT working have been identified, including enhanced quality of life 
(Rummans et al., 2006), increased use of adjuvant chemotherapy (MacDermid et al., 2009)’ 
and improved post-operative (Wille-Jørgensen et al., 2013) and long-term survival (Munro et 
al., 2015). The importance of MDT assessment for patients with metastatic CRC has also been 
demonstrated. In a population-based study of Swedish registry data, patients with metastatic 
CRC discussed in a CRC MDT were more commonly referred for surgery to resect secondary 
metastases  than those who were not (Segelman et al., 2009). The extent of the implementation 
of the Calman-Hine report has been studied in a region of England, and although its 
recommendations were found to be associated with improvements in processes and outcomes 
of care for CRC patients, the extent of implementation was reportedly variable (Morris et al., 
2006). 
 
CRC MDTs should consist of a core team of members who have particular interest and 
expertise in this area. Core members of the team include CRC surgeons, an oncologist, a 
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diagnostic radiologist, a pathologist, clinical nurse specialists and a meeting co-ordinator (The 
Association of Coloproctology of Great Britain and Ireland, 2007). Every patient with a new 
diagnosis of CRC should be discussed as well as patients with newly identified recurrent or 
metastatic disease. This team will determine whether a patient has clearly resectable, 
borderline resection or unresectable metastatic disease and if referral to a further specialist 
team is warranted.  
 
There are more than 1500 cancer MDTs currently active in the United Kingdom, and the 
annual cost, in staff time alone, is over £100 million (Taylor et al., 2010). As well as being 
resource intensive, a scarcity of administrative support and variable team member attendance 
may be further barriers to efficient MDT functioning. In a 2004 report, half of the UK Cancer 
Networks surveyed described an absence of administrative support for MDTs and problems 
with MDT coordinator funding (National Audit Office, 2002). Attendance at colorectal MDT 
meetings is particularly variable with some core members, especially oncologists, reportedly 
participating infrequently (Kelly et al., 2003).  
 
 Organisation of hepatobiliary services 
At the same time that CRC services were being overhauled within the NHS, it was recognised 
that upper gastrointestinal (UGI) (an umbrella term for oesophagogastric and hepatobiliary) 
cancer services in England were fragmented in their delivery and complex UGI procedures 
were often being undertaken by general surgeons working as lone practitioners in small and 
medium sized hospitals (Siriwardena, 2007). Multiple studies have demonstrated an 
association between hospital volume and operative mortality following certain surgical 
procedures (Birkmeyer et al., 2002), with much of the apparent effect attributable to individual 
surgeon volume (Birkmeyer et al., 2003). Evidence of the impact of high-volume providers 
on patient outcome following both oesophagogastric and hepatobiliary procedures led to 
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major changes in UGI cancer service structure at the turn of the millennium (Strong et al., 
1994, Sosa et al., 1998).  
 
In 2001 the Clinical Outcomes Group in the UK set out a reform strategy including several 
specific recommendations, primarily that UGI services should be delivered by units with 
sufficiently large catchment populations (Department of Health, 2001). This move toward 
service centralisation, with the aim of concentrating skills, technologies and MDT in one 
location,  led to major changes in the delivery of UGI cancer services in England (Palser et 
al., 2009). Membership of the hepatobiliary MDT usually consists of two or more specialist 
liver surgeons, a diagnostic and interventional radiologist with expertise in hepatobiliary 
disease, an oncologist, a histopathologist and a clinical nurse specialist (Garden et al., 2006). 
The Association of Upper Gastrointestinal Surgeons (AUGIS) (2016) now recommends each 
hepatobiliary centre in the UK should serve a minimum population of two million, and should 
be performing in excess of 100 liver resection for primary and metastatic liver tumours per 
year.  In recently published plans to improve cancer services, the NHS in England has 
recommended an evaluation of whether cancer surgery would benefit from further 
centralisation (NHS England, 2016). 
 
 Referral practices 
It is expected that each CRC MDT should identify a hepatobiliary MDT which will receive 
referrals and provide surgery for patients suitable for hepatic resection. In addition to this a 
liver surgeon is considered part of the ‘extended team’ of a CRC MDT (The Association of 
Coloproctology of Great Britain and Ireland, 2007). NICE (2011a) have published guidelines 
regarding the referral of patients with metastatic CRC to specialist MDTs. These state that “if 
both primary and metastatic tumours are considered resectable, anatomical site-specific MDTs 
should consider initial systemic treatment followed by surgery, after full discussion with the 
patient”. There may also be specific guidelines issued from individual hepatobiliary MDTs to 
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their referring CRC MDTs regarding referral criteria. It is important that any decisions 
regarding the planning of treatment from both the CRC MDT and the hepatobiliary MDT are 
communicated effectively to patients in a prompt manner.  
 
1.6 Factors influencing surgical resection rate 
The true number of patients presenting with CRC liver metastases who have potentially 
surgically resectable disease is not known. Neoadjuvant down-staging chemotherapy, two-
stage hepatectomy and portal vein embolisation have resulted in a patient subgroup with 
potentially resectable disease who were previously thought to be ineligible for surgery. These 
advances may have increased the proportion of patients for whom surgical resection is possible 
by up to 20% (Bismuth et al., 1996, Fusai and Davidson, 2003, Adam et al., 2004). 
Improvements in pre-operative staging and increased utilisation of PET-CT may conversely 
have reduced the number of patients classified as having potentially resectable disease due to 
better detection of irresectable disseminated disease at presentation (Lykoudis et al., 2014). 
Population based studies from Sweden and the US reported 4% and 6% of patients with CRC 
undergo liver resection respectively (Cummings et al., 2007, Hackl et al., 2011). There is 
evidence to suggest that liver resection in patients with CRC liver metastases may be under-
utilised (Morris et al., 2010). The advances in patient management, the expanding criteria for 
resection and the centralisation of hepatobiliary services have resulted in new complexities 
for CRC MDTs in the management of patients with CRC liver metastases.  
 
 Inter-hospital and geographical variation in liver resection rates 
The NBOCA reports wide inter-hospital and regional variation in many aspects of the 
management and outcomes in patients with CRC in England and Wales. Two-year mortality 
rates are particularly variable and it may be that the care received by patients with metastatic 
disease contributes towards this disparity (nboca.org.uk, 2016). It is known that the 
implementation of guidelines has the potential to influence the utilisation of surgery and 
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reduce variation in patient care across geographic areas (Reames et al., 2014). Therefore, the 
lack of consensus guidelines in many aspects of the management of patients with CRC liver 
metastases may contribute to regional variation in care in this patient cohort.   
 
Regional variation in liver resection rates in CRC patients was initially studied by Morris et 
al. (2010). The reported liver resection rates amongst 114,115 patients undergoing major 
resection for CRC in the English NHS between 1998 and 2004 varied significantly across 
regions (1.1-4.3%) and hospitals (0.7-6.8%).  Significant variation in rates of liver resection 
has also been reported in more recent studies of European cohorts ('t Lam-Boer et al., 2015, 
Norén et al., 2016, Angelsen et al., 2017). Although Noren et al. (2016) reported similar liver 
resection rates across regions of Sweden in 3,149 patients with liver-limited synchronous CRC 
liver metastases, patients treated at university hospitals were more likely to undergo liver 
resection than those treated at district hospitals thus contributing to inter-hospital variation in 
care. In a study of 10,520 patients in the Netherlands Cancer Registry with synchronous CRC 
liver metastases, t’ Lam-Boer et al. (2015) reported inter-hospital variation of 2-26% in liver 
resection rates.  
 
 Advancing age 
The fastest growing subset of the Western population is that of people living over the age of 
65 years. Although the overall age structure of the population is evolving, the common cancer 
types will remain, such that CRC will continue to be the third most common cancer diagnosis 
(Anaya et al., 2011). Therefore, the number of elderly patients requiring CRC treatment is 
likely to rise substantially. At present, the median age for diagnosis of CRC in England is 72 
years with over 40% of patients aged 75 years or over at diagnosis (nboca.org.uk, 2016).  
 
The effect of an aging population on the epidemiology of CRC liver metastases has not been 
formally studied, however considering the growth of the elderly population and improvement 
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in diagnostic techniques, the number of elderly patients with CRC liver metastases will likely 
increase over the coming years. Long-term survival in patients with synchronous metastatic 
CRC appears to be improving in younger patients. The same trend, however, is not seen in the 
elderly population, thus raising concerns over our ability to adapt available treatments for 
older patients (Sorbye et al., 2013).  
 
Studies have consistently demonstrated elderly patients to be less likely to undergo liver 
resection than younger patients (Leporrier et al., 2006, Morris et al., 2010, Norén et al., 2016, 
Angelsen et al., 2017). Morris et al. (2010) reported each 10-year increase in age of CRC 
patients to be associated with an odds ratio (OR) of 0.63 for undergoing liver resection. 
 
This negative selection towards elderly patients may be clinically appropriate. Liver surgery 
is not without risk, and must be balanced against the potential for improvement in survival.  
The aging process is associated with a gradual decline in organ system reserve and our ability 
to respond to stressful stimuli (Leal et al., 2016). In terms of the liver, advancing age is 
associated with a decline in physiological reserve, alterations in hepatic microcirculation, and 
a reduction in liver volume, capacity to eliminate free radicals and response to growth factors 
(Aalami et al., 2003, Schmucker and Sanchez, 2011). This is thought to result in delayed 
hepatic regeneration in the elderly population, leading some to question whether advanced age 
should be a relative contraindication to liver resection (Petrowsky and Clavien, 2005). As our 
understanding of the biology of liver repair in the elderly has developed, so too has critical 
care management, thus improving operative safety.  
 
The current evidence regarding the outcomes of elderly patients undergoing hepatectomy is 
conflicting and studies evaluating liver resection for CRC liver metastases in this group 
specifically present differing results. In studies including both minor and major liver resection 
there are reports that age has no association with 90-day mortality (Leal et al., 2016) and 
conversely that advancing age is associated with a poor outcome  (Booth et al., 2015, Cook et 
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al., 2012). Similarly, in studies restricted to major hepatic resection there are reports showing 
no association between advancing age and 90-day mortality (Menon et al., 2006, Bell et al., 
2017) and that age is independently associated with increased risk of 90-day mortality (Reddy 
et al., 2011a).  
 
Many of these previous studies are single centre, categorise patients into one of two groups 
based on an age cut off (usually 70 years) and include only a small number of patients in the 
elderly group. Also, due to an under-representation of high-risk patients in such studies, it is 
acknowledged that these results may not be realised in the general population (Asiyanbola et 
al., 2008). 
 
There is a paucity of population-based studies reporting outcomes in this cohort. Those that 
are published restrict the analysis to patients 65 years and older or do not describe outcome 
according to age group. In a recent population-based study, Booth et al. (2017) studied 1,310 
patients classified into three age groups, younger than 65 years, 65 to 74 years, and 75 years 
or older, undergoing liver resection for CRC liver metastases between 2002 and 2009 in 
Ontario, Canada. There were comparatively few patients aged 75 years and older included 
(n=174). In addition, the role of minimally invasive, and parenchyma sparing techniques in 
liver resection in the elderly population has not been established.  
 
 Social deprivation 
Even in the UK where there is a universal entitlement to healthcare within the NHS, the health 
inequalities between the most deprived and least deprived areas are showing little sign of 
reducing (Newton et al., 2015). People living in the most deprived areas of England in 2013 
have not yet reached the levels of life expectancy that less deprived groups had in 1990 
(Newton et al., 2015). The reported life expectancy for men in 2013 ranged from 75 years in 
the most deprived area in North West England to 83 years in the least deprived area of East of 
England.  
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Socioeconomic inequalities in survival have been reported for most adult cancers worldwide 
(Kogevinas and Porta, 1997, Coleman et al., 2004, Woods et al., 2006). The improved cancer 
survival that has occurred over the last two decades has been reflected more in patients living 
in affluent areas than for those living in deprived areas. It is estimated that 11% of deaths from 
common cancers would be avoided if survival for all patients was as high as in the most 
affluent group (Ellis et al., 2012). 
 
Poorer cancer-specific and overall survival in CRC patients  in lower socioeconomic groups 
has been reported in US (Aarts et al., 2010), European (Eloranta et al., 2010, Dejardin et al., 
2014) and UK (Jeffreys et al., 2006, Møller et al., 2012, Dejardin et al., 2014) populations. 
The origins of these disparities in survival are still not fully understood. Although late stage 
at presentation is a commonly cited cause of the lower survival amongst more deprived 
patients, studies applying multiple regression analysis to correct for stage have reported this 
difference to remain (Hole and McArdle, 2002, Wrigley et al., 2003).  Evidence now also 
points to  differential access to treatment within the healthcare system (Lejeune et al., 2010) . 
Access to specialist care is known to favour the affluent (Dixon et al., 2007) and lower rates 
of primary CRC resection (Pollock and Vickers, 1998, Tilney et al., 2009, Raine et al., 2010) 
and use of chemotherapy (Lemmens et al., 2005, McGory et al., 2006, Aarts et al., 2010) in 
less affluent patients have been demonstrated.  
 
Relatively little is known about the influence of socioeconomic status on liver resection rates, 
with population-based studies reporting conflicting findings. A study of selection for liver 
resection in an English CRC population diagnosed from 1998-2004 demonstrated higher 
socioeconomic status to independently predict liver resection (Morris et al., 2010).  Similarly, 
Wiggans et al. (2015), reported that affluent patients were over-represented amongst a 
regional English cohort of patients undergoing liver resection when compared to the 
demographics of the local population.  In contrast, a population-based study of patients with 
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synchronous liver-limited metastases in Sweden did not find either income, or education, to 
be independently associated with liver resection (Norén et al., 2016). 
 
 Access to specialist input 
As highlighted in this introduction, the treatment pathway to be negotiated for patients with 
CRC liver metastases, particularly those with synchronous metastases, may be complex with 
a lack of consensus regarding multiple aspects of care. Providing these patients optimal 
treatment requires increasingly specialised expertise.  
 
There is evidence to suggest that some patients with resectable liver disease are not referred 
to hepatobiliary teams for discussion (Jones et al., 2012, Young et al., 2013). These patients 
may therefore be denied potentially curative treatment. A survey of the attitudes of colorectal 
surgeons in the UK towards referral practices for patients with CRC liver metastases 
performed in 2000, reported that only half of surgeons would refer a patient with bilobar 
metastases and only a quarter would refer if the patient had bilobar disease and more than 
three metastases (Heriot et al., 2004).  
 
The complexities of the technical and oncological rationale influencing decision-making in 
CRC patients was highlighted by Jones et al. (2012). These authors analysed regional CRC 
MDT data from 2009, and out of 53 patients with CRC liver-limited metastases who had 
undergone palliative chemotherapy at a regional UK oncology centre without previous 
hepatobiliary MDT discussion, 63% were found by a panel of blinded liver surgeons to have 
potentially resectable disease prior to commencement of chemotherapy. The following year, 
Young et al. (2013) published an analysis of patients presenting with new CRC liver 
metastases across a 12 month period in a cancer network which consisted of a hepatobiliary 
specialist centre and seven attached hospitals. There were 131 patients identified who were 
deemed by the CRC MDTs to be fit for liver resection but to have inoperable disease and 
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therefore were not referred to the hepatobiliary MDT. When the cases of these patients were 
reviewed by hepatobiliary surgeons and radiologists at the specialist centre, 29% were 
considered to have operable disease with a further 15% having equivocal imaging. A recent 
regional study in the UK, similarly demonstrated 42% of CRC patients with liver-limited 
metastatic disease not referred to a hepatobiliary MDT over a 6 month period had resectable 
or potentially resectable disease. A further 36% may have been suitable for a clinical trial 
(Thillai et al., 2016). 
 
1.7 Aim of thesis 
The literature search performed in this Chapter has highlighted several gaps in the current 
evidence regarding the management and outcomes of patients with CRC liver metastases. The 
overall aim of this thesis was to describe several aspects of the surgical management and 
outcomes of patients with CRC liver metastases in England using routinely collected national 
data. This thesis examines four specific clinical topics in depth and can be broadly grouped 
into the domains: service provision, accessibility, and outcomes.  
 
 The impact of the centralisation of hepatobiliary services in England on colorectal 
cancer patients with synchronous liver metastases  
The positive impact of assessment by specialist MDT on outcomes for CRC patients is well 
documented. Local studies have demonstrated that patients with potentially operable liver 
metastases may be missing out on surgical resection due to their cases not being discussed 
within a hepatobiliary MDT.  
 
Liver surgical services in England have undergone a complete restructure over the last two 
decades with the centralisation of such services to create higher-volume units. This may have 
particularly impacted upon CRC MDTs based at hospitals that do not offer liver specialist 
services.  
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Little is known about the impact of the centralisation of hepatobiliary services on CRC patients 
in England, although limited European data suggests on-site access to liver surgery may 
increase the rate of liver resection. The first study of this thesis investigated how the presence 
of hepatobiliary surgical services on-site at the hospital of diagnosis of CRC effects the rate 
of liver resection in patients with synchronous CRC liver metastases, and importantly, if this 
changes patient survival.  
 
 Effect of socioeconomic status on selection for liver resection and survival in 
patients with synchronous colorectal cancer liver metastases 
As discussed above, social deprivation is associated with poorer long-term survival in CRC 
patients in the UK. The cause of this disparity is not fully understood. More deprived patients 
are known to be at a higher risk of emergency and delayed presentation of CRC (Wallace et 
al., 2014) resulting in more advanced disease at diagnosis (Clegg et al., 2009). However stage 
at presentation only appears to partly explain the poorer survival and process factors such as 
access to services may also contribute (Lejeune et al., 2010). 
 
Studies of the impact of socioeconomic deprivation on liver resection rates and survival have 
reported conflicting results (Morris et al., 2010, Wiggans et al., 2015). No previous study has 
examined socioeconomic status as an independent predictor of mortality in this cohort. The 
study presented in Chapter 4 investigates how socioeconomic deprivation is associated with 
rate of liver resection and overall survival in patients with synchronous CRC liver metastases. 
This study also examines if any survival inequalities related to deprivation within this cohort 
are explained by differences in rates of liver resection. 
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 The timing of liver resection in relation to colorectal cancer resection in patients 
with colorectal cancer and synchronous liver metastases 
Without widely accepted guidelines for clinicians regarding the surgical timing of bowel 
resection in relation to liver resection for patients with synchronous disease, patient 
management can be challenging. Although the popularity of alternative strategies for the 
timing of resection of synchronous CRC metastases in relation to colorectal cancer resection 
has increased in recent years, it is not known how these approaches are being used in England 
and how patients are being selected for each strategy.  
 
The study presented in Chapter 5 was therefore undertaken to investigate temporal trends in 
the surgical strategy used in CRC patients with synchronous liver metastases, and the 
demographic and clinical characteristics of the patients selected for each approach. The study 
used landmark analysis and propensity matching techniques in comparing the long-term 
outcomes of patients, thus addressing several of the methodological flaws in previous 
publications of this nature.  
 
 The impact of advancing age on outcomes in patients undergoing hepatectomy for 
colorectal cancer liver metastases 
The reported post-operative and long-term outcomes in the elderly undergoing liver resection 
for CRC liver metastases vary. This may reflect that previous studies have been limited by 
small patient numbers, long-recruitment periods and a single centre design.  
 
Within an aging population it is critical that the role of newer interventions such as 
laparoscopic surgery and parenchyma sparing techniques, and outcomes of common surgical 
procedures in the older patient are well characterised to allow clinicians to present accurate 
information regarding the potential risks and benefits to patients.  
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The final study of the thesis aimed to compare characteristics of patients having liver resection 
by age and to investigate advancing age as a prognostic factor for post-operative outcomes 
and long-term survival in patients with CRC liver metastases.  
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2. Chapter 2: Methods 
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The general methodology of this thesis is described below, and the specific methodology for 
the analysis conducted in each individual study is detailed in the relevant chapter.  
 
2.1 Data sources 
The primary source of data for the research presented in this thesis was the NBOCA database. 
Data derived from the audit dataset was linked with other data sources, to provide the 
comprehensive dataset required for further analysis.   
 
 The National Bowel Cancer Audit 
The NBOCA collects data on over 30,000 patients diagnosed with CRC in England and Wales 
each year and has been running in its current form since 2010. The aim of the audit is to 
measure the quality of care and survival of patients with CRC treated within the NHS in 
England and Wales. The NBOCA is commissioned by the Healthcare Quality Improvement 
Partnership (HQIP) and funded by NHS England and the Welsh Government.  Participation 
in the NBOCA is mandatory for hospital trusts and the NBOCA is listed as one of the 58 
programmes which NHS England advises trusts to prioritise for participation and inclusion in 
their quality accounts (NHS England, 2017). In addition to this, it is data from the NBOCA 
that is published by ACPGBI as part of Clinical Outcomes Publication (The Association of 
Coloproctology of Great Britain and Ireland, 2016). This has improved clinician engagement 
in NBOCA data collection, therefore increasing both data completeness and accuracy.  
 
The NBOCA is carried out by the Clinical Effectiveness Unit (CEU) of the Royal College of 
Surgeons (RCS) of England in partnership with the ACPGBI and NHS Digital. The 
ACPGBI provides clinical leadership and direction, while NHS Digital provide project 
management and technical infrastructure. A project team, comprised of clinicians, 
epidemiologists and data analysts, work together to run the audit. The audit meets on a bi-
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annual basis with a clinical advisory group which includes clinicians, commissioners, and 
charity and patient representatives.   
 
 Inclusion criteria 
The audit includes all patients with a new diagnosis of primary CRC. Included patients must 
be: 
• Aged 18 or over 
• Diagnosed with CRC, with one of the following International Statistical 
Classification of Diseases and Related Health Problems 10th Revision (ICD-10) 
codes (World Health Organisation, 2011): 
• C17.0 Malignant neoplasm of caecum 
• C18.2 Malignant neoplasm of ascending colon 
• C18.3 Malignant neoplasm of hepatic flexure 
• C18.4 Malignant neoplasm of transverse colon 
• C18.5 Malignant neoplasm of splenic flexure 
• C18.6 Malignant neoplasm of descending colon 
• C19.0 Malignant neoplasm of colon with rectum 
• C20.0 Malignant neoplasm of rectum 
 
 Exclusion criteria 
Patients with recurrent CRC, or a second primary CRC are not included in the audit.  
 
 Audit dataset 
The majority of data items are collected by NHS trusts in England as part of the Cancer 
Outcomes and Services Dataset (COSD).  
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The following data items are included in the final NBOCA dataset: 
 
Patient variables: NHS number, date of birth, surname, forename, postcode and 
gender. These data items are predominantly used for linkage purposes and, apart 
from gender, are not available to the analysts.  
 
Tumour variables: Site of cancer, pre-treatment T-stage, pre-treatment N-stage, 
pre-treatment M-stage. This also includes data regarding the source of diagnosis, 
date of diagnosis, the treatment intent (curative/ palliative), planned treatment and 
anaerobic threshold (if applicable).  
 
Surgery variables: Date of surgery, American Society of Anesthesiologists (ASA) 
class, surgical urgency, consultant General Medical Council (GMC) code, primary 
procedure, surgical access and post-operative care. 
 
Pathological variables: Circumferential excision margin, number of lymph nodes 
examined, number of lymph nodes positive, pathological T-stage, pathological N-
stage, pathological M-stage, size of lesion, tumour type, differentiation, vascular or 
lymphatic invasion.  
 
Neo-adjuvant and adjuvant treatment variables: Neo-adjuvant treatment 
provider, neo-adjuvant treatment type, adjuvant treatment provider and adjuvant 
treatment type. 
 
 Major colorectal cancer resection 
Major resection is defined in NBOCA data according to the below procedures: 
• Right hemicolectomy 
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• Extended right hemicolectomy 
• Transverse colectomy 
• Left hemicolectomy 
• Sigmoid colectomy 
• Anterior Resection 
• Abdomino Perineal Excision of Rectum 
• Pelvic exenteration 
• Hartmann's procedure 
• Total colectomy and ileorectal anastomosis 
• Total excision of colon and rectum ± anastomosis of ileum to anus + pouch 
 
 Data collection 
The NBOCA data is prospectively collected. The dataset is designed to collect information 
at the time of the CRC MDT meeting. Since March 2014, patient data has been collected via 
NHS Digital’s Clinical Audit Platform (CAP) system.  
 
The Health Act 2009 requires that trusts demonstrate their participation National Clinical 
Audits via their Quality Accounts (Government, 2009).  Since 2012 it has been a 
requirement that these Quality Accounts are externally audited.   
 
 Case ascertainment 
The case ascertainment reported by the NBOCA audit has remained consistently high over the 
last five years. This is expressed as a ratio of the number of patients registered in the NBOCA 
(the numerator) to the number of patients newly recorded in HES data with an ICD-10 code 
indicating a diagnosis of CRC. The case ascertainment for the NBOCA was reported to be 
95% for patients diagnosed from 31st March 2015 to 1st April 2016 resection (nboca.org.uk, 
53 
 
2016). The results of the studies presented in this thesis therefore may be considered 
generalisable and representative of the current management and outcomes of CRC patients. 
 
 Type two objections 
Patients who do not want their personal confidential information to be shared, for purposes 
other than for their direct care, can register a type 2 opt-out with their GP practice. These 
patients are not included in the calculation of case ascertainment. This is estimated to be 
around 2% of the UK population, and therefore the exclusion of patients who have registered 
a type 2 objection, although should be considered, is not likely to have had a significant 
influence on the overall results presented (NHS Digital, 2016).  
 
 Ethical Approval 
The NBOCA is considered to be exempt from the UK National Research Ethics Committee 
approval as it involves analysis of data for services. Section 251 approval was obtained for 
the collection of the personal health data from the Ethics and Confidentiality Committee. 
 
 Organisation of services 
Data regarding the services available at hospital trusts was collected in November 2015. An 
electronic survey was designed and then initially piloted at 10 sites. Feedback was gathered 
from those who completed the pilot survey and the survey was modified. The final survey was 
circulated to the CRC clinical lead for all 142 English NHS hospital trusts treating more than 
10 CRC patients per year. Those who failed to respond within 1 month were followed up with 
a telephone reminder. 
 
 Hospital Episode Statistics 
The studies presented in this thesis derive much of the presented data from the Hospital 
Episode Statistics (HES) inpatient database. HES is described as a ‘data warehouse’ 
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containing details of patients' demographic characteristics as well as their main and 
supplementary diagnoses and operations (NHS Digital, 2017). The HES database is linked to 
NBOCA data to allow more in-depth analyses to be performed. 
 
Each record in HES describes a period of care for a patient under a particular hospital 
consultant and is known as a Finished Consultant Episode (FCE). For each FCE, 
administrative data is captured, including date of admission and discharge (allowing length 
of stay to be determined). Clinical information is captured in the HES database in the form 
of alphanumeric codes.  
 
The International Statistical Classification of Diseases and Related Health Problems 10th 
Revision (ICD-10) (World Health Organisation, 2011) is used to record diagnoses in the 
HES dataset. Within each episode there is a data field to record a primary diagnosis, and a 
further 19 data fields for secondary diagnoses.  
 
Operative and other interventional procedures are recorded using Office of Population 
Censuses and Surveys Classification of Surgical Operations and Procedures (4th revision) 
(OPCS-4) codes in up to 24 operative fields (NHS Classifications Service, 2007). These 
correspond to primary procedure, secondary procedure and so on. Each of the operative 
fields is associated with a ‘date of operative procedure’ data field.  
 
 Mortality database from the Office for National Statistics 
Patient date of death and cause of death was obtained from the Office for National Statistics 
(ONS) records (Office for National Statistics, 2014). In this dataset the underlying cause of 
death is listed as a single ICD-10 code based on the death certificate generated from an 
automated programme operated by the ONS. The codes listed in Table 2.1Error! Reference 
source not found. were considered to represent a CRC cancer related death.  
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Table 2.1 ICD-10 codes used to identify CRC cancer specific deaths 
4-digit code Description 
C180, C181, C182, C183, 
C184, C185, C186, C187, 
C188, C189 
Malignant neoplasm of colon 
C19X Malignant neoplasm of rectosigmoid junction 
C20C Malignant neoplasm of rectum 
C260 Malignant neoplasm of intestinal tract, part unspecified 
C269, C768 Malignant neoplasm of ill-defined sites within digestive system 
C762 Malignant neoplasm of abdomen 
C770, C771, C772, C773, 
C774, C775, C778, C779 
Secondary and unspecified malignant neoplasm of lymph nodes 
C780, C781, C782, C783, 
C784, C785, C786, C787, C788 
Secondary malignant neoplasm of respiratory and digestive organs 
C790, C791, C792, C793, 
C794, C795, C796, C797, C798 
Secondary malignant neoplasm of other sites 
D374 Neoplasm uncertain colon 
D375 Neoplasm uncertain rectum 
D377 Neoplasm uncertain/ unknown behaviour other digestive organs 
C97X Malignant neoplasms of independent (primary) multiple sites 
 
 Methods for administrative data 
 Royal College of Surgeons Charlson comorbidity score 
The Royal College of Surgeons (RCS) Charlson comorbidity score was used to calculate 
patient comorbidity. This is a comorbidity score consisting of 14 disease categories  
developed for use with administrative data in the UK by the RCS Comorbidity Consensus 
Group (Armitage and van der Meulen, 2010). The RCS Charlson score was developed with 
surgical patients in mind, and validated in patients undergoing elective surgery.  
 
A patient is considered to have a comorbid condition if an ICD-10 code included in the RCS 
Charlson Score, as shown in Appendix 9.1, was present in any of the first seven diagnosis 
fields of either the index admission or a hospital admission in the year preceding diagnosis. 
The original score includes ‘metastatic solid tumour’ and ‘any malignancy’ but this item is 
routinely excluded when the score is applied to cancer patients. The Charlson comorbidity 
score was considered in three categories: 0, 1 or 2 and more.  
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 The Index of Multiple Deprivation 
Socioeconomic status was calculated according to the English Indices of Deprivation and was 
based on the patient’s postcode (Noble M et al., 2007). This measure is based on 37 indicators 
organised across 7 distinct domains of deprivation. These are combined to calculate the Index 
of Multiple Deprivation (IMD). The 7 domains of deprivation are combined using the 
following weights: 
 
1) income deprivation (22.5%) 
2) employment deprivation (22.5%) 
3) education, skills and training deprivation (13.5%) 
4) health deprivation and disability (13.5%) 
5) crime (9.3%) 
6) barriers to housing and services (9.3%) 
7) living environment deprivation (9.3%) 
 
This is an overall measure of deprivation experienced by those living in a particular area and 
is calculated for 32,844 neighbourhoods (termed Lower layer Super Output Area (LSOA)) in 
England. Every such neighbourhood, which covers an average population of around 1500 
people or 400 households, is ranked according to its level of deprivation relative to that of 
other areas. Patients are grouped into five socioeconomic categories based on quintiles of the 
national ranking of these areas. 
 
 Emergency readmission 
An emergency readmission was defined as one where the hospital admission within 30-days 
of liver resection  in the HES record was coded as one of the following: ‘Emergency: via 
Accident and Emergency (A&E) services’ (21), ‘Emergency: via general practitioner (GP)’ 
(22), ‘Emergency: via Bed Bureau, including the Central Bureau’ (23), ‘Emergency: via 
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consultant outpatient clinic’ (24) or ‘Emergency: other means, including patients who arrive 
via the A&E department of another healthcare provider’ (28).  
 
 Return to theatre 
Reoperation was defined as any return to theatre for an intra-abdominal procedure or wound 
complication on the index admission, or on a subsequent admission to hospital within 30 days 
of the initial liver resection. The codes used to define return to theatre were those used by 
Burns et al. (2012) with additional codes previously identified using a strategy to identify 
frequent procedure codes amongst patients with poor outcomes (Burns et al., 2013). Procedure 
codes indicating a return to theatre occurring up until midnight on the day of liver resection 
could not be distinguished from the original procedure, resulting in a requirement of at least 
one day between the liver resection and the procedure code identifying return to theatre.  
 
 Data linkage 
The NBOCA database was linked to HES and the ONS death register for each patient. Data 
were linked using a hierarchical deterministic approach (Li et al., 2006). Deterministic 
methods are based on exact-match comparisons of a combination of variables that allow 
unique discrimination. The patient identifiers used for linkage were NHS number, date of 
birth, sex and postcode. In 2016, 93% of patients undergoing major surgery at English trusts 
in the audit could be linked to HES. Multiple imputation (as discussed in Section 2.2.5) was 
used to impute data for patients who could not be linked to HES.  
 
 Coding accuracy within Hospital Episode Statistics data 
HES data provided information regarding the site of metastases, and liver resection 
procedures, allowing analyses which would not have been possible using the NBOCA dataset 
alone. The primary use of the HES database, as well as the premise on which it is designed, is 
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for administrative purposes. Therefore, despite its increasing use in epidemiological research, 
the potential for coding inaccuracies and the impact of such errors must be considered.  
 
The routine coding of information about episodes of hospital care has now become a central 
feature of the NHS. In recent years there have been changes to coding practices which may 
have improved the accuracy of coding. In the white paper “Equity and excellence: Liberating 
the NHS” the government showed a strong commitment to ensuring that information is 
collected and used to inform patient choice (Department of Health, 2010). As a result NHS 
Choices now publishes metric and quality indicators in the public domain. These are based 
largely upon HES data (gov.uk, 2017).  Furthermore, hospitals trusts are now paid based on 
coding data. Errors in coding are known to have a significant impact on payment accuracy and 
as a result there is significant interest from commissioners in ensuring accuracy (Payment by 
Results data assurance framework, 2014).  
 
Given the increased engagement from trusts in improving administrative data accuracy in 
recent years, HES data is generally considered sufficient for use in most circumstances. A 
systematic review of studies comparing routine discharge statistics about an episode of 
hospital care with the original medical record, reported the coding accuracy to be high, with 
an accuracy of 80% for diagnoses and 84% for procedures (Burns et al., 2012).  
 
HES data was used to capture information regarding the presence of synchronous liver 
metastases for the analyses presented in Chapters 3, 4 and 5. In the study in Chapter 3, which 
includes patients diagnosed from 2010 to 2014, 13% of CRC patients were found to have a 
HES code recorded for liver metastases at the time of diagnosis. In Chapter 4, a slightly more 
recent cohort of patients were included (those diagnosed from 2011 to 2015), and a higher 
proportion of patients, 15%, were found to have liver metastases at diagnosis. Although the 
true proportion of CRC patients with synchronous liver metastases at diagnosis is unknown, 
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these figures are similar to those reported by previous European population-based studies 
using registry data (Manfredi et al., 2006, Norén et al., 2016).  
 
Despite this, as only 40 to 50% (depending on the time period examined) of patients with 
metastatic disease recorded in NBOCA data had an ICD-10 code for a metastasis recorded in 
HES, it must be inferred that liver metastases are under-recorded in HES data. There were 
however several strategies used to validate the findings and to reduce the risk of bias from the 
use of incomplete data. As discussed in Chapter 3 and 4, although the true incidence of 
synchronous liver metastases in this patient cohort is unknown, the odds ratio to estimate 
likelihood of undergoing liver resection remains a valid measure of association in the same 
way that it is valid in a case control study if under-recording is not dependent on the risk factor 
under investigation. This is demonstrated in Table 3.2 to be the case for both on-site 
hepatobiliary services and socioeconomic status which are the focus of investigation in 
Chapters 3 and 4 respectively.  
 
Due to the under-recording of metastases in HES data, patients with liver metastases detected 
during the course of follow up were excluded when investigating patient access to liver 
resection. This is because NBOCA collects data on only the presence of metastases at the time 
of diagnosis, and not on metachronous disease detected as part of follow up. Therefore, the 
validation step of comparing the characteristics of patients with metachronous disease in the 
HES dataset to the NBOCA dataset, as performed in Chapter 3 for patients with synchronous 
disease, was not possible. 
 
2.2 Statistical analysis 
The statistical methods used throughout this thesis are discussed below. Further details may 
also be found in the specific chapter. STATA® version 14.1 (StataCorp, College Station, 
Texas, USA) was used for all analyses. 
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 Multi-level models 
The analyses in Chapter 3 and Chapter 4 include individual patient variables as well as an 
institutional variable (presence of hepatobiliary surgical services on-site). This is considered 
a multi-level model. Observations from data with a hierarchical structure may be correlated 
with one another, termed ‘clustering’. With clustered data, estimated standard errors in a 
conventional regression are smaller than actual standard errors due to failure to account for 
the similarity of responses among observations within the same cluster (Vaughn, 2008). This 
underestimation of standard errors causes an increase in likelihood of a Type I error. Hence 
for the analyses used in Chapters 3 and 4, multilevel logistic regression models with random 
intercepts, and Cox regression with shared frailty, were used to allow for clustering within 
hospital trusts.  
 
 Competing risks analysis 
Kaplan-Meier survival analysis and Cox proportional hazard regression models were 
originally developed to describe all-cause mortality, as opposed to incident disease. When 
these approaches are used to describe outcomes other than all-cause mortality, the presence of 
a related competing risk, such as death, may lead to biased results (Gooley et al., 1999, 
Southern et al., 2006). In Chapter 6 where the primary outcome was death attributable to a 
CRC related cause, death attributable to a non-CRC cause serves as a competing event. For 
example, a CRC patient who dies of a myocardial infarction is no longer at risk of death 
attributed to CRC. This is a particular consideration when studying a geriatric population, in 
whom the risk of death from other causes is higher. The use of traditional methods, without 
accounting for the competing risk of death, can overestimate the risk of the outcome of 
interest. Therefore, for the analysis of cancer-specific mortality in the 3 years following liver 
resection according to patient age, a competing risks model was used to reduce the risk of such 
bias.  
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 Propensity score-matched analysis 
Propensity score-matching was used to control for imbalances between the patient cohorts in 
Chapter 5. This presented several advantages to logistic regression. In propensity score-
matching, the collection of confounders which may predict the outcome of interest are 
collapsed into a single variable, the propensity score (Austin, 2011a). This therefore allows 
more confounders to be accounted for than in a logistic regression model. For the analysis in 
Chapter 5, components of the Charlson comorbidity score were included individually rather 
than in a cumulative single value. In addition, it would be very unlikely that a patient in the 
bowel-first group would have the demographic, clinical and pathological characteristics to be 
eligible for both a simultaneous and a liver-first approach. Therefore, a further advantage of 
propensity score-matching was that it allowed the comparison to be restricted to only bowel-
first patients eligible for a specific alternative approach. 
 
 Landmark survival analysis 
To compare long-term survival between patients undergoing the bowel-first, liver-first and 
simultaneous surgical strategies, the analysis in Chapter 4 uses a landmark analysis to correct 
for the bias inherent in the time-to-event outcome between patient cohorts. In the landmark 
method, a fixed time after a baseline data is selected as a landmark for conducting the analysis 
of survival. Only patients alive at the landmark time are included in the analysis (Anderson et 
al., 1983, Dafni, 2011). As this study only includes patients in the staged groups who survive 
to undergo a second intervention, a traditional survival analysis from date of diagnosis would 
introduce bias in favour of bowel- and liver-first patients. This is because patients who die 
after the first procedure would be excluded by definition. Furthermore, patients in the staged 
cohorts have their interventions at different time points following diagnosis, again introducing 
bias in a traditional survival analysis.  
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 Dealing with missing data 
There are a number of proposed methods for dealing with missing data. The simplest is known 
as a complete case analysis and involves omitting all cases with missing data. The primary 
problem with this approach is that data may not be missing at random. For example, elderly 
patients, those with more comorbidities and more advanced disease have been shown to be 
more likely to have missing staging data (Gurney et al., 2013). Therefore, excluding these 
patients can result in lack of generalisability in the results. Furthermore, the effect of missing 
data in several domains may result in the exclusion of large proportion of the original sample, 
reducing study power (Sterne et al., 2009).  
 
The National Clinical Audit Advisory Group (2011) recommends the use of multiple 
imputation using chained equations for approaching missing data in registries. This method 
uses a patient’s other risk factors to predict the information that is missing, whilst taking into 
account the uncertainty due to their missing data. Firstly, chained equations were used to 
create 10 copies of the dataset with the missing values replaced by imputed values. Following 
this, the model of interest was fitted to each of the imputed datasets and standard errors were 
calculated using Rubin’s rules (White et al., 2011). Multiple imputation was used throughout 
this thesis to fill in risk factor information when reporting adjusted outcomes. 
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3. Chapter 3: The impact of hepatobiliary service 
centralisation on treatment and outcomes in patients 
with colorectal cancer and liver metastases 
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3.1 Introduction 
Evidence has emerged over the last decade that centralisation of specialist surgical services to 
create higher volume units improves patient outcomes (Birkmeyer et al., 2003, Munasinghe 
et al., 2015). This has had a significant effect on both organisational infrastructure and clinical 
practice within the NHS (Siriwardena, 2007, Palser et al., 2009). The English Department of 
Health (2001) published guidelines recommending that hepatobiliary surgery services should 
be delivered by units with sufficiently large catchment populations. As a result, hepatobiliary 
services have been centralised in a hub-and-spoke arrangement. In recently published plans to 
improve cancer services the NHS in England has recommended an evaluation of whether 
cancer surgery would benefit from further centralisation (National Cancer Transformation 
Board, 2016). 
 
NICE recommends that if a CRC MDT considers both primary and metastatic tumours are 
potentially resectable, the patient should be referred to a specialist hepatobiliary surgery team 
(National Institute for Health and Care Excellence, 2011b). If referral pathways are working 
effectively, patients diagnosed with CRC and liver metastases at hospital trusts with a 
specialist hepatobiliary team on site should have similar liver resection rates and survival as 
those diagnosed at hospital trusts without a specialist hepatobiliary team. However, there is 
evidence from regional studies to suggest that there is considerable inter-hospital variation in 
referral rates from colorectal MDTs to hepatobiliary MDTs (Young et al., 2013). 
 
The aim of this study was to outline the structure of hepatobiliary services for patients with 
CRC liver metastases in England and then use this data to compare the liver resection rate and 
survival outcomes in patients diagnosed with CRC and synchronous metastases limited to the 
liver at a centralised hepatobiliary centre (hub) with those at hospital trusts without 
hepatobiliary services (spokes).  
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3.2 Methods 
 Study population 
All patients registered in the NBOCA dataset diagnosed with primary CRC between 1st April 
2010 and 31st March 2014 with synchronous liver metastases who underwent a major CRC 
resection in English NHS hospitals were considered for inclusion in this study.   
 
 Data items and definitions 
 Secondary metastases  
The site of metastases was identified from HES data using diagnostic information coded 
according to ICD-10. Liver metastases were identified in HES data because the NBOCA 
records only the presence, but not the site, of metastatic disease. Patients were considered to 
have metastatic disease at diagnosis if a HES code was recorded up to 1 year before and 30 
days after diagnosis of CRC. A year before CRC diagnosis was chosen to include patients who 
are found to have metastases before determining the site of the primary CRC. The codes 
detailed in Table 3.1 were used to identify those with secondary metastases. Patients were 
considered to have liver-limited metastases if an ICD-10 code for liver metastases (C787) was 
recorded in HES, with no further secondary metastases also recorded, in the period of 1 year 
before and up 30 days following CRC diagnosis.  
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Table 3.1 ICD-10 diagnostic codes recorded in HES data used to identify patients with 
secondary metastases 
4-digit code Description 
C780 Secondary malignant neoplasm of lung 
C781 Secondary malignant neoplasm of mediastinum 
C782 Secondary malignant neoplasm of pleura 
C783 Secondary malignant neoplasm of other & unspecified respiratory organs 
C784 Secondary malignant neoplasm of small intestine 
C786 Secondary malignant neoplasm of retroperitoneum & peritoneum 
C787 Secondary malignant neoplasm of liver 
C788 Secondary malignant neoplasm of other & unspecified digestive organs 
C790 Secondary malignant neoplasm of kidney & renal pelvis 
C791 Secondary malignant neoplasm of other & unspecified urinary organs 
C792 Secondary malignant neoplasm of skin 
C793 Secondary malignant neoplasm of brain & cerebral meninges 
C794 Secondary malignant neoplasm of other & unspecified parts nervous system 
C795 Secondary malignant neoplasm of bone and bone marrow 
C796 Secondary malignant neoplasm of ovary 
C797 Secondary malignant neoplasm of adrenal gland 
C798 Secondary malignant neoplasm of other specified sites 
 
Of all patients undergoing major surgery for CRC identified in the NBOCA database to have 
metastatic disease at diagnosis, 41.1% (4,098 of 9,966) had a metastasis code recorded in HES 
data. This highlighted the under-recording of metastases in HES data.  
 
Cohort study designs usually allow for the direct calculation of relative risk from incidences, 
however in this study the true incidence of liver metastases in the population was not known. 
This therefore likens the design to a case-control study in which the proportion of cases in the 
entire population-at-risk is unknown. In such circumstances it is the odds ratio, and not the 
risk ratio, that provides a valid measure of relative risk (Pearce, 1993). This approach would 
be valid in investigating the impact of on-site hepatobiliary surgical services on liver resection 
dependent on two conditions being met. Firstly, the completeness of recording of metastases 
in HES must be independent of the patient being diagnosed in a hub or spoke. Secondly, 
patients recorded in HES data as having liver metastases must be representative of all patients 
with liver metastases. This was evaluated by two methods. The first was by comparing the 
completeness of recording of metastases in HES between hub and spoke hospital trusts. The 
67 
 
second was comparing the characteristics of patients with metastases, irrespective of their site, 
identified in the NBOCA database and corresponding patients in the HES database 
 
3.2.2.1.1 Completeness of recording of metastases between hub and spoke hospital trusts 
Of the 9966 patients who underwent resection of the primary CRC and had a record of 
metastatic disease in the NBOCA data set, 41.1% of those from spoke hospital trusts (3,141 
of 7,644) and 41.2% of those from hub hospitals trusts (957 of 2,322) had a metastasis code 
recorded in HES. Therefore, the recording of metastases appeared to be consistent between 
both types of hospital.  
 
3.2.2.1.2 Characteristics of patients with metastases in NBOCA and HES data 
For the second step in the validation of the use of HES data for capturing metastases, the 
demographic and clinical characteristics of patients with metastases recorded in NBOCA data 
were compared with those with metastases recorded in HES data. There were slightly more 
patients who had an emergency admission, urgent surgery and T4 disease identified in the 
HES database with metastatic disease than in the NBOCA, but patient characteristics were 
otherwise similar, as shown in Table 3.2.  
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Table 3.2 Comparison of characteristics of patients recorded as having metastatic disease at 
diagnosis in the NBOCA compared to those with a metastasis code in HES, restricted to those 
patients undergoing major resection 
 
Patients recorded as having 
metastatic disease in NBOCA 
N=9,966 
Patients recorded as having 
metastatic disease in HES 
N=6,001 
Hepatobiliary 
services 
Hub 2,322 (23.3) 1,401 (23.3) 
Spoke 7,644 (76.7) 4,600 (76.7) 
Sex 
Men 5,455 (54.7) 3,252 (54.2) 
Women 4,511 (45.3) 2,749 (45.8) 
Age group 
18-64 3,589 (36) 2,120 (35.3) 
65-74 3,163 (31.7) 1,892 (31.5) 
75-84 2,618 (26.3) 1,592 (26.5) 
>=85 596 (6) 397 (6.6) 
Index of 
Multiple 
Deprivation 
1 (least deprived) 1,590 (16.0) 989 (16.6) 
2 1,791 (18.1) 1,115 (18.7) 
3 2,107 (21.2) 1,236 (20.7) 
4 2,208 (22.3) 1,326 (22.2) 
5 (most deprived) 2,226 (22.4) 1,303 (21.8) 
Missing 44 32 
Admission 
Elective 6,323 (66.3) 3,202 (55.8) 
Emergency 3,218 (33.7) 2,532 (44.2) 
Missing 425 267 
CRC resection 
surgical urgency  
Elective/ scheduled 6,439 (65.5) 3,354 (57) 
Urgent/ emergency 3,396 (34.5) 2,529 (43) 
Missing 131 118 
Charlson co-
morbidity score 
0 6,810 (70.7) 4,009 (69.1) 
1 2,174 (22.6) 1,361 (23.5) 
≥2 644 (6.7) 434 (7.5) 
Missing 338 197 
ASA grade 
1 1,070 (12) 545 (10.4) 
2 4,564 (51) 2,512 (47.7) 
3 2,812 (31.4) 1,832 (34.8) 
4 506 (5.7) 376 (7.1) 
Missing 1,011 736 
Cancer site 
Ascending colon 1,098 (11) 722 (12) 
Caecum 2,218 (22.3) 1,541 (25.7) 
Rectosigmoid 695 (7) 360 (6) 
Descending colon 335 (3.4) 217 (3.6) 
Hepatic flexure 439 (4.4) 286 (4.8) 
Rectum 1,673 (16.8) 690 (11.5) 
Sigmoid colon 2,453 (24.6) 1,463 (24.4) 
Splenic flexure 309 (3.1) 214 (3.6) 
Transverse colon 746 (7.5) 508 (8.5) 
T-stage at 
diagnosis 
T0 53 (0.6) 28 (0.5) 
T1 116 (1.2) 51 (0.9) 
T2 454 (4.7) 206 (3.6) 
T3 3,845 (39.7) 1,911 (33.6) 
T4 5,228 (53.9) 3,492 (61.4) 
Missing 270 313 
N-stage at 
diagnosis 
N0 2,516 (25.9) 1,304 (22.9) 
N1 3,125 (32.2) 1,788 (31.4) 
N2 4,058 (41.8) 2,595 (45.6) 
Missing 267 314 
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 Liver resection 
All HES records including admissions up to 31 March 2015 were searched for codes indicating 
a liver resection. The OPCS-4 codes detailed in Table 3.3 were used to identify those patients 
who underwent liver resection.  
  
Table 3.3 OPCS-4 codes recorded in HES data used to identify liver resection 
 
 
 Hepatobiliary services 
Data regarding the location of a specialist hepatobiliary teams were collected in November 
2015 as part of the organisational audit discussed in Chapter 2.1.2. For hospital trusts not 
offering hepatobiliary services, the hospital trust to which the majority of patients were 
referred was ascertained. Survey responses were validated using two approaches. 
 
The first was by using linked HES records. Patients who underwent liver resection were 
grouped by their trust of diagnosis according to NBOCA data. Following this, the hospital 
trust at which the majority of liver resection procedures were performed for patients in that 
trust (according to the provider code recorded in HES data) was identified.  
 
4-digit code Description 
J021 Right hemihepatectomy 
J022 Left hemihepatectomy 
J023 Resection of segment of liver 
J024 Wedge excision of liver 
J026 Extended right hemihepatectomy 
J027 Extended left hemihepatectomy 
J028 Other specified partial excision of liver 
J029 Unspecified partial excision of liver 
J031 Excision of lesion of liver NEC 
J035 Excision of multiple lesions of liver 
J038 Other specified extirpation of lesion of liver 
J039 Unspecified extirpation of lesion of liver 
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The second was by comparing the employing trusts of the consultant members of the Great 
Britain and Ireland Hepato-Pancreato-Biliary Association (GBIHPBA) to those trusts 
identified as providing hepatobiliary services in the organisational survey.  
 
This allowed the hospital trusts with and without a specialist hepatobiliary team on-site to be 
mapped in a ‘hub and spoke’ model. 
 
 Statistical analysis 
The statistical significance of differences in patient characteristics in hub and spoke hospital 
trusts were assessed using the χ2 test. Multivariable random-effects logistic regression was 
used to estimate the odds ratio of liver resection by presence of specialist hepatobiliary 
services on site, adjusted for the following risk factors: sex, cancer site, IMD quintile, age 
group, admission type, surgical urgency, Charlson comorbidity score, T-stage, N-stage and 
ASA class. A random intercept was modelled for each hospital trust to reflect the possible 
clustering of results within hospital trusts. Missing values for the risk factors were imputed 
with multiple imputation. 
 
Survival was compared between patients with liver metastases diagnosed at hospital trusts 
with versus without a specialist hepatobiliary team. To avoid the need to censor patients, 
survival analyses were restricted to patients diagnosed before 1st April 2013 (with a minimum 
follow-up of two years from the last date of death available from ONS data). Survival curves 
were estimated using the Kaplan–Meier method and differences were tested using the log rank 
test.  Comparisons were made adjusting for other risk factors using a multivariable Cox 
proportional hazards model with a shared frailty factor, again to reflect the possible clustering 
of results within hospitals. 
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3.3 Results 
 Structure of hepatobiliary services 
All 142 English hospital trusts treating more than ten patients with CRC per year responded 
to the 2015 electronic survey. There were 23 hospitals trusts identified that diagnose and treat 
patients with CRC and provide on-site hepatobiliary surgical services, known as hubs. This 
number corresponded with the site in the procedural codes of the liver resection episode 
according to HES data. There were 27 trusts with consultant hepatobiliary surgeons registered 
in GBIHPBA. Four of these trusts were found to be no longer offering liver resection services 
in 2015 as further centralisation has occurred over recent years, therefore corresponding with 
survey responses and HES data.  
 
 Study cohort 
The NBOCA contained linked HES records of 137,262 patients aged 18 years or more with a 
primary CRC diagnosed between 1st April 2010 and 31st March 2014. Some 17,829 patients 
(13.0%) with a code of secondary malignant neoplasm of the liver (C787) recorded up to 1 
year before and 30 days after a diagnosis of CRC were identified. Of these, 6,699 patients with 
a HES code of another site of metastasis were excluded. A further 6,583 patients who did not 
have a CRC resection were excluded. As a result, data from 4,547 patients were available for 
analysis (Figure 3.1). Liver resection was performed in 1,956 of these patients (43.0%).  
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Figure 3.1 Flow chart of patient inclusion and exclusion 
 
 Patient characteristics 
Patients diagnosed in hubs tended to have higher ASA class (P=0.026) and lower deprivation 
(P<0.001) compared with those diagnosed elsewhere (Table 3.4). There was no statistically 
significant difference in any other patient or tumour characteristic. 
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Table 3.4 Demographic, clinical and tumour characteristics of patients with liver metastases 
undergoing CRC resection according to whether a specialist hepatobiliary surgery team was 
available on site 
 
Spoke hospitals 
(n = 3,466) 
Hub hospitals 
(n = 1,081) 
P-value 
Age (years) 
18–64 1,319 (38.1) 449 (41.5) 
0.150 
65–74 1,161 (33.5) 376 (34.8) 
75–84 813 (23.5) 217 (20.1) 
≥ 85 173 (5.0) 39 (3.6) 
Sex ratio M : F 2,059 : 1407 633 : 448 0.636 
Index of 
Multiple 
Deprivation 
1 (least deprived) 450 (13.10) 224 (20.7) 
<0.001 
2 657 (19.1) 225 (20.8) 
3 729 (21.2) 219 (20.3) 
4 792 (23.1) 210 (19.4) 
5 (most deprived) 806 (23.5) 202 (18.7) 
Missing 32 1 
Admission 
Elective 2,227 (66.0) 702 (67.2) 
0.474 Emergency 1,145 (34.0) 342 (32.8) 
Missing 94 37 
Urgency of 
CRC resection 
Elective/scheduled 2,256 (66.0) 721 (68.4) 
0.152 Urgent/emergency 1,161 (34.0) 333 (31.6) 
Missing 49 27 
Charlson 
comorbidity 
score 
0 2,400 (70.6) 760 (72.0) 
0.336 
1 776 (22.8) 220 (20.8) 
≥ 2 222 (6.5) 76 (7.2) 
Missing 68 25 
ASA fitness 
grade 
I 404 (13.3) 100 (10.1) 
0.026 
II 1,603 (52.6) 524 (53.0) 
III 871 (28.6) 316 (32.0) 
IV or V 168 (5.5) 49 (5.0) 
Missing 420 92 
Cancer site 
Ascending colon 388 (11.2) 110 (10.2) 
0.212 
Caecum 665 (19.2) 191 (17.7) 
Rectosigmoid 273 (7.9) 75 (6.9) 
Descending colon 126 (3.6) 37 (3.4) 
Hepatic flexure 156 (4.5) 52 (4.8) 
Rectum 551 (15.9) 194 (17.9) 
Sigmoid colon 938 (27.1) 326 (30.2) 
Splenic flexure 112 (3.2) 26 (2.4) 
Transverse colon 257 (7.4) 70 (6.5) 
T-stage 
T0 22 (0.7) 7 (0.7) 
0.727 
T1 32 (1.0) 6 (0.6) 
T2 156 (4.7) 50 (4.8) 
T3 1,577 (47.4) 507 (48.9) 
T4 1,540 (46.3) 466 (45.0) 
Missing 139 45 
N-stage 
N0 819 (24.6) 249 (24.1) 
0.889 
N1 1,136 (34.1) 361 (34.9) 
N2 1,374 (41.3) 425 (41.1) 
Missing 137 46 
 
 
 Liver resection 
Liver resection was performed more frequently in hubs: 545 of 1,081 patients (50.4%) who 
were diagnosed in the 23 hospital trusts with a specialist hepatobiliary surgery team had a liver 
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resection, compared with 1,411 of 3,466 (40.7%) diagnosed elsewhere (crude OR 1.48, 95% 
confidence interval (CI) 1.29 to 1.70). With adjustment for differences between the patient 
groups, those diagnosed at hubs remained more likely to undergo liver resection (adjusted 
odds ratio 1.52, 95% CI 1.20 to 1.91). 
 
A difference in liver resection rates between hubs and spokes was seen across most regions of 
the country. Comparison of liver resection rates in hubs with the average rates in spokes that 
referred to them, indicated that 17 of 23 hubs had higher liver resection rates than their 
respective spokes’ average. 
 
 Survival 
Median follow-up for surviving patients was 41.9 months. Survival was better in hubs (median 
30.6 months compared with 25.3 months in spokes; P<0.001) (Figure 3.2), and remained so 
when differences in patient and tumour characteristics were taken into account (adjusted 
hazard ratio (HR) 0.83, 95% CI 0.75 to 0.91). 
 
There was no difference in median survival between patients diagnosed at hubs and spokes 
when the analysis was restricted to only patients who had liver resection (P= 0.620) and only 
those who did not undergo liver resection (P=0.749). 
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Figure 3.2 Kaplan-Meier curves of survival after CRC diagnosis in patients with synchronous 
liver metastases, according to diagnosis at hub or spoke: A all patients, B patients who had 
liver resection and C patients who did not undergo liver resection. A P<0.001, B P=0.620, C 
P=0.749 (log rank test) 
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3.4 Discussion 
 Summary of findings 
In this national cohort of patients with CRC and liver metastases, those who were diagnosed 
at hubs were more likely to undergo liver resection and have better survival than patients 
diagnosed at spokes, after adjusting for patient and tumour characteristics. This discrepancy 
was present in over three-quarters of hubs and spokes in the country. As there was no 
difference between hubs and spokes in the survival of patients in this cohort who underwent 
liver resection and in those who did not, the improved overall survival for patients diagnosed 
at hubs was likely to be due to the increased rate of liver resection. 
 
 Study limitations 
13% of CRC patients from this study period were found to have a HES code recorded for liver 
metastases at the time of diagnosis, whereas others have found corresponding percentages 
ranging from 14% to 20% (Leporrier et al., 2006, Manfredi et al., 2006). Despite it appearing 
likely that metastases are under-recorded in HES data, almost all patients who had a liver 
resection had a recorded liver metastases code thus potentially creating a source of bias. 
Although this will result in an underestimate of the risk ratio (the ratio of the observed 
percentages of patients who had a liver resection following diagnosis in a hub (50%) and the 
corresponding percentage in spokes (41%), it will not affect the odds ratio presented. As 
explained in the Section 3.2.2, this odds ratio is a valid measure of the relative risk if patients 
with liver metastasis recorded in HES are representative, and if the likelihood that a liver 
metastasis is recorded in HES is the same in hub and spoke hospitals. If liver metastases were 
more likely to be recorded in the hubs than in the spokes (which is the most probable situation 
if the assumption is not met), this would underestimate the odds ratio and only further 
strengthen the conclusion that liver resection rates were higher in hospital trusts with specialist 
hepatobiliary services. 
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A further limitation of HES data is that it does not contain information regarding the volume 
and distribution of liver metastases. It is therefore not possible to know which of the patients 
who did not undergo a liver resection had potentially operable disease. It is, however, unlikely 
that the burden of liver metastases in patients would vary substantially between hospital trusts 
after risk-adjustment for IMD quintile. As chemotherapy is often administered on an out-
patient basis, reliable information regarding its use is also not available in HES data and 
therefore unknown for this patient cohort.  
 
The patients diagnosed in spoke hospitals were more socially deprived than patients diagnosed 
in hub hospitals. This may reflect the demography of the areas served by the spoke hospitals, 
or may indicate that less deprived patients are more likely to travel to a specialist hub unit. 
The comparisons of the liver resection rates and survival across spokes and hubs were risk 
adjusted for deprivation and other factors, so that this difference in deprivation did not bias 
the results.  
 
 Comparison to other studies of service centralisation 
These results mirror those of a study of 95,818 patients diagnosed with lung cancer in English 
NHS Trusts between 2008 and 2012 (Khakwani et al., 2015). The study demonstrated 
differences in access to surgery according to hospital of diagnosis. 17% of patients who were 
first seen in a ‘surgical centre’ underwent resectional surgery compared to 12% of patients 
who were first seen in a ‘non-surgical centre’. The present study of CRC patients with liver 
metastases demonstrates not only differences in access to liver surgery between patients 
diagnosed in hospital trusts with and without a specialist team but also significant differences 
in patient survival.  
 
The results of the present study, conducted on a national level, confirm the findings of previous 
single-centre or single-region studies demonstrating the need to improve referral rates from 
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spoke hospital trusts to hub hospital trusts with specialist hepatobiliary services on-site 
(Lordan et al., 2009, Jones et al., 2012, Young et al., 2013, Thillai et al., 2016). A national 
study of 27,990 CRC patients treated in Sweden between 2007 and 2011 also demonstrated 
higher liver resection rates in patients treated at hub hospitals with on-site hepatobiliary 
services (Norén et al., 2016). However, they did not find improved patient survival in hub 
hospitals compared to those diagnosed at spoke hospitals.  
 
 Conclusions 
The present study, restricted to CRC patients with synchronous liver-limited metastasis at 
diagnosis, demonstrates that variation in the rate of liver resection in England is still present. 
Furthermore, it indicates that hepatobiliary service centralisation, with the existence of a hub-
and-spoke arrangement, may be part of the explanation. Any further centralisation of cancer 
services should take into consideration the impact on equity of access to services. These 
findings suggest that access to specialist hepatobiliary services is inadequate for patients 
diagnosed in spoke hospitals trusts. 
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4. Chapter 4: Effect of socioeconomic status on selection 
for liver resection and survival in patients with 
synchronous colorectal cancer liver metastases 
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4.1 Introduction 
Reducing health inequities has been a longstanding priority of the UK government with more 
than 20 billion pounds spent between 1997 and 2007 on a dedicated strategy to target this 
(Mackenbach, 2011). Moving forwards, the Cancer Research Taskforce for England, which is 
working to develop a cancer survival improvement strategy on behalf of NHS England, has 
recommended that tackling of variation is a top priority over the next five years (National 
Cancer Transformation Board, 2016). The relationship between cancer and socioeconomic 
status has been studied extensively, with agreement that social factors strongly influence 
treatment and survival (Jeffreys et al., 2006, Aarts et al., 2010, Eloranta et al., 2010, Ellis et 
al., 2012, Møller et al., 2012, Dejardin et al., 2014). 
 
Relatively little is known of the impact of socioeconomic status on liver resection rates and 
no previous study has examined socioeconomic status as an independent predictor of mortality 
in patients with metastatic CRC. The aim of the study detailed in this Chapter was to describe 
how socioeconomic deprivation is associated with rates of liver resection and survival in 
patients with synchronous CRC liver metastases in England. This study also examines if any 
survival inequalities related to deprivation within this cohort are explained by differences in 
rates of liver resection. 
 
4.2 Methods 
 Study population 
Data from patients included in the NBOCA were linked to Hospital Episode Statistics (HES) 
data. In this study all patients recorded in the NBOCA dataset with a diagnosis of primary 
CRC from 1st January 2011 to 31st December 2015 with synchronous liver-limited metastases 
were included. 
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 Data items and definitions 
 Secondary metastases 
HES records were used to identify the presence of synchronous liver and extra-hepatic 
metastases as detailed in Chapter 3.2.2.1. Patients identified with extra-hepatic metastases 
were excluded from the analysis.  
 
Of all patients identified in the NBOCA to have metastatic disease at diagnosis, 50.3% (12,301 
out of 24,476) had a metastasis code recorded in HES data. This was higher than found in the 
analysis in Chapter 3 (41.1%), due to the use of a more recent patient cohort. Given the under-
recording of metastases in HES data, the use of odds ratios are a valid measure of the impact 
of socioeconomic status on liver resection rates in this cohort as long as: i) the data 
completeness of recording of metastases in HES is independent of socioeconomic status, and 
ii) patients recorded as having metastases in HES are representative of all patients with 
metastases. This was validated in the same ways as previously described in Chapter 3 and 
detailed below.  
 
4.2.2.1.1 Completeness of recording of metastases in according to deprivation 
The first validation step was to compare the completeness of recording of metastases in HES 
between the most deprived quintile and the least deprived quintile. In the most deprived 
quintile 51.4% (2,148 out of 4,179) of patients recorded as having metastatic disease in 
NBOCA data had a metastasis code recorded in HES, compared to 48.4% (2,513 out of 5,196) 
in the least deprived quintile.  
 
4.2.2.1.2 Characteristics of patients with metastases in NBOCA and HES data 
The second step was to compare the characteristics of patients with metastases, irrespective 
of their site, identified in the NBOCA database and corresponding patients in the HES 
database. As shown in Table 3.2, there was no difference in the distribution of IMD quintile 
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between patients recorded as having metastatic disease in NBOCA data and patients recorded 
as having metastatic disease in HES data.  
 
 Procedural codes 
All HES records in the year following the date of CRC diagnosis were searched for codes 
indicating a liver resection, as detailed in Chapter 3.3.4.   
 
 Study endpoints 
The primary endpoints were undergoing liver resection within one year of date of CRC 
diagnosis and three-year all cause survival from date of CRC diagnosis. These two outcomes, 
as well as demographic and tumour characteristics, were compared between IMD quintiles to 
highlight any differences between groups of increasing deprivation.  
 
As a sensitivity analysis, patients who died within 90-days of CRC resection were excluded 
from the analysis of likelihood of undergoing liver resection.  
 
 Statistical analysis 
The statistical significance of differences in patient characteristics according to IMD quintile 
were assessed using the χ2 test.  Multivariable random-effects logistic regression was used to 
estimate the odds ratio of liver resection by IMD quintile, firstly adjusted for the following 
risk factors: gender, age, Charlson comorbidity score, primary cancer site within the colon and 
rectum, admission type, T-stage and N-stage. A further model was fitted additionally adjusting 
for the presence of hepatobiliary surgical services on-site. A random intercept was modelled 
for each hospital trust to reflect the possible clustering of results within trusts. Missing values 
for the risk factors were imputed with multiple imputation using chained equations. Survival 
curves were estimated using the Kaplan–Meier method. Difference in 3-year survival after 
diagnosis between IMD quintiles was tested with the log rank test. Comparisons were made 
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adjusting for other risk factors using a multivariable Cox proportional hazards model with a 
shared frailty factor, again to reflect the possible clustering of results within hospitals.  
 
4.3 Results 
 Study population 
There were 18,899 patients out of the 130,554 patients diagnosed with primary CRC from 1st 
January 2011 to 31st December 2015 with synchronous liver metastases (14.5%) identified 
from NBOCA linked HES data. Of these, 5,243 patients were excluded due to recorded extra-
hepatic metastases, resulting in a final cohort of 13,656 CRC patients with synchronous liver-
limited metastases. This group formed the study population, and the demographic data divided 
into quintiles of deprivation, is summarised in Table 4.1. Patients in the lower socioeconomic 
quintiles tended to be younger, have more comorbidities, have rectal cancer, and more 
commonly had an emergency presentation leading to CRC diagnosis.  
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Table 4.1 Characteristics of patients according to IMD quintile 
  
  
  
  
IMD quintile  
1 (most 
deprived) 
N=2,233 
(%) 
2  
N=2,628 
(%) 
3 
 N=2,886 
(%) 
4 
N=3,009 
(%) 
5 (least 
deprived) 
N=2,890 
(%) 
P-value 
Sex 
Male 1,398 (62.6) 1,561 (59.4) 1,764 (61.1) 1,810 (60.2) 1,711 (59.2) 
0.089 
Female 835 (37.4) 1,067 (40.6) 1,222 (38.9) 1,199 (39.9) 1,179 (40.8) 
Age 
<65 830 (37.2) 889 (33.8) 1,004 (34.8) 888 (29.5) 934 (32.3) 
<0.001 65-74 671 (30.1) 752 (28.6) 846 (29.3) 915 (30.4) 829 (28.7) 
>74 732 (32.8) 987 (37.6) 1,036 (35.9) 1,206 (40.1) 1,127 (39.0) 
Site 
Right 762 (34.1) 871 (33.1) 1,015 (35.2) 1,130 (37.6) 1,074 (37.2) 
0.002 Left 886 (39.7) 1,100 (41.9) 1,196 (41.4) 1,190 (40.0) 1,110 (38.4) 
Rectum 585 (26.2) 657 (25.0) 675 (23.4) 689 (22.9) 706 (24.4) 
Charlson 
comorbidity 
score 
0 1,130 (55.4) 1,364 (56.5) 1,695 (63.5) 1,777 (64.1) 1,711 (65.3) 
<0.001 
1 604 (29.6) 743 (30.8) 671 (25.1) 717 (25.9) 676 (25.8) 
2 306 (15.0) 308 (12.8) 305 (11.4) 279 (10.1) 233 (8.9) 
Missing 193 213 215 236 270 
T-stage 
0-2 104 (6.1) 133 (6.6) 135 (6.0) 161 (6.9) 186 (7.9) 
0.170 
3 880 (51.7) 1,043 (51.7) 1,164 (51.9) 1,203 (51.5) 1,262 (53.8) 
4 719 (42.2) 842 (41.7) 943 (42.1) 970 (41.6) 898 (38.3) 
Missing 530 610 644 675 544 
N-stage 
0 340 (19.8) 461 (22.7) 473 (20.9) 501 (21.4) 502 (21.4) 
0.495 
1 710 (41.4) 820 (40.3) 887 (39.1) 936 (39.9) 943 (40.1) 
2 665 (38.8) 754 (37.1) 906 (40.0) 908 (38.7) 905 (38.5) 
Missing 518 593 620 664 540 
Emergency 
admission 
No 1,257 (61.7) 1,539 (63.8) 1,752 (65.5) 1,835 (66.2) 1,880 (71.3) 
<0.001 Yes 782 (38.4) 875 (36.3) 921 (34.5) 936 (33.8) 757 (28.7) 
Missing 194 214 213 238 253 
Hepatobiliary 
services on-site 
No 593 (26.6) 482 (18.3) 507 (17.6) 506 (16.8) 590 (20.4) 
<0.001 
Yes 1,640 (73.4) 2,146 (81.7) 2,379 (82.4) 2,503 (83.2) 2,300 (79.6) 
Liver resection 
No 1,937 (86.7) 2,217 (84.4) 2,411 (83.5) 2,517 (83.7) 2,351 (81.4) 
<0.001 
Yes 296 (13.3) 411 (15.6) 475 (16.5) 492 (16.4) 539 (18.7) 
 
 Liver resection 
Overall 2,213 out of 13,656 patients with synchronous liver-limited CRC metastases had a 
liver resection (16.2%). Liver resection was performed more frequently in patients in the least 
deprived IMD quintile when compared to those in the most deprived quintile (18.7% vs. 
13.3%, p<0.001).  
 
With adjustment for differences in patient and institutional characteristics, patients in the least 
deprived quintile remained more likely to undergo liver resection than patients in the most 
deprived quintile, with a trend of increasing chance of liver resection with decreased quintile 
of deprivation (least deprived vs. most deprived IMD quintile OR 1.42, 95% CI 1.18 to 1.70) 
(Table 4.2). 
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Table 4.2 Odds ratio of undergoing liver resection adjusted for patient, tumour and hospital 
characteristics 
  
  
Odds ratio 
(95% CI) 
P-
value 
Odds ratio 
(95% CI) 
adjusted for 
patient and 
tumour 
characteristics 
P-
value 
Odds ratio (95% 
CI) adjusted for 
patient, tumour 
and hospital 
characteristics 
P-
value 
IMD quintile 
1 (most deprived) 1 
<0.001 
1 
0.005 
1 
0.003 
2 1.21 (1.02-1.42) 1.22 (1.02-1.46) 1.24 (1.03 to 1.48) 
3 1.29 (1.10-1.52) 1.30 (1.09-1.56) 1.32 (1.1 to 1.58) 
4 1.30 (1.11-1.53) 1.29 (1.08-1.54) 1.30 (1.09 to 1.56) 
5 (least deprived) 1.47 (1.25-1.73) 1.41 (1.18-1.68) 1.42 (1.18 to 1.70) 
Gender 
Male - - 1 
0.18 
1 
0.187 
Female - - 1.07 (0.97-1.20) 1.07 (0.97 to 1.20) 
Age 
<65 - - 1 
<0.001 
1 
<0.001 
65-74 - - 0.66 (0.59-0.74) 0.66 (0.59 to 0.74) 
75-84 - - 0.32 (0.27-0.36) 0.31 (0.27 to 0.36) 
>=85 - - 0.07 (0.05-0.11) 0.07 (0.05 to 0.11) 
Emergency 
admission 
No - - 1 
<0.001 
1 
<0.001 
Yes - - 0.44 (0.38-0.50) 0.44 (0.38 to 0.5) 
Charlson 
comorbidity 
score 
0 - - 1 
0.469 
1 
0.454 1 - - 0.99 (0.88-1.12) 0.99 (0.87 to 1.12) 
2 - - 0.89 (0.73-1.07) 0.88 (0.73 to 1.07) 
 Cancer site 
Right - - 1 
<0.001 
1 
<0.001 Left - - 1.21 (1.08-1.38) 1.22 (1.07 to 1.38) 
Rectum - - 0.96 (0.83-1.10) 0.96 (0.83 to 1.1) 
T-stage 
0-2 - - 1 
<0.001 
1 
<0.001 3 - - 1.11 (0.91-1.36) 1.1 (0.9 to 1.35) 
4 - - 0.84 (0.68-1.04) 0.84 (0.68 to 1.04) 
N-stage 
0 - - 1 
<0.001 
1 
<0.001 1 - - 0.62 (0.54-0.70) 0.62 (0.54 to 0.7) 
2 - - 0.41 (0.36-0.48) 0.42 (0.36 to 0.48) 
Hepatobiliary 
services on-site 
No - - - 
- 
1 
0.003 
Yes - - - 1.38 (1.12 to 1.7) 
 
 Sensitivity analysis 
When patients who died within 90-days of CRC resection (N=795) were excluded from the 
analysis, patients in the least deprived quintile remained more likely to undergo liver resection 
than patients in the most deprived quintile (Table 4.3).  
 
Table 4.3 Odds ratio of undergoing liver resection with the exclusion of patients who died 
within 90-days of major CRC resection 
 IMD quintile Odds ratio (95% CI) P-value 
1 (most deprived) 1 
<0.001 
2 1.18 (1.00-1.39) 
3 1.29 (1.10-1.52) 
4 1.27 (1.08-1.50) 
5 (least deprived) 1.46 (1.24-1.72) 
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 Survival 
Median follow up was 45 months. There was a significant difference in all-patient survival, 
regardless of receipt of liver resection, according to IMD quintile. Three-year survival for 
patients in the most deprived quintile was 17.4% compared to 22.3% for patients in the least 
deprived quintile (p<0.001) (Table 4.4). This remained so when differences in patient and 
institutional characteristics were taken into account (least deprived vs. most deprived IMD 
quintile hazard ratio (HR) 1.20, 95% C.I. 1.11 to 1.30) (Table 4). Adding liver resection as a 
covariate in the multivariable model attenuated this effect (least deprived vs. most deprived 
IMD quintile HR 1.15, 95% C.I. 1.06 to 1.24).  
 
When survival analysis was restricted to patients undergoing a liver resection, there was no 
significant difference in unadjusted (Table 4.4) or adjusted (Table 4.5) survival according to 
IMD quintile. In patients not undergoing liver resection, patients in the least deprived group 
had better 3-year survival then those in the most deprived group (7.3% vs. 9.3%; P<0.001). 
This difference remained after adjusting for differences in patient characteristics.  
 
Table 4.4 Unadjusted 3-year survival from date of colorectal diagnosis according to IMD 
quintile for all patients (P<0.001) and restricted to patients undergoing liver resection 
(P=0.742) and those not undergoing liver resection (P<0.001) 
IMD quintile 
 
All patients 
Patients undergoing liver 
resection 
Patients not undergoing 
liver resection 
3-year survival % (95% CI) 
1 (most deprived) 17.4 (15.7-19.1) 65.5 (59.7-70.1) 7.3 (6.0-8.8) 
2 19.0 (17.4-20.7) 71.3 (66.7-75.4) 6.8 (5.6-8.0) 
3 19.0 (17.4-20.5) 67.7 (63.2-71.8) 7.2 (6.1-8.4) 
4 19.5 (18.0-21.1) 69.0 (54.6-72.9) 7.8 (6.5-8.9) 
5 (least deprived) 22.3 (20.7-24.0) 69.3 (65.1-73.2) 9.3 (8.0-10.7) 
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Table 4.5 Hazard ratio of 3-year survival after CRC diagnosis adjusted for demographic, 
tumour and intuitional factors, for all patients and restricted to patients undergoing liver 
resection and not undergoing liver resection 
  
  
All patients 
P-
value 
Liver resection 
patients 
P-
value 
No liver resection 
patients 
P-
value 
IMD quintile 
1 (most 
deprived) 
1 
<0.001 
1 
0.568 
1 
<0.001 
2 1.05 (0.97 to 1.14) 1.02 (0.79 to 1.32) 0.98 (0.91 to 1.06) 
3 1.08 (0.99 to 1.15) 0.89 (0.7 to 1.14) 1.02 (0.93 to 1.1) 
4 1.14 (1.05 to 1.23) 0.93 (0.74 to 1.19) 1.1 (1.01 to 1.19) 
5 (least 
deprived) 
1.20 (1.11 to 1.30) 0.97 (0.76 to 1.23) 1.16 (1.08 to 1.27) 
Gender 
Male 1 
0.220 
1 
0.572 
1 
0.142 
Female 0.97 (0.93 to 1.02) 0.93 (0.8 to 1.06) 0.96 (0.92 to 1.01) 
Age 
<65 1 
<0.001 
1 
<0.001 
1 
<0.001 
65-74 0.78 (0.74 to 0.82) 0.89 (0.76 to 1.05) 0.85 (0.8 to 0.91) 
75-84 0.5 (0.47 to 0.53) 0.65 (0.53 to 0.79) 0.62 (0.58 to 0.66) 
>=85 0.31 (0.47 to 0.53) 0.3 (0.17 to 0.52) 0.45 (0.49 to 0.49) 
Emergency 
admission 
No 1 
<0.001 
1 
<0.001 
1 
<0.001 
Yes 0.56 (0.53 to 0.59) 0.69 (0.57 to 0.83) 0.63 (0.6 to 0.66) 
Charlson 
comorbidity 
score 
0 1 
<0.001 
1 
0.484 
1 
<0.001 1 0.95 (0.9 to 1) 0.93 (0.78 to 1.1) 0.93 (0.88 to 0.99) 
2 0.85 (0.79 to 0.91) 0.79 (0.61 to 1.04) 0.85 (0.79 to 0.92) 
Cancer site 
Right 1 
<0.001 
1 
0.003 
1 
<0.001 Left 1.22 (1.16 to 1.28) 1.32 (1.11 to 1.56) 1.15 (1.09 to 1.22) 
Rectum 1.10 (1.04 to 1.18) 0.99 (0.81 to 1.2) 1.14 (1.06 to 1.2) 
T-stage 
0-2 1 
<0.001 
1 
0.022 
1 
0.012 3 1.05 (0.95 to 1.16) 0.71 (0.51 to 0.98) 1.06 (0.96 to 1.18) 
4 0.91 (0.83 to 1.01) 0.57 (0.41 to 0.81) 0.99 (0.88 to 1.1) 
N-stage 
0 1 
<0.001 
1 
<0.001 
1 
<0.001 1 0.69 (0.65 to 0.74) 0.64 (0.53 to 0.78) 0.79 (0.74 to 0.85) 
2 0.56 (0.52 to 0.6) 0.49 (0.4 to 0.6) 0.69 (0.65 to 0.75) 
Hepatobiliary 
services on-site 
No 1 
0.040 
1 
0.411 
1 
0.215 
Yes 1.10 (1.00 to 1.20) 0.92 (0.77 to 1.09) 1.06 (0.97 to 1.15) 
 
 
4.4 Discussion 
 Summary of findings 
In this study it is demonstrated that socioeconomic deprivation is associated with lower rates 
of liver resection and poorer 3-year survival amongst CRC patients with synchronous liver-
limited metastases. This was irrespective of differences in demographic, tumour related and 
institutional factors. Socioeconomic deprivation was no longer associated with poorer 
outcomes when only patients undergoing liver resection were considered. 
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 Patient survival according to socioeconomic status 
The findings in this study show that socioeconomic differences in survival in patients with 
CRC liver metastases can be explained in part by inequalities in rates of liver resection. These 
findings, which mirror those reported in non-metastatic CRC (Nur et al., 2008), ovarian cancer 
(Abdel-Rahman et al., 2014) and lung cancer (Forrest et al., 2015) suggest equal treatment 
yields equal outcome, regardless of deprivation. For patients who did not undergo liver 
resection, socioeconomic deprivation continued to be associated with poorer survival after 
controlling for differences in patient and tumour characteristics. For this palliative cohort 
survival outcomes may relate to utilisation of chemotherapy (Lemmens et al., 2005, McGory 
et al., 2006, Aarts et al., 2010, Paterson et al., 2014), or enrolment in clinical trials (Sharrocks 
et al., 2014), both reportedly lower in more deprived patients. Data regarding these variables 
were not available and therefore not included in the multivariable model.  
 
 Explanation for disparity in liver resection rates 
There are a number of obstacles to overcome for a patient with CRC liver metastases to 
undergo a liver resection. In patients undergoing the traditional bowel-first approach for 
resection of liver metastases, they must survive the resection of their primary tumour, they 
must recover sufficiently from this operation to potentially undergo further surgery, they must 
be referred to a hepatobiliary multidisciplinary team (MDT) for consideration of surgical 
resection and finally their metastases must be deemed operable. A patient’s socioeconomic 
status may influence how they negotiate this complex pathway. Within a publicly-funded 
health system it is an uncomfortable notion that socioeconomic status can influence treatment, 
and thus survival, for patients with CRC liver metastases. There are several mechanisms to 
explain why a patient’s socioeconomic status may influence rates of liver resection, including 
stage of disease at presentation, presence of comorbidities, access to local services, clinical 
decision making and health-seeking behaviour.  
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 Patient factors 
Although clinical and pathological characteristics in CRC patients are associated with both 
socioeconomic status and likelihood of liver resection, controlling for such differences did not 
account for the differences in liver resection rates. The presence of comorbidity, more 
prevalent in patients in lower socioeconomic groups in our cohort, can impact upon a patient’s 
fitness for liver resection. After adjusting for differences in both ASA class and Charlson 
comorbidity score, the association between less deprivation and increased likelihood of liver 
resection remained. Patients with higher levels of deprivation are also more likely to suffer 
post-operative complications and mortality related to primary CRC resection that render them 
unfit for liver resection (Møller et al., 2012). However, as shown in the sensitivity analysis, 
when patients who died within 90 days of major CRC resection were excluded, the difference 
in rates of liver resection remained. More advanced disease stage at diagnosis is cited as one 
of the main causes of disparity in cancer related treatment and outcomes according to social 
status (Mitry and Rachet, 2006). However, this was not a factor in this study cohort, where 
there was not a statistically significant difference in stage according to level of deprivation. 
 
 Access to specialist care 
Differences in liver resection rates according to socioeconomic status in this cohort may also 
relate to access to specialist care. This is particularly pertinent when considering services, such 
as hepatobiliary surgery, that exist in a centralised system. There is now evidence to suggest 
that the presence of specialist hepatobiliary services on-site at the hospital of treatment 
increases liver resection rates amongst patients with CRC liver metastases (Norén et al., 2016). 
Deprived patients were more commonly diagnosed at a hospital trust with no hepatobiliary 
services on site. Ability to travel for healthcare may be lower amongst more deprived patients 
and therefore the necessity to travel to access hepatobiliary services may preferentially 
disadvantage those of a lower socioeconomic status (Crawford et al., 2009). However, 
90 
 
controlling for the on-site presence of specialist services in the study cohort did not reduce the 
effect of deprivation on likelihood of liver resection.  
 
 Clinical decision making 
A patient’s socioeconomic status may also modify the behaviour of the treating clinicians and 
cause inequalities in access to specialist care. There is an element of discretion by clinician 
practitioners in many stages of the patient pathway prior to surgery for CRC liver metastases. 
Although few surgeons would admit to altering their management of patients due to 
deprivation, clinicians may consider more deprived patients to have a lack of social support 
(Cavalli-Björkman et al., 2012), or be less able to travel to specialist services (Crawford et al., 
2009) and therefore be less likely to refer these patients to a hepatobiliary MDT for 
consideration of liver resection. 
 
 Health-seeking behaviour 
Finally, a patient’s health seeking behaviour may partly explain this finding. Low health 
literacy is associated with less use of healthcare services and poorer health outcomes 
(Berkman et al., 2011). As a result, more deprived patients may be less likely to actively seek 
referral to a hepatobiliary unit than more affluent patients (Wiggans et al., 2015).  
 
 Study limitations 
HES data does not contain information regarding the distribution or size of liver metastases, 
an important factor in determining the operability of liver metastases. It was therefore not 
possible to ascertain whether liver resection rates reflected clinically appropriate decision 
making or inequity. In addition, around 20% of T-stage and N-stage data is missing from 
NBOCA data. Importantly, there was no difference in proportion of missing data according to 
IMD quintile. Missing values were imputed using multiple imputation to minimise the bias 
associated with excluding patients with missing values.  As chemotherapy is usually 
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administered on an outpatient basis, the HES dataset does not contain details regarding its 
provision. Adjuvant chemotherapy is less frequently used in more deprived patients and 
differences in its use may account in part for the reported variation in rates of liver resection 
and survival inequality in patients who did not undergo liver resection (Lemmens et al., 2005, 
McGory et al., 2006, Aarts et al., 2010, Paterson et al., 2014).  A further limitation of HES is 
the under-reporting of liver metastases. Some 15% of patients with CRC were found to have 
a HES code recorded for liver metastases at the time of diagnosis, whereas other population-
based studies have reported corresponding percentages of up to 20%. However, as explained 
in the methods section, the odds ratio can be used as a valid measure of the impact of 
socioeconomic status on resection rates as socioeconomic status does not affect the recording 
of metastases in HES.  
 
 Conclusions 
In conclusion, this study has demonstrated that more deprived CRC patients with synchronous 
liver metastases have worse survival than more affluent patients in England. Lower rates of 
liver resection in poorer CRC patients is likely to be a major contributory factor. As both the 
patient and tumour characteristics and institutional variables included in the multivariable 
model in this study did not account for the differences in liver resection rates according to 
socioeconomic status, this suggests that is it is differences in the availability of services or in 
decision making by socioeconomic status that account for the differences observed. Targeted 
efforts should be made by healthcare providers to ensure equitable access to specialist care for 
this cohort.  
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5. Chapter 5: The timing of liver resection in relation to 
colorectal cancer resection: current practice and 
survival  
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5.1 Introduction 
The traditional approach to managing patients with CRC and synchronous liver metastases 
has been to resect the primary tumour, and then in the absence of disease progression, perform 
a liver resection. In recent years, improvements in surgical, radiological and anaesthetic 
techniques have resulted in a challenge to this approach, with the feasibility of both a liver-
first approach and a simultaneous resection having been demonstrated.  
 
Despite the fact that around 20% of patients with CRC are reported to have synchronous liver 
metastases at the time of initial diagnosis, selection criteria for each modality are not well 
defined. There is an absence of randomised evidence comparing the three strategies and the 
literature investigating both the liver-first and simultaneous approach is derived largely from 
high-volume single centres (Brouquet et al., 2010) and multi-institutional case series. (Mayo 
et al., 2013). Several studies have failed to include, or only have very small numbers in their 
liver first or simultaneous groups (Reddy et al., 2007, Mayo et al., 2013, Silberhumer et al., 
2016, Welsh et al., 2016), or they group the liver-first and bowel-first patients together as a 
“staged” cohort (Lykoudis et al., 2014). The largest previous population based study of  the 
characteristics and outcomes of patients with synchronous CRC and liver metastases included 
patients diagnosed over a twenty year period (1982-2011) with only 28 patients in the liver-
first group (Mayo et al., 2013).  
 
It is not known how these approaches are being utilised in England, how patients are being 
selected for each strategy and whether comparable outcomes are being achieved. The aim of 
the study presented in this chapter was to describe trends in surgical strategy in the 
management of patients with synchronous liver-limited CRC over time and factors influencing 
patient selection. The study also sought to compare long-term survival in patients undergoing 
either the liver-first or simultaneous approach compared to the bowel-first strategy.  
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5.2 Methods 
 Study population 
All patients registered in the NBOCA dataset diagnosed with primary CRC between 1st 
January 2010 and 31st December 2015 who underwent an elective major CRC resection and 
liver resection for synchronous liver-limited metastases in English NHS hospitals were 
considered for inclusion in this study.   
 
 Data items and definitions 
 Liver resection 
All HES records including admissions up to 1st January 2017 were searched for codes 
indicating a liver resection. Liver resection was stratified into ‘major’ and ‘minor’ according 
to the definition suggested by the Second International Consensus Conference on laparoscopic 
liver resection in which a minor resection is one in which 2 or fewer Couinaud segments are 
removed and a major resection is one in which 3 or more segments are removed 
(Wakabayashi, 2014). The extent of liver resection and its corresponding OPCS-4 description 
and code is shown in Table 5.1.   
 
Table 5.1 Liver resection type according to OPCS-4 code and description 
 
 
 
4-digit code Description Liver resection type 
J021 Right hemihepatectomy Major 
J022 Left hemihepatectomy Major 
J023 Resection of segment of liver Minor 
J024 Wedge excision of liver Minor 
J026 Extended right hemihepatectomy Major 
J027 Extended left hemihepatectomy Major 
J028 Other specified partial excision of liver Minor 
J029 Unspecified partial excision of liver Minor 
J031 Excision of lesion of liver NEC Minor 
J035 Excision of multiple lesions of liver Minor 
J038 Other specified extirpation of lesion of liver Minor 
J039 Unspecified extirpation of lesion of liver Minor 
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Patients were considered to have a simultaneous resection when a liver resection code was 
recorded on the day of CRC resection, a liver-first approach if a liver resection code was 
recorded within the year preceding resection of CRC, or a bowel-first approach if a liver 
resection code was recorded within the year following CRC resection. 
 
 Additional liver procedures 
HES records were searched for evidence of ablative procedures performed on the same day as 
liver resection and portal vein embolisation performed in the 6 months preceding liver 
resection. The OPCS-4 codes used are displayed in Table 5.2.  
 
Table 5.2 OPCS-4 codes used to indicate thermal ablation or portal vein embolisation 
 
 Secondary metastases 
As described in Chapter 3, patients were considered to have liver-limited metastases if an 
ICD-10 code for liver metastases was recorded in HES, with no further code for secondary 
metastases also recorded, in the period of 1 year before and up 30 days following CRC 
diagnosis.  
 
 Hepatobiliary services 
An electronic survey completed by the CRC lead for each hospital trust as described in Chapter 
3 was used to collect data regarding the presence of an on-site hepatobiliary MDT. 
 
 
4-digit code Description 
J033 Thermal ablation of single lesion of liver 
J034 Thermal ablation of multiple lesions of liver 
J083 Endoscopic microwave ablation of lesion of liver using laparoscope 
J102 Percutaneous transluminal embolisation of portal vein 
J124 Percutaneous radiofrequency ablation of lesion of liver 
J125 Percutaneous thermal ablation of lesion of liver NEC 
J126 Percutaneous chemical ablation of lesion of liver 
J127 Percutaneous microwave ablation of lesion of liver 
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 Statistical analysis and outcome measures 
As discussed in Section 2.2.4 a landmark analysis was undertaken to compare survival. 
Individuals who survived a minimum of 1 year after diagnosis or, if the second procedure had 
not been undertaken in the year following diagnosis, more than 90-days from their second 
procedure, were included in the landmark analysis. Patients who died during the exposure 
window were excluded from analysis. Median follow-up from the date of diagnosis was 50 
months. Therefore, four-year survival was presented to avoid censoring the majority of 
patients. 
 
Characteristics of the treatment groups were compared using the χ2 test. Due to differences in 
patient and disease characteristics in patients typically considered eligible for a liver-first or 
simultaneous approach, the choice of strategy for an individual patient is usually between the 
bowel-first approach and the liver-first approach, or the bowel-first approach and the 
simultaneous approach. Therefore, two separate long-term survival comparisons were made: 
bowel-first vs. liver-first and bowel-first vs. simultaneous. The potential biases to the survival 
analysis associated with differences in patient characteristics were accounted for by propensity 
score matching. Multivariable logistic regression models were used to generate the propensity 
scores. The following variables were candidates for inclusion: sex, primary CRC site within 
the colon or rectum, IMD quintile, age group, T-stage, N-stage, ASA grade (at time of CRC 
resection), major/minor liver resection. Instead of including Charlson comorbidity score, the 
individual indicator variable for each comorbidity was entered. One to one nearest neighbour 
matching without replacement was performed. The one to one ratio was chosen to minimise 
bias in accordance with recommendations (Austin, 2010) and callipers of 0.33 were used (0.2 
of the standard deviation of the logit of the propensity score) (Austin, 2011b). The distribution 
of all the model factors in the bowel-first and the simultaneous group and the bowel-first and 
the liver-first group were compared. The balance in the covariates across the treatment groups 
was considered to be achieved if the standardised differences were less than 10% (Austin and 
Mamdani, 2006).  
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The Kaplan-Meier method was used to compare long-term survival in the matched and pre-
matching cohort. Comparison of survival probabilities in the pre-matching group was 
performed with the log rank test. A Cox regression analysis was performed on the propensity 
matched cohort using a robust standard error to allow for the clustering on the pairs.  
 
5.3 Results 
 Study cohort 
A flow diagram detailing study inclusion and exclusion is shown in Figure 5.1. Of the 163,171 
patients in the NBOCA database diagnosed with CRC between 1st April 2010 and 31st March 
2015, there were 1,830 patients with synchronous liver-limited metastases who underwent an 
elective CRC and liver resection. 
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Figure 5.1 Flow chart of patient inclusion and exclusion  
 
 
 
 Patient selection and characteristics 
Of 1,830 patients who underwent both a CRC and liver resection, 270 (14.8%) patients 
underwent a liver-first approach, 259 (14.2%) a simultaneous approach and 1,301 (71.1%) a 
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bowel-first approach. The proportion of patients undergoing either a liver-first or simultaneous 
approach increased over the period, from 59 out of 249 patients (26.8%) in 2010 to 99 out of 
278 patients (35.6%) in 2015, p<0.001 (Figure 5.2).  
 
Figure 5.2 Trends in surgical strategy over study period according to year of diagnosis  
 
Baseline demographics and clinico-pathological characteristics for patients having both a liver 
resection and CRC resection according to treatment strategy are outlined in Table 5.3. Patients 
in the liver-first group were younger, had lower T-stage and N-stage and more commonly had 
a rectal cancer primary than patients in the bowel-first and simultaneous cohorts. In addition, 
a higher proportion had rectal cancer and underwent a major liver resection. Combined liver 
ablation, two-stage resection and portal vein embolisation, were used more frequently in the 
liver-first cohort. 
 
In comparison, patients in the simultaneous group tended to be older, had a right sided CRC 
primary tumour and typically underwent a minor liver resection. These patients were more 
commonly diagnosed in hospital trusts with on-site hepatobiliary services when compared to 
patients undergoing a bowel-first or liver-first approach.  
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Table 5.3 Clinico-pathological characteristics and surgical details of patients diagnosed with 
synchronous liver metastases undergoing CRC resection and liver resection (n=1,830) 
 
Liver-first 
n=270 (%) 
Simultaneous 
n=259 (%) 
Bowel-first 
n=1,301 (%) 
P-value 
Sex 
Male 173 (64.1) 141 (54.4) 814 (62.6) 
0.033 
Female 97 (35.9) 118 (45.6) 487 (37.4) 
CRC site 
Right side 21 (7.8) 134 (51.7) 356 (27.4) 
<0.001 
 
Left side 97 (35.9) 71 (27.4) 630 (48.4) 
Rectum 152 (56.3) 54 (20.9) 315 (24.2) 
IMD quintile 
1 (most deprived) 27 (10.1) 45 (17.5) 153 (11.8) 
0.110 
2 53 (19.9) 51 (19.8) 233 (18.0) 
3 56 (21.0) 52 (20.2) 269 (20.8) 
4 71 (26.6) 54 (21.0) 293 (22.6) 
5 (least deprived) 60 (22.5) 55 (21.4) 346 (26.7) 
Missing 3 0 11 
Age (years) 
<60 122 (45.2) 73 (28.2) 397 (30.5) 
<0.001 60-70 88 (32.6) 81 (31.3) 472 (36.3) 
>70 60 (22.2) 105 (40.5) 432 (33.2) 
Charlson 
comorbidity score 
0 163 (61.1) 158 (61.7) 849 (66.6) 
0.097 
1 85 (31.8) 70 (27.3) 325 (25.5) 
≥2 19 (7.1) 28 (10.9) 100 (7.9) 
Missing 3 3 27 
T-stage 
T0-2 45 (17.3) 21 (8.2) 102 (8.0) 
<0.001 
T3 173 (66.5) 146 (56.8) 790 (62.0) 
T4 42 (16.2) 90 (35.0) 382 (30.0) 
Missing 10 2 27 
N-stage 
N0 100 (38.5) 78 (30.5) 390 (30.6) 
0.042 
N1 94 (36.2) 110 (43.0) 484 (38.0) 
N2 66 (25.4) 68 (26.6) 401 (31.5) 
Missing 10 3 26 
ASA class (at CRC 
resection) 
1/2 187 (75.1) 169 (70.4) 995 (81.0) 
<0.001 3/4 62 (24.9) 71 (29.6) 234 (19.0) 
Missing 21 19 72 
Major liver resection 127 (47.0) 40 (15 4) 535 (41.1) <0.001 
Combined ablation 41 (15.2) 20 (7.7) 148 (11.4) 0.026 
Two stage resection 10 (3.7) 2 (0.8) 21 (1.6) 0.026 
Portal vein embolisation 31 (11.5) 16 (6.2) 153 (11.8) 0.030 
Hepatobiliary surgery on-site 72 (26.7) 138 (53.3) 269 (20.7) <0.001 
 
 Variation by hospital trust of diagnosis 
There was wide variation in surgical strategy according to hospital trust of diagnosis (Figure 
5.3). In 18 out of 132 (13.6%) of hospital trusts, all patients diagnosed with synchronous liver-
metastases who underwent a liver resection, were treated with the bowel-first approach. There 
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were 19 hospital trusts (14.4%) in which more than 50% of patients underwent either the 
simultaneous or the liver-first approach.  
 
Figure 5.3 Variation in surgical strategy according to English National Health Service 
hospital trust of diagnosis  
 
 
 Survival 
Four-year survival in the landmark analysis for the unmatched cohort was 59.2% (95% CI  
56.5-62.1) in the bowel-first group, 58.8% (95% CI 50.6-66.1) in the liver-first group and 
59.6% (95% CI 50.4-66.7) in the simultaneous group. Kaplan-Meier survival curves for the 
unmatched cohorts are shown in Figure 5.4. 
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Figure 5.4 Landmark analysis of survival according to surgical strategy in all patients, A 
P=0.638, B P=0.788 (log rank test) 
 
 
 
 Matched survival analysis 
After propensity score-matching was performed across patients included in the landmark 
analysis, there were 198 matched bowel-first patients in the bowel-first vs. simultaneous 
comparison, and 207 matched bowel-first patients in the bowel-first vs. liver-first comparison. 
The patient, tumour and operative characteristics of the bowel-first patients matched to the 
simultaneous cohort and those of the bowel-first patients matched to the liver-first cohort were 
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quite different. Table 5.4 shows that the characteristics of the matched bowel-first patients 
reflect the patients in each of the simultaneous and liver-first cohorts. 
 
Table 5.4 Clinico-pathological characteristics and surgical details of propensity score-
matched patients 
  
  
Liver-first 
N=207 (%) 
Bowel-first 
N=207 (%) 
 
Bowel-first 
N=198 (%) 
Simultaneous 
N=198 (%) 
Sex 
Male 132 (63.8) 140 (67.6) 
 
108 (54.6) 104 (52.5) 
Female 75 (36.2) 67 (32.4) 
 
90 (45.5) 94 (47.5) 
CRC site 
Right side 12 (5.8) 8 (3.9) 
 
94 (47.5) 84 (42.4) 
Left side 77 (37.2) 54 (26.1) 
 
58 (29.3) 69 (34.9) 
Rectum 118 (57.0) 145 (70.1) 
 
46 (23.2) 45 (22.7) 
IMD quintile 
1 (most deprived) 20 (9.7) 22 (10.6) 
 
37 (18.7) 48 (24.2) 
2 40 (19.3) 41 (16.8) 
 
35 (17.7) 34 (17.2) 
3 45 (21.7) 52 (25.1) 
 
35 (17.7) 37 (18.7) 
4 54 (26.1) 52 (25.1) 
 
45 (22.7) 42 (21.2) 
5 (least deprived) 48 (23.2) 40 (19.3) 
 
46 (23.2) 37 (18.7) 
Age group 
18-64 95 (45.9) 98 (47.3) 
 
55 (27.8) 63 (31.8) 
65-74 66 (31.9) 65 (31.4) 
 
65 (32.8) 57 (28.8) 
75-84 46 (22.2) 44 (21.3) 
 
78 (39.4) 78 (39.4) 
Charlson 
comorbidity score 
0 131 (63.3) 126 (60.9) 
 
121 (61.1) 128 (64.7) 
1 61 (29.5) 65 (31.4) 
 
56 (28.3) 52 (26.3) 
≥2 15 (7.3) 16 (7.7) 
 
21 (10.6) 18 (9.1) 
T-stage 
T0-2 37 (17.9) 49 (23.7) 
 
18 (9.1) 18 (9.1) 
T3 140 (67.6) 130 (62.8) 
 
113 (57.1) 117 (59.1) 
T4 30 (14.5) 28 (13.5) 
 
67 (33.8) 63 (31.8) 
T-stage 
N0 79 (38.2) 85 (41.1) 
 
64 (32.3) 72 (36.4) 
N1 77 (37.2) 73 (35.3) 
 
84 (42.4) 80 (40.4) 
N2 51 (24.6) 49 (23.7) 
 
50 (25.3) 46 (23.2) 
ASA class (at 
CRC resection) 
1/2 160 (77.3) 153 (73.9) 
 
145 (73.2) 148 (74.8) 
3/4 47 (22.7) 54 (26.1) 
 
53 (26.8) 50 (25.3) 
Liver resection 
type 
Major 98 (47.3) 106 (51.2) 
 
27 (13.6) 26 (13.1) 
Minor 109 (52.7) 101 (48.8) 
 
171 (86.4) 172 (86.9) 
 
Kaplan-Meier survival curves for the matched cohorts are shown in Figure 5.5. Survival 
analysis on the propensity score-matched groups showed there to be no evidence of a 
difference in four-year survival between the bowel-first and simultaneous cohort (HR 0.92 
(95% CI 0.80-1.06)), or between the bowel-first and liver-first cohort (HR 0.99 (95% CI 0.82-
1.19)). Note that in Figure 5.5 the survival curve of the matched bowel-first patients is 
different due to the different patient characteristics of the two matched cohorts. 
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Figure 5.5 Landmark analysis of survival in propensity score-matched patients according to 
surgical strategy 
 
 
5.4 Discussion 
 Summary of main findings 
This population-based cohort study is the first to provide an overview of national practice in 
the management of patients presenting with CRC and synchronous liver-limited metastases. 
This study shows a growing popularity of the liver-first and simultaneous approach, yet wide 
inter-hospital variation in patient management. The clinico-pathological characteristics of 
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patients undergoing alternative strategies were quite distinct, confirming that these are 
generally performed in highly selected patients. There was no evidence of a long-term survival 
difference of the bowel-first strategy compared to the liver-first or simultaneous strategy.   
 
 Study limitations 
The HES database does not include information regarding the extent or distribution of liver 
metastases, an important factor in determining management decisions particularly regarding 
the use of simultaneous resection. It is, however, unlikely that the burden of liver metastases 
and other patient and surgical characteristics, would vary sufficiently across the country to 
account for the inter-hospital differences in surgical approach.  
 
Patients were only included in this study if they underwent both CRC resection and liver 
resection. When comparing both operative mortality and long-term mortality in this cohort, it 
should be considered that to complete the treatment, patients in both the liver-first and bowel-
first group must survive, and recover sufficiently from, the initial operation. There is 
inevitably patient ‘drop-out’ from such complex and prolonged treatment pathways, which 
may be significant. Several single centre cohort studies have reported that between 16 to 35% 
of liver-first and bowel-first patients fail to proceed to the second operation (Brouquet et al., 
2010, Welsh et al., 2016, Sturesson et al., 2017). This is not only related to operative 
morbidity. Proponents of a staged approach argue that the assessment of disease progression 
during the interval between first resection and second resection allows those with a poor 
prognosis to be excluded from surgery (Slesser et al., 2013). A potential disadvantage of the 
simultaneous approach is that it does not allow for such an assessment period. Studies 
comparing outcomes between staged and simultaneous cohorts will therefore over-sample 
patients with favourable tumour biology in the staged population, leading to selection bias in 
favour of the staged approaches.  
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The direct comparison of survival in these groups from time of diagnosis is a common feature 
of studies in patients with synchronous CRC liver metastases, and leads to bias in favour of 
the staged cohorts. Although the use of a landmark survival analysis addresses this bias it does 
come with its own disadvantages. These include the need to set a, somewhat arbitrary, choice 
of landmark time point. One year following the date of diagnosis was selected for the analysis 
in Chapter 5 as over 90% of patients have undergone their second operation by this time point. 
The choice of landmark time point must also take into account that the longer the time period 
set from diagnosis, the more patients die before this time and therefore are excluded from the 
study, thus losing statistical power.  
 
 Survival according to surgical approach 
The landmark survival analysis of the matched cohorts in the present study showed no 
evidence of a difference in long-term survival between patients undergoing an alternative 
strategy to those undergoing a bowel-first approach.  
 
At which time point to begin the comparison of the three groups varies throughout the 
literature. In the analysis of 1,004 patients who completed one of the three treatment strategies, 
Mayo and co-authors (2013) analysed long-term survival from 90-days after the date of the 
liver-directed operation. This analysis therefore included the post-operative mortality 
associated with CRC resection for patients in the liver-first group, yet no post-operatively 
mortality for patients in the liver-first and simultaneous cohort. Brouquet and co-authors 
(2010) analysed survival in 142 patients from the date of the last surgery, therefore comparing  
post-operative mortality of a combined liver and CRC resection in simultaneous patients to a 
single procedure in staged patients. In both of the aforementioned methods, the survival 
analysis start date for each patient varied from the date of diagnosis. In this study, survival in 
each cohort was estimated conditional on a patient’s survival to the landmark time to reduce 
such time bias.  
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 Patient characteristics according to surgical approach 
The clinico-pathological characteristics of patients undergoing a simultaneous and liver-first 
strategy were quite distinct. A liver-first approach is commonly used in patients with more 
extensive hepatic disease (De Rosa et al., 2013). This was suggested in the present cohort by 
the high rate of major liver resection in the liver-first group as well as increased used of 
techniques to maximise the future liver remnant. Liver-first patients will have been deemed 
by the colorectal and hepatobiliary MDTs fit enough to withstand systemic chemotherapy 
followed by two major operations. It therefore follows that liver-first patients in the present 
cohort were younger and had less comorbidities than those in the bowel-first cohort. There 
also may be more treatment directed at attempting to cure a younger fitter patient. 
Synchronous resection increases the complexity of the surgical procedure and it is therefore 
notable that patients selected for a simultaneous approach tended to be older and have a higher 
ASA grade than patients undergoing alternative approaches. The safety of simultaneous 
resection when involving a minor resection in combination with high or low risk CRC 
resection has been demonstrated (Shubert et al., 2015, Kelly et al., 2015) and it may be 
considered clinically appropriate to offer this strategy to higher risk patients with low volume 
liver disease to avoid the cumulative morbidly and mortality of separate interventions.  
 
 Inter-hospital variation in surgical strategy 
There was wide variation in surgical approach according to hospital trust of diagnosis 
reflecting no clear consensus as to optimal management. The presence of a hepatobiliary team 
on-site appeared to impact upon decision-making, as patients diagnosed at hospital trusts with 
such services on-site were more likely to undergo a simultaneous or liver first approach. 
Patients diagnosed at hospital trusts with no hepatobiliary MDT on-site may be undergoing 
CRC resection prior to referral to a hepatobiliary MDT for consideration of liver resection. 
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 Conclusions 
This study shows that a liver-first or synchronous approach can achieve similar survival rates 
in selected cases to the conventional bowel-first approach for CRC patients with synchronous 
liver limited metastases. The study has also indicated there to be substantial variation in how 
patients with synchronous disease are managed. This suggests that there is scope for increased 
resection rates of liver metastases in either the liver-first or the simultaneous settings. To 
achieve this patients with synchronous disease should be discussed by a hepatobiliary MDT 
early in their pathway.     
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6. Chapter 6: The impact of advancing age on outcomes in 
patients undergoing hepatectomy for colorectal cancer 
liver metastases 
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6.1 Introduction 
There are noticeable differences in the incidence trends of CRC between countries. These 
differences are particularly marked in the individual risk at a given age, known as the age-
standardised rate (ASR) (Papamichael et al., 2015). Over the last 25 years the ASR fell by 
more than 30% in the United States, while over the same period in the UK although unchanged 
in women, the ASR rose by 30% in men (Cancer Research UK, 2017). As mortality from non-
cancer causes such as heart disease reduces, an elderly population at a high risk of developing 
bowel cancer remains. Currently in the UK the highest incidence of colorectal cancer 
diagnosis is in older patients and more than 40% of diagnoses are made in patients 75 years 
and over (nboca.org.uk, 2016).  
 
The older population is consistently under-represented in clinical trials and institutional case 
series, and as a result outcomes in this cohort are also less well characterised (Aapro et al., 
2005). It is well accepted that in general, major surgery in the elderly can be associated with 
significant risk. A study of more than 4 million patients in the UK found hospital mortality 
after surgery to be 1.9% (0.44% in elective procedures and 5.4% in emergency procedures). 
In patients with a mean age of 75 years, mortality rose to 12.3% (Pearse et al., 2006). 
 
Elderly patients with CRC liver metastases are less likely to undergo liver resection (Leporrier 
et al., 2006, Morris et al., 2010, Norén et al., 2016, Angelsen et al., 2017). Concerns over their 
physical and mental frailty may preclude specialist referral. Surgical risk stratification remains 
one of the most important aspects of management in elderly patients and there is therefore a 
need to better characterise outcomes in this patient cohort (Tan et al., 2012). This information 
is used to inform operative decisions, choice of peri-operative management and to discuss risk 
with patients. 
 
The aim of this chapter was to investigate the impact of age on surgical risk and long-term 
survival following liver resection, in patients with resected primary colorectal cancer.  
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6.2 Methods 
 Study population 
Patients diagnosed with primary CRC between 1st April 2010 and 31st March 2016 in English 
NHS hospital trusts included in the NBOCA dataset who had undergone major CRC resection 
were eligible for inclusion.  
 
 Liver procedure 
All HES records including admissions up to 31st March 2016 were searched for codes 
indicating a liver resection, portal vein embolisation and ablation procedure as described in 
Chapters 3 and 5. Liver resection was stratified into ‘major’ or ‘minor’ according to the 
resection of three or more Couinaud segments as described in Chapter 4.   
 
 Surgical access 
 To ascertain surgical access, the additional procedural codes shown in  Table 6.1 indicating 
a minimally invasive technique were searched for. When these were in the same spell as a 
procedure code for resection this was assumed to represent a minimally invasive liver 
resection.  
 
 Table 6.1 OPCS-4 procedure codes used to identify minimally invasive liver resection 
 
 Outcome measures 
To investigate age as a risk factor for poor post-operative outcomes, 90-day mortality, 30-day 
emergency readmission, 30-day unplanned return to theatre, length of stay and overall and 
cancer specific 3-year survival was compared between age groups.  
4-digit code Description 
Y751 Laparoscopically assisted approach to abdominal cavity 
Y752 Laparoscopic approach to abdominal cavity 
Y753 Robotic minimal access approach to abdominal cavity 
Y754 Hand assisted minimal access approach to abdominal cavity 
Y758 Other specified minimal access to abdominal cavity 
Y759 Unspecified minimal access to abdominal cavity 
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 Statistical analysis 
Comparisons of patient and tumour characteristics between different age groups undergoing 
liver resection were performed using the χ2 test. The Kaplan-Meier method was used to 
describe overall survival and the log rank test for overall survival differences.  
 
The Cox-proportional hazards model was used to evaluate the impact of age on 90-day 
mortality and 3-year mortality adjusted for differences in patient, tumour and surgical 
characteristics. The following variables were included: gender, age, IMD quintile, year of 
diagnosis, comorbidities, primary tumour site, primary tumour pathological T-stage, N-stage 
and M-stage, laparoscopic/ open liver resection and major/ minor liver resection. The model 
for three-year mortality additionally included an interaction between follow-up time (0-90 
days after surgery vs. 90 days-3 years after surgery) and each of the above risk factors. This 
allowed risk factors to have a different effect shortly after surgery and in the longer term. 
 
A Fine and Gray (1999) competing risks proportional hazards model was used to evaluate the 
impact of age on cancer-specific 3-year mortality adjusted for differences in patient, tumour 
and surgical characteristics (26). The competing risks model allows the effect of deaths from 
other causes to be accounted for. The same risk-factors were included in the competing risks 
model as the Cox regression model, including interactions between follow-up time (0-90 days 
after surgery vs. 90 days-3 years after surgery) and each risk factor. The cumulative incidence 
of cancer-specific mortality according to age and extent of liver resection was determined after 
adjusting for competing risks.  
 
Missing values for the risk factors above were imputed with multiple imputation using 
chained equations creating 10 datasets and using Rubin’s rules to combine estimates (27).  
The same variables included in the final multivariable model were included in the 
imputation model. 
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6.3 Results 
 Study cohort 
Of the 117,005 patients undergoing major resection of CRC from 1st April 2010 to 31st March 
2016, a total of 6,081 (5.9%) underwent liver resection (Figure 6.1).  
 
Figure 6.1 Flow diagram of patient inclusion and exclusion 
 
 Patient characteristics 
The characteristics of study patients undergoing liver resection are shown in Table 6.2. 
Patients aged ≥75 years tended to have more comorbidities (Charlson comorbidity score ≥2, 
≥75 years vs. <65 years, 12.5% vs. 4.1%, P<0.001) and a higher ASA class (ASA 3/4/5, ≥75 
years vs. <65 years, 31.4% vs. 15.7%, P<0.001), and more commonly had right sided colonic 
primary tumour (≥75 years vs. <65 years, 37.4% vs. 20.4%, P<0.001) and less advanced nodal 
disease (N2 ≥75 years vs. <65 years, 30.7s% vs. 20.7%, P<0.001) than younger patients. 
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Patients aged ≥75 years more commonly underwent a liver resection for metachronous disease 
(M0 at CRC diagnosis ≥75 years vs. <65 years, 64.8% vs. 49.4%, P<0.001). There was no 
significant difference in the proportion of patients undergoing a major or minor liver resection 
according to age (minor liver resection ≥75 years vs. <65 years, 67.0% vs. 64.3%, P=0.105). 
Laparoscopic liver resection was used more commonly in the elderly (≥75 years vs. <65 years, 
17.7% vs. 13.8%, P=0.006) but both thermal ablation (≥75 years vs. <65 years, 9.0% vs. 
12.9%, P<0.001) and portal vein embolisation (≥75 years vs. <65 years, 7.5% vs. 10.5%, 
P=0.005) were used less commonly with advancing age.  
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Table 6.2 Clinico-pathological characteristics of patients diagnosed with primary CRC 
undergoing liver resection (N=6,081) 
 
 Crude outcomes 
Unadjusted post-operative outcomes are displayed in Table 6.3. Overall 90-day mortality was 
2.1% (130/6,081) in patients undergoing liver resection. The 90-day mortality increased with 
 
<65 years 
N=2,829 
(%) 
65-74 years 
N=2,070 
(%) 
≥75 years 
N=1,182 
(%) 
Total 
N=6,081 
(%) 
P-value 
Gender 
Male 1,706 (60.3) 1,389 (67.1) 755 (63.9) 3,850 (63.3) 
<0.001 
Female 1,123 (39.7) 681 (32.9) 427 (36.1) 2,231 (36.7) 
Charlson 
comorbidity 
score 
0 1,987 (72.2) 1,227 (60.9) 670 (58.7) 3,884 (65.7) 
<0.001 
1 653 (23.7) 601 (29.8) 328 (28.8) 1,582 (26.8) 
≥2 114 (4.1) 188 (9.3) 143 (12.5) 445 (7.5) 
Missing 75 54 41 170 
IMD quintile 
1 (most deprived) 421 (15.0) 275 (13.4) 155 (13.2) 851(14.1) 
<0.001 
2 570 (20.3) 321 (15.6) 192 (16.3) 1,083 (17.9) 
3 606 (21.5) 440 (21.4) 263 (22.3) 1,309 (21.6) 
4 574 (20.4) 516 (25.1) 293 (24.9) 1,383 (22.9) 
5 (least deprived) 644 (22.9) 504 (24.5) 274 (23.3) 1,422 (23.5) 
Missing 14 14 5 33 
Primary CRC 
site 
Right side 578 (20.4) 603 (29.1) 442 (37.4) 1,623 (26.7) 
<0.001 Left side 1,381 (48.8) 879 (42.5) 490 (41.5) 2,750 (45.2) 
Rectum 870 (30.8) 588 (28.4) 250 (21.2) 1,708 (28.1) 
Emergency 
presentation 
of CRC 
No 2,324 (83.5) 1,776 (87.1) 986 (85.8) 5,086 (85.2) 
0.002 Yes 459 (16.5) 264 (12.9) 163 (14.2) 886 (14.8) 
Missing 46 30 33 109 
ASA class (at 
CRC 
resection) 
1 609 (25.7) 236 (13.3) 77 (7.4) 922 (17.8) 
<0.001 
2 1,398 (58.9) 1,107 (62.4) 634 (61.1) 3,139 (60.5) 
3 340 (14.3) 406 (22.9) 303 (29.2) 1,049 (20.2) 
4/5 27 (1.4) 26 (1.5) 23 (2.2) 76 (1.5) 
Missing 455 295 145 895 
T-stage 
0-2 278 (10.4) 243 (12.5) 133 (11.9) 654 (11.4) 
0.030 
3 1,640 (61.1) 1,220 (62.6) 684 (61.0) 3,544 (61.6) 
4 767 (28.6) 486 (24.9) 304 (27.1) 1,557 (27.1) 
Missing 144 121 61 326 
N-stage 
0 883 (32.9) 724 (37.0) 474 (42.1) 2,081 (36.1) 
<0.001 
1 978 (36.4) 753 (38.5) 418 (37.2) 2,149 (37.3) 
2 824 (30.7) 478 (24.5) 233 (20.7) 1,535 (26.6) 
Missing 144 115 57 316 
Liver 
resection 
indication 
Metachronous 
disease 
1,291 (49.4) 1,073 (55.8) 704 (64.8) 3,068 (54.6) 
<0.001 Synchronous 
disease 
4,320 (50.6) 851 (44.2) 383 (35.2) 2,554 (45.4) 
Missing 218 149 95 459 
Liver 
resection type 
Minor resection 1,795 (63.5) 1,324 (64.0) 792 (67.0) 3,911 (64.3) 
0.105 
Major resection 1,034 (36.6) 746 (36.0) 390 (33.0) 2,170 (35.7) 
Liver 
resection 
access 
Open 2,440 (86.3) 1,751 (84.6) 973 (82.3) 5,164 (84.9) 
0.006 
Laparoscopic 389 (13.8) 319 (15.4) 209 (17.7) 917 (15.1) 
Combined ablation 365 (12.9) 176 (8.5) 106 (9.0) 647 (10.6) <0.001 
Portal vein embolisation 296 (10.5) 176 (8.5) 89 (7.5) 561 (9.2) 0.005 
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advancing age (<65 years: 0.9% (26/2,829), 65-74 years: 2.8% (57/2,070) and ≥75 years: 4.0% 
(47/1,182); P<0.001). There was no significant difference in rates of either return to theatre 
within 30-days or emergency readmission within 30-days according to patient age. The 
median length of stay following liver resection was 6 days (inter-quartile range (IQR) 5-8), 
and there was no significant difference according to patient age.  
 
Table 6.3 Post-operative outcome following liver resection according to age 
  
Total 
N=6,081 
(%) 
<65 years 
N=2,829 
(%) 
65-74 years 
N=2,070 
(%) 
≥75 years 
N=1,182 
(%) 
P-value 
90-day mortality 130 (2.1) 26 (0.9) 57 (2.8) 47 (4.0) <0.001 
Emergency readmission (30-days) 91 (1.5) 53 (1.9) 31 (1.5) 12 (1.0) 0.205 
Return to theatre (30-days) 204 (3.4) 76 (3.7) 42 (3.6) 86 (3.0) 0.438 
Median length of stay in days (IQR) 6 (5-8) 6 (4-8) 6 (5-9) 7 (5-10) 0.835 
 
There was increased unadjusted 90-day mortality for older patients undergoing both major 
and minor liver resection, as shown in Table 6.4. 
 
Table 6.4 90-day mortality according to extent of liver resection and age 
  
All patients 
(%) 
<65 years 
(%) 
65-74 years 
(%) 
≥75 years 
(%) 
P-value 
Major liver resection 65/ 2,170 (3.0) 14/ 1,034 (1.4) 27/ 746 (3.6) 24/ 390 (6.2) <0.001 
Minor liver resection 65/ 3,911 (1.7) 12/ 1,795 (0.7) 30/ 1,324 (2.3) 23/ 792 (2.9) <0.001 
 
Median follow up was 36.4 months. Overall 3-year survival (<65 years: 60%; 65-74 years: 
56%, and ≥75 years: 51%) decreased with advancing age (P<0.001).  
 
 
 Risk-adjusted outcomes 
The effect of advancing age on outcomes following liver resection when adjusted for 
differences in patient and tumour characteristics was most pronounced early in the follow-up 
period (90-day mortality ≥75 years vs. <65 years HR 4.65 95% CI 2.7-8.1) (Table 6.5). The 
results from the full multivariable models are presented in Appendix 9.2.  
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Table 6.5 The impact of age upon mortality amongst patients undergoing liver resection 
adjusted for other patient and tumour characteristics 
 Age 
(years) 
0-90 days 
All-cause 
mortality 
Hazard Ratio 
(95% CI) 
P-value 
90 days-3 years 
All-cause mortality 
Hazard Ratio 
(95% CI) 
P-value 
90 days-3 years 
Cancer-specific 
mortality 
Hazard Ratio 
(95% CI) 
P-value 
<65 1 
P<0.001 
1 
P<0.001 
1 
P<0.001 65-74 2.88 (1.67 to 4.97) 1.07 (0.90 to 1.17) 1.01 (0.90 to 1.14) 
≥75 4.25 (2.38-7.57) 1.41 (1.23 to 1.61) 1.26 (1.09 to 1.45) 
 
Age was an independent risk factor for mortality (P<0.001), however, in the period of 90-days 
to 3-years following liver resection, mortality in patients aged 65-74 years was similar to those 
aged <65 (overall mortality: HR 1.07, 95% CI 0.90-1.17; cancer-specific mortality: HR 1.03, 
0.92-1.16). Age ≥75 years was associated with both increased risk of overall mortality (HR 
1.47, 95% CI 1.30-1.68) and cancer-specific mortality (HR 1.30, 95% CI 1.13-1.49). The 3-
year cumulative incidence of cancer-specific mortality stratified by age and extent of liver 
resection is demonstrated in Figure 6.2. 
 
Figure 6.2 Cumulative incidence curves for cancer-specific mortality stratified according to 
age group and extent of liver resection 
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Sub-group analysis confirmed age to be an independent prognostic factor for both 90-day and 
longer term mortality in patients undergoing major and minor liver resection. 
 
6.4 Discussion 
 Summary of findings 
This population based cohort study using prospectively collected national audit data, included 
over 6,000 patients, 3,252 of whom were aged 65 years and over. Estimates of surgical risk 
and long-term survival are presented by age group, both crude and adjusted for other risk 
factors. Although elderly patients were at increased risk of post-operative mortality following 
liver resection, the length of stay and rates of return to theatre and emergency readmission 
were comparable to younger patients. Over half of patients 75 years and over undergoing liver 
resection for CRC liver metastases were alive 3 years following their resection.  
  
 Post-operative outcomes in the older patient 
Clinicians will frequently have to decide if major surgery is justified in an elderly patient. 
Balancing the post-operative risks with the oncological benefits is a key step in the decision-
making process. Studies have consistently demonstrated elderly patients to be less likely to 
undergo liver resection than younger patients (Leporrier et al., 2006, Morris et al., 2010, 
Norén et al., 2016, Angelsen et al., 2017). This may be due to later presentation of disease, 
physiological fitness, or a perception that radical surgery is less likely to be of benefit. Elderly 
patients undergoing liver resection in this cohort had more comorbidities and higher ASA 
class than younger patients suggesting that elderly patients are not being refused liver resection 
due to the presence of pre-existing health conditions.  
 
For elderly patients undergoing major liver resection, 3-year survival reaches nearly 50%, thus 
far exceeding median survival in patients who do not undergo liver resection (Stillwell et al., 
2010). Despite this, post-operative mortality needs to be acceptable. Previous reports of 90-
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day mortality in elderly patients undergoing liver resection present conflicting results. Some 
have shown no association between age and post-operative mortality (Leal et al., 2016) and 
in others age is reported to be a predictive factor (Cook et al., 2012, Booth et al., 2015). Even 
when the study population is restricted to patients undergoing major liver resection, reported 
outcomes in the elderly compared to younger patients are mixed (Menon et al., 2006, Reddy 
et al., 2011a, Bell et al., 2017). This study supports the view that age is an independent 
predictor of 90-day mortality following both minor and major liver resection.  
 
This study found no increase in measures of morbidity such as return to theatre, length of stay 
and emergency readmission in elderly patients undergoing liver resection. This is supported 
by previous literature demonstrating that although elderly patients experience similar major 
morbidity to younger patients, they are more likely to experience minor complications 
including urinary tract and chest infections (Mann et al., 2008). The increased post-operative 
mortality in the elderly cohort suggests that those patients who do suffer a complication of 
surgery are more likely to die as a result due to poorer physiological reserve.  
 
 Thermal ablation 
Despite there being no significant difference in the proportion of patients undergoing major 
liver resection according to age, combined thermal ablation was used less commonly in the 
elderly. Advancing age is associated with a decline in physiological reserve, hepatic size, 
blood flow and rate of liver regeneration (Aalami et al., 2003, Schmucker and Sanchez, 2011). 
This places the older patient at an increased risk of post-operative liver failure, the most 
common cause of significant morbidity and mortality following liver resection (Rahbari et al., 
2011, Anaya et al., 2011). Thermal ablation of small lesions in combination with a liver 
resection may facilitate complete tumour clearance, whilst preserving parenchyma (Evrard et 
al., 2014). This strategy may be an acceptable alternative to a higher risk major liver resection 
in the elderly population. This study did not examine patients undergoing ablative techniques 
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alone with no liver resection, but there is evidence that thermal ablation is associated with 
lower complication rates and an improved health-related quality of life than surgery (Loveman 
et al., 2014). The LAVA (Liver Resection Surgery Versus Thermal Ablation for Colorectal 
LiVer MetAstases) trial is currently seeking to address this (ISRCTN registry, 2017).  
 
 Laparoscopic liver resection 
Laparoscopic liver resection is rapidly gaining momentum (Wakabayashi et al., 2015b). 
Randomised trials of laparoscopic versus open liver resection are awaited, but there is recent 
evidence to suggest that a laparoscopic approach in the elderly population is associated with 
lower morbidity and a shorter hospital stay than an open approach (Cauchy et al., 2016, 
Martínez-Cecilia et al., 2017). This study shows that 18% of liver resections for CRC liver 
metastases in the elderly population are performed laparoscopically, significantly higher than 
the 14% observed in the younger cohort. This suggest that hepatobiliary surgeons in the UK 
prefer a minimally invasive approach in the older population. 
 
 Study limitations 
Elderly patients undergoing liver resection are reportedly less likely to receive both 
neoadjuvant and adjuvant chemotherapy (Adam et al., 2010). As chemotherapy is often 
administered on an outpatient basis, reliable information regarding its use is not available in 
HES and therefore unknown for this patient cohort. Differences in its use according to age 
may account for the poorer cancer-specific survival demonstrated in patients aged ≥75 years.  
 
The analysis included only including patients undergoing major CRC resection and liver 
resection within the same time period, patients with metachronous disease will be under-
represented. To reduce bias associated with this, year of diagnosis was included as a variable 
in the multivariable model. 
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 Conclusions 
Patients aged 65-74 years were not at increased risk of long term mortality following liver 
resection compared to younger patients after taking into account patient and tumour 
characteristics. Although an age of greater than 75 years was a predictor of poorer survival 
particularly in the early post-operative period, elderly patients undergoing liver resection had 
3-year survival of over 50%. This study highlights the need for improved predictors of early 
post-operative mortality to aid patient selection and better inform both clinicians and patients.  
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7. Chapter 7: Discussion 
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The aims of this thesis were to investigate the surgical management and outcomes of patients 
with CRC liver metastases in England using routinely collected national data. Having 
reviewed the current literature in Chapter 1, several knowledge gaps were identified which 
this thesis addresses in four individual studies. These broadly investigate service provision, 
selection for liver resection, trends and utilisation of surgical approaches, and post-operative 
outcomes in patients with CRC liver metastases. The results of these studies have highlighted 
several important issues which may have significant future implications for clinical practice.  
 
7.1 Implications for clinical practice 
 Achieving equitable access within a centralised system 
There are longstanding recommendations to centralise specialist services for both cancer and 
non-cancer care within the English NHS (Department of Health, 2001). High volume is 
associated with improved outcome particularly for cancer types involving complex surgery 
such as oesophagogastric, urological and hepatobiliary (Sosa et al., 1998, Glasgow et al., 
1999, Birkmeyer et al., 2002, Birkmeyer et al., 2003). Increased patient volumes in specialist 
centres allows greater experience and expertise across teams working at these sites.  
 
Equity in access to healthcare is an important policy objective in England where specialist 
services should be available to everyone regardless of location. The centralisation of services 
into higher volume units can place increased travel demands on patients. The Calman and 
Hine (1995) report states that “All patients should have access to a uniformly high quality of 
care as close to the patient's home as possible’ and that ‘services should be planned to 
minimise travelling times whilst maintaining the highest standards of specialist care’ (Calman 
and Hine, 1995). These recommendations have introduced a challenge with regard to the 
delivery of high quality specialist care whilst ensuring that travel times are minimised. 
Although some geographical inequalities in access to healthcare are inevitable due the travel 
required for patients living in rural areas, these are unacceptable when they disproportionally 
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impact upon particular patient groups, such as the elderly and more socioeconomically 
deprived (Exworthy and Peckham, 2006). There is evidence to suggest that in the UK longer 
distance to a specialist cancer centre is associated with more advanced disease at diagnosis 
and poorer survival and a recent study examining the geographical location of specialist 
services for four common cancers within the UK, including colorectal, found areas with longer 
mean travel times also to have poorer relative survival rates after adjustment for area 
deprivation (Murage et al., 2016). 
 
The Cancer Research Taskforce is working to develop a five year cancer survival 
improvement strategy on behalf of NHS England with recommendations in place to evaluate 
whether service configuration for surgery merits further centralisation (National Cancer 
Transformation Board, 2016). The results presented in Chapter 3 suggest centralisation of 
surgical services may act as a double-edged sword. Further centralisation should therefore be 
undertaken with caution. As the Cancer Research Taskforce moves forward with its five-year 
plan it is imperative to ensure that specialist services are able to deliver equitable care to those 
not based at the specialist centre. The results presented in this thesis highlight several possible 
areas where services may be restructured to achieve this and which are discussed below.  
 
 Routine hepatobiliary MDT referral 
Previous evidence from local studies in the UK suggests that it is variation in rates of referral 
from CRC MDTs to hepatobiliary MDTs which may contribute towards regional variation in 
liver resection rates (Jones et al., 2012, Young et al., 2013). Colorectal MDTs based at hospital 
trusts with no on-site hepatobiliary services may have less awareness of the availability of 
novel chemotherapy agents and sophisticated interventional radiological techniques which 
have resulted in a widening of the definition of resectable liver metastases (Pawlik et al., 
2008). The routine referral of all patients diagnosed with CRC and liver metastases for 
discussion at a hepatobiliary MDT meeting would be an effective strategy for improving 
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equity of access for those diagnosed at non-specialist centres. A survey of hepatobiliary 
surgeons within the UK reported 65% would support this (Qureshi et al., 2012). However, as 
the majority of patients with metastatic CRC would not benefit from resection but rather 
palliative treatment, this strategy may delay palliative therapy for these patients and would 
also prove resource intensive for hepatobiliary MDTs. More feasible future strategies to 
ensure the timely input from hepatobiliary surgeons into the care of patients with CRC liver 
metastases would include the regular attendance of hepatobiliary surgeons at spoke CRC 
MDTs, the delivery of education programmes from hepatobiliary MDTs to CRC surgeons, 
and the routine use of video-conferencing between hepatobiliary and CRC MDTs. 
 
 Increased cross-site working 
The analysis in Chapter 5 which demonstrates higher simultaneous resection rates in patients 
diagnosed at trusts with on-site hepatobiliary surgical services, suggests that patients may be 
undergoing CRC resection at spoke trusts prior to a referral to a hepatobiliary MDT. There are 
national guidelines in place recommending that colorectal surgeons perform a minimum of 20 
elective CRC resections per year (The Association of Coloproctology of Great Britain and 
Ireland, 2007). This is important to ensure that skills are kept up to date and quality standards 
are maintained. At present, if patients with synchronous liver metastases diagnosed at a spoke 
hospital are deemed suitable to undergo a simultaneous bowel and liver resection, this will 
usually occur at the hub hospital. The bowel resection component of this procedure is therefore 
unlikely to be performed by a CRC surgeon based at the spoke trust. Colorectal surgeons 
working at spoke hospitals may favour a staged approach to ensure that their minimum 
numbers are met. Future attention should therefore be given to improving the opportunity for 
cross-site working for both hepatobiliary and colorectal surgeons within hub and spoke 
hospitals, to ensure that such targets are not a consideration in the management of patients 
with synchronous disease.  
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 Nationally agreed referral guidelines 
Inequalities in specialist referrals have been found to be more likely to occur in the absence 
of explicit guidelines (McBride et al., 2010). NICE recommended for the diagnosis and 
management of patients with CRC that “if both primary and metastatic tumours are 
considered resectable, anatomical site-specific MDTs should consider initial systemic 
treatment followed by surgery” (National Institute for Health and Care Excellence, 2014). 
There are, however, an absence of widely accepted guidelines for colorectal MDTs of what 
should be considered ‘resectable’ disease, leaving referral practices to local policy and a 
clinician’s own judgement. The implementation therefore of clearly defined and nationally 
agreed referral protocols may reduce inequity in access (Siriwardena, 2007).  
 
 Advanced colorectal cancer MDT 
Since 2013 Aintree University Hospital NHS Foundation Trust has operated a weekly MDT 
meeting specifically for patients with advanced CRC in the Mersey area (Hore et al., 2014). 
The move away from the traditional organ-specific approach to a disease specific approach, 
may act to streamline patient management and improve equity of access. In addition, all 
specialists (including a hepatobiliary surgeon, thoracic surgeon and colorectal cancer surgeon) 
involved in the treatment of patients with advanced cancer are present at each meeting. If this 
Liverpool model can be demonstrated to be both feasible, cost-effective, and result in 
improved patient outcomes, this structure may be rolled out across other regions.  
 
 Targeting specific patient groups 
It is not only patients who are geographically remote from specialist surgical centres who 
appear to be disadvantaged in terms of access to specialist treatment. The results presented in 
Chapter 4 demonstrate that more socioeconomically deprived patients are also less likely to 
undergo liver resection, independent of other risk factors such as patient comorbidity and stage 
of primary cancer. This difference was also independent of the presence of hepatobiliary 
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specialist services on site. The positive influence of providing the same care to more deprived 
patients as less deprived patients was clearly highlighted; social deprivation was no longer 
associated with increased risk of long-term mortality when the analysis was restricted to 
patients undergoing liver resection. 
 
Reducing health inequalities in England is an ambitious task. In the summer of 2016 the UK’s 
new Prime Minister announced that tackling health inequalities and addressing unwarranted 
variations in cancer outcomes was to be a key priority for the current government (Barr et al., 
2017). In addition, equity in the delivery of care is outlined as a key strategy in the Cancer 
Research Taskforce’s five year plan (National Cancer Transformation Board, 2016). The 
findings presented in this thesis suggest that a concerted effort from healthcare professionals 
to ensure equitable access to specialist care for more deprived patients with CRC liver 
metastases may serve to improve survival in this patient cohort. 
 
 Reducing the risks of liver resection 
The results presented in Chapter 6 confirm that advancing age is a risk factor for poorer 
outcomes following liver resection, particularly in the early post-operative period. However, 
long-term survival may be achieved in these elderly patients. This raises the question of how 
to firstly predict, and then optimise, patients at particular risk of poor post-operative outcomes 
so that this potential survival benefit may be achieved for more patients.  
 
New knowledge is emerging that frailty, a syndrome characterised by a decreased 
physiological reserve, is a better predictor of mortality and morbidity than chronological age 
(Partridge et al., 2012). Traditionally, frailty has been measured by combining a patient’s past 
medical history, physical examination, and an assessment of physical and functional status. 
These factors however may be time consuming to measure and are often subjective (Amrock 
et al., 2014). In 2011, 70 variables included within a frailty index developed by the Canadian 
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Study of Health and Aging were mapped onto the American College of Surgeons National 
Surgical Quality Improvement Program (ACS-NSQIP) dataset (Velanovich et al., 2013). 
However, due to the significant extra burden of data collection and the lack of consensus 
regarding the optimal frailty assessment tool, particularly for use in population-based data, 
this was not incorporated into later versions of the database. There have subsequently been 
further attempts to use population-based data to measure frailty in patients undergoing liver 
resection. Gani et al. (2017), using the NSQIP hepatectomy targeting database, developed a 
frailty index to predict adverse post-operative clinical outcomes following liver resection. The 
model included ASA class, Body Mass Index (BMI), serum albumin, haematocrit, underlying 
pathology and type of liver resection, demonstrating an Area under Receiving Operating 
Characteristics curve of 0.68 on validation. Further evaluation of this index in external cohorts 
will be required for its use to become routine in the elderly population considering liver 
resection. 
 
The association between low functional capacity, as determined by cardiopulmonary exercise 
testing (CPET), and poor patient outcome following non-cardiopulmonary surgery is well 
established (Older et al., 1993). A recent randomised clinical trial reported improvements in 
the scores achieved in CPET following a 4-week pre-habilitation programme in a cohort of 
patients undergoing liver resection for CRC liver metastases (Dunne et al., 2016). The further 
assessment of pre-habilitation as a tool to improve outcomes following liver resection with 
the focus on an elderly cohort is warranted.  
 
The results presented in Chapter 6 demonstrate that thermal ablation in combination with liver 
resection is used less frequently in the elderly population. Combining thermal ablation with 
liver resection takes advantage of the ability of ablation to destroy small tumours whilst 
sparing parenchyma. This may be a rational de-escalating strategy compared to more extensive 
hepatectomy and has been shown to be well tolerated and achieve adequate tumour clearance 
(Evrard et al., 2014). It is not clear why ablation was used less often in elderly patients in the 
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study cohort, but considering the 6% post-operative mortality following major liver resection 
demonstrated in patients over 75 years compared to 4% following minor liver resection, there 
may be scope for an increased role of this strategy.   
 
 Need for randomised evidence of timing strategies 
The lack of consensus guidelines and the complexities involved in the care of patients with 
CRC and synchronous liver metastases is not only reflected in the variation in specialist 
referrals. The results shown in Chapter 5 highlight wide regional variation in the timing of 
liver resection in relation to resection of the primary CRC. This suggests lack of consensus on 
two key decisions in the surgical management of patients with synchronous liver metastases: 
firstly, if a staged or simultaneous resection should be performed, and secondly, whether the 
bowel or the liver should be operated first. The logical next step in producing quality evidence 
to guide hepatobiliary MDTs about the optimal management for these patients would be a 
randomised trial. The data presented in Chapter 5 provides evidence of equipoise in long-term 
survival between treatment options, as well as data regarding national practice and trends. This 
will be important in guiding future studies in this cohort. 
 
7.2 Methodological considerations 
 Registry data 
The results presented in this thesis are based on data collected specifically for the NBOCA 
and administrative data. There are several advantages to using such data for epidemiological 
research. Having large cohorts of patients to study allows the statistical power to perform 
subgroup analysis and, in regression analyses, the ability to adjust for a wide range of clinico-
pathological characteristics.  
 
There are, however, general limitations in using registry data. Primarily, these datasets were 
not designed to answer any specific scientific question, therefore desirable data for a particular 
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study may have not been collected. There are several important examples in this thesis when 
individual studies may have benefited from more detailed information in specific areas. 
 
Firstly, the use of chemotherapy was not able to be analysed. Systemic treatment is an 
important aspect of the management of patients with CRC liver metastases. It may be offered 
both in the neoadjuvant and adjuvant setting, and also with the aim of converting patients with 
inoperable disease to resectable. Although the NBOCA collects data regarding chemotherapy 
use for the primary CRC, it does not collect data regarding chemotherapy directed at 
metastases. As chemotherapy is often administered on an outpatient basis, reliable information 
regarding its use is also not available from HES data. Chemotherapy data would have been 
particularly informative when analysing outcomes in the elderly population undergoing liver 
resection. Elderly patients undergoing liver resection in a US and a French cohort were found 
to be less likely to undergo both neo-adjuvant and adjuvant chemotherapy (Adam et al., 2010, 
Booth et al., 2015). Therefore, the poor cancer-specific survival following liver resection 
reported in Chapter 6 may in part reflect less frequent chemotherapy use in the elderly.  
 
The second important item of data that was not available relates to MDT referral and 
discussion. As highlighted in this thesis, the management of patients with CRC liver 
metastases is complex and can involve input from a range of subspecialty teams based at 
different geographical sites. The results from Chapter 3 suggest patients diagnosed at hospital 
trusts with no on-site hepatobiliary surgical services are less likely to undergo liver resection. 
There may be a range of mechanisms behind this which cannot be fully explored without 
analysing referral practices. The NBOCA or HES data does not include information regarding 
if and when a patient was referred to a site-specific MDT. The inclusion of this data would 
help differentiate whether it is a lack of referral from the local CRC MDTs to hepatobiliary 
MDTs, a delay in referral from the CRC MDTs, or differences in decision-making according 
to referral centre at the hepatobiliary MDTs, that is contributing to this finding.  
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A further potential limitation of using routinely collected national data is the impact of missing 
data. Particularly relevant for this thesis is under-recording of metastases, as discussed in 
Chapter 3, and missing staging data. Despite stage at diagnosis being integral to guiding 
treatment options and to the likelihood of survival, missing staging data in NBOCA is a 
particular issue in patients not undergoing major resection. In 2015/16 NBOCA data, 10% of 
patients who did not undergo major CRC resection did not have recorded T-stage (either 
radiological or pathological), compared to just 2% in patients who underwent surgery 
(nboca.org.uk, 2016). As the analyses in Chapters 3, 5 and 6 were restricted to patients who 
had undergone a CRC resection, data completeness for these studies were generally good. In 
the analysis of the impact of socioeconomic status on rates of liver resection presented in 
Chapter 4, all CRC patients with synchronous liver metastases were included, regardless of 
whether they had undergone CRC resection. As a result, around 20% of patients in this study 
had missing T-stage and N-stage data. Importantly, there was no difference in the proportion 
of missing data according to IMD quintile thus limiting the bias associated with this missing 
data.  
 
 Definitions 
To perform analyses and create subgroups within the study population several rules were 
applied. Although these were based on recommendations, as highlighted in Chapter 1 there is 
a board range of terminology and definitions currently in use in patients with CRC liver 
metastases.  
 
 Synchronous versus metachronous disease 
Understanding of what constitutes synchronous, and therefore metachronous liver metastases, 
varies. In this thesis, patients were considered to have synchronous disease when a metastasis 
code was recorded in HES data up to a year before, and up to 30-days after the diagnosis of 
CRC. This was based on recommendations from an international consensus group (Adam et 
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al., 2015). The inclusion of patients with recorded metastases at a longer time period, for 
example 3 months from diagnosis, would have the benefit of capturing more patients. 
However, retaining a tighter time interval for the definition of synchronous reduced the risk 
of including patients with metachronous disease and as discussed previously, the use of HES 
data to identity metachronous disease could not be validated. In addition, the analysis in 
Chapter 5 investigates the timing of liver resection in relation to CRC resection. It was 
therefore important to only include patients who had clinically detected liver metastases at the 
time of diagnosis to ensure they would also potentially be candidates for a simultaneous or 
liver-first approach. Relaxing the definition of synchronous metastases would artificially 
increase the number of patients in the bowel-first group due to including patients with 
metachronous disease.  
 
 Major versus minor liver resection 
As discussed in Chapter 1 there is a range of definitions used in the literature to define major 
liver resection. Major liver resection for the analyses performed in this thesis was defined as 
resection of three or more segments. This includes left hemihepatectomy, which was not 
reported by Reddy et al. (2011b) to increase the risk of morbidity and mortality when 
compared to resection of two segments or less. Categorising this cohort of patients as 
undergoing a major liver resection, as done in Chapter 6, may have resulted in an 
underestimation of the true risk of major liver resection in the elderly cohort.  
 
With evidence suggesting that parenchymal sparing liver resection does not increase the risk 
of local disease recurrence, there are an increasing number being performed (Mise et al., 
2016). If a non-anatomical resection of three or more non-adjoining segments of the liver is 
made, this would constitute a major resection, with the associated risks, yet could not be 
accounted for by OPCS-4 codes used in the HES dataset. Such a procedure may be coded as 
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J023 “resection of segment of liver”, J024 “wedge excision of liver” or J028 “unspecified 
partial excision of liver” and would be classified as a minor resection in the analysis.  
 
 Estimating risk in elderly patients 
Chapter 6 examines the impact of advancing age on post-operative and long-term outcomes 
following liver resection. The study population was divided into three groups, those less than 
65 years, those 65 to 74 years, and those 75 years and more. There are however several 
limitations associated with this arbitrary division.  
 
Firstly, the cut-off point at which an adult is considered ‘old’ or ‘elderly’ has not been well 
defined (Pallis et al., 2010). Previous studies reporting the outcomes of liver resection in the 
older population, use an age of 65, 70 or 75 years to define elderly. This limits the conclusions 
that may be drawn from comparing these results. 
 
Secondly, although it has long been recognised that advanced age can carry increased risk of 
mortality and morbidity after surgery, the aging process is not a uniform phenomenon. 
Chronological age fails to address the heterogeneity in the overall health of the older 
population (Huisingh-Scheetz and Walston, 2017). For the prediction of surgical 
complications amongst the older population, a number of measures may be considered, only 
some of which may be derived from NBOCA data. In the study presented in Chapter 6, age 
related differences in ASA class and Charlson comorbidity score were able to be accounted 
for. Although these assessments go some way towards determining the physical function of a 
patient in the pre-operative setting, they have not been adapted for specific use in the elderly 
population (Mistry et al., 2017). Given that the NBOCA or HES database does not include 
haematological or biochemical measures, the hepatectomy frailty score described above was 
not able to be replicated in the analysis for Chapter 6. Until such time as a validated measure 
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of surgical risk in the elderly which may be applied to large UK national datasets is developed, 
the use of chronological age as a proxy measure is necessary. 
 
7.3 Future work 
Although these studies have highlighted several important issues relating to access to services 
for CRC patients, further investigation into the cause of these disparities will be important in 
determining future strategy. The development of the NBOCA dataset as well as current and 
future linkages with other administrative databases provides several opportunities for future 
research. Areas that may warrant further investigation are discussed below. 
 
 Targeting local practice 
The use of audit and administrative datasets for the work in this thesis have allowed a picture 
of the management of patients with CRC liver metastases on a national level to be presented. 
However, this data alone cannot provide the level of detail required to establish the reasons 
behind the differences in liver resection rates according to hospital of diagnosis and further 
investigation at a local level is required. A prospective audit performed by individual regions, 
could capture information regarding the number of patients referred from CRC MDTs to 
hepatobiliary MDTs and the timeliness of these referrals. A concurrent review both of the 
physical systems in place for these referrals and the local guidelines regarding referral 
practices could accompany this. Local data from regions found to have higher rates of liver 
resection at a national level using NBOCA linked HES data could be compared to those with 
lower rates to establish key differences in these systems. This could then facilitate a targeted 
quality improvement programme to be delivered at a local level.  
 
 Evaluating the impact of “IMPACT”  
The ACPGBI and the Pelican Cancer group are together working on a new programme aimed 
at improving the outcomes for patients with advanced and metastatic colorectal cancer. Part 
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of the IMPACT (Improving the Management of Patients with Advanced Colorectal Tumours) 
initiative will involve an education programme for members of the CRC MDT. During 2018 
and 2019, 14 regional one-day workshops will be delivered across the UK, to which key 
members (surgeon, palliative care, radiologist, oncologist, pathologist and clinical nurse 
specialist) from each local CRC MDT will be invited. At these workshops a range of clinical 
presentations of advanced CRC will be discussed, including synchronous and metachronous 
liver metastases. It is hoped that this programme will act to improve communication between 
MDTs and raise awareness of treatment options, particularly in developing concept such as 
the widening criteria for resection of CRC liver metastases. NBOCA linked HES data could 
evaluate the effect of the IMPACT programme by comparing local and national liver resection 
rates and survival in CRC patients with liver metastases, before and after its implementation. 
 
 Timing surgical resection in rectal cancer patients 
The management of patients with synchronous liver-limited metastases secondary to a primary 
rectal cancer presents specific challenges when compared to patients with a primary colonic 
cancer. Firstly, the majority of patients with stage IV rectal carcinoma will have an advanced 
rectal tumour that should be treated locally with long-course chemoradiotherapy. Secondly, 
symptomatic patients with rectal cancer and synchronous liver-limited metastases may be 
managed initially by decompression with a colostomy or self-expanding metal stent instead 
of primary resection. Thirdly, there is growing evidence to support that the liver first strategy 
in stage IV rectal cancer may enable more patients to complete full treatment protocols. 
Fourthly, there is contention regarding the safety of performing a resection involving pelvic 
dissection as a synchronous procedure with liver resection. Finally, particularly pertinent in 
patients managed according to a bowel-first or synchronous approach, there is the 
consideration of stoma creation, and the feasibility and timing of stoma reversal.  
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Most studies, similar to that performed in Chapter 5, investigate the practice and outcomes 
regarding the timing of liver resection and bowel resection in a combined cohort of colonic 
and rectal cancer patients. In the future an analysis could be performed focusing on rectal 
cancer patients with the aim of describing at a national level aspects of the management and 
outcomes, as detailed above, that are specific to rectal cancer patients. With the benefit of an 
extra two years’ worth of NBOCA data to that presented in Chapter 5, there would be a final 
cohort of around 800 rectal cancer patients with synchronous liver-limited metastases. No 
previous population based study has described the outcomes specifically of rectal cancer 
patients. Furthermore, the NBOCA has been recently granted access to the Systemic Anti-
Cancer Therapy and the Radiotherapy database. Use of these datasets, linked to NBOCA and 
HES data, would allow the inclusion of data regarding neoadjuvant chemotherapy, 
chemoradiotherapy, and adjuvant chemotherapy. The HES database could be used to analyse 
national practice regarding emergency decompression, as well as defunctioning stoma 
formation and subsequent reversal.  
 
7.4 Concluding comments 
The use of linked national datasets for the research presented in this thesis has allowed a 
unique insight into the current trends, management and outcomes of patients with CRC liver 
metastases in England over the last seven years. This has highlighted several key areas where 
care may be improved in the future.  
 
Firstly, amongst patients with synchronous CRC liver metastases, there are specific patient 
populations who have poorer survival than would be expected. This appears to relate to 
inequalities in provision of liver resection. It is important therefore as cancer services undergo 
further centralisation in coming years that healthcare professionals are aware of this inequity 
and take responsibility to ensure that these patients are offered equal care.  
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Secondly, there is currently wide inter-hospital variation in the timing of liver resection in 
relation to CRC in England. This is not only influenced by patient factors, but also institutional 
factors, such as the on-site presence of hepatobiliary services. This highlights the impact of 
the absence of clear guidelines and referral pathways for managing patients with synchronous 
CRC liver metastases.  
 
Finally, major liver resection, even within a highly selected population of patients 75 years 
and over, is associated with 90-day mortality of 6%. This analysis highlighted there may be 
further scope to use strategies to reduce the extent of liver resection in the elderly population 
and that there is a need for improved predictors of early post-operative mortality to aid patient 
selection. 
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9. Appendix 
9.1 Charlson comorbidity score 
Table 9.1 Charlson comorbidity score 
Disease category ICD-10 codes 
Myocardial infarction I21,  I22*, I23*, I252 
Congestive cardiac failure I11, I13, I255, I42, I43, I50, I517 
Peripheral vascular disease I70–I73, I770, I771, K551, K558, K559, R02, Z958, Z959 
Cerebrovascular disease G45, G46, I60–I69 
Dementia A810, F00–F03, F051, G30, G31 
Chronic pulmonary disease I26, I27, J40–J45, J46*, J47, J60–J67, J684, J701, J703 
Rheumatological disease M05, M06, M09, M120, M315, M32–M36 
Liver disease B18, I85, I864, I982, K70, K71, K721, K729, K76, R162, Z944 
Diabetes mellitus E10–E14 
Hemiplegia or paraplegia G114, G81–G83 
Renal disease 
I12, I13, N01, N03, N05, N07, N08, N171*, N172*, N18, N19*, N25, Z49, Z940, 
Z992 
Any malignancy C00–C26, C30–C34, C37–C41, C43, C45–C58, C60–C76, C80–C85, C88, C90–C97 
Metastatic solid tumour C77–C79 
AIDS/HIV infection B20–B24 
*Indicates an acute condition that should be used to define comorbidity only if present in a record of a previous 
hospital admission within the preceding 12 months. 
AIDS, acquired immune deficiency syndrome; HIV, human immunodeficiency virus. 
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9.2 Multivariable model for risk of mortality following liver resection 
Table 9.2 Multivariable model for risk overall mortality within 0-90 days and 90-days- 3-
years, and cancer specific mortality 90-days- 3-years following liver resection  
  
  
90-day mortality 
(95% CI) 
90-days to 3-year 
mortality (95% CI) 
90-days to 3-year 
mortality cancer 
specific mortality 
(95% CI) 
Age 
<65 years 1 1 1 
65-74 years 2.88 (1.67 to 4.97) 1.11 (0.90 to 1.17) 1.01 (0.90 to 1.14) 
≥75 years 4.25 (2.38 to 7.57) 1.41 (1.23 to 1.61) 1.26 (1.09 to 1.45) 
Gender 
Male 1 1 1 
Female 0.72 (0.47 to 1.12) 0.97 (0.87 to 1.07) 0.99 (0.89 to 1.10) 
IMD quintile 
1 (most deprived) 1 1 1 
2 1.13 (0.55 to 2.33) 0.84 (0.71 to 1.00) 0.83 (0.69 to 0.99) 
3 1.21 (0.61 to 2.39) 0.87 (0.74 to 1.02) 0.87 (0.73 to 1.03) 
4 1.20 (0.61 to 2.37) 0.85 (0.72 to 0.99) 0.9 (0.76 to 1.07) 
5 (least deprived) 1.24 (0.63 to 2.44) 0.84 (0.71 to 0.98) 0.83 (0.70 to 0.98) 
Charlson 
comorbidity score 
0 1 1 1 
1 1.17 (0.72 to 1.91) 0.98 (0.86 to 1.11) 0.92 (0.8 to 1.06) 
≥2 2.22 (1.19 to 4.16) 1.09 (0.86 to 1.11) 0.95 (0.8 to 1.06) 
Emergency CRC 
presentation 
No 1 1 1 
Yes 1.14 (0.68 to 1.94) 1.23 (1.08 to 1.41) 1.26 (1.10 to 1.45) 
ASA class (at 
CRC resection) 
1 1 1 1 
2 1.2 (0.58 to 2.51) 1.17 (1.01 to 1.36) 1.17 (1.00 to 1.37) 
3 2.04 (0.95 to 4.37) 1.37 (1.15 to 1.64) 1.26 (1.05 to 1.52) 
4/5 2.02 (0.43 to 9.42) 2.07 (1.37 to 3.14) 1.82 (1.18 to 2.82) 
Primary CRC site 
Right side 1 1 1 
Left side 1.07 (0.67 to 1.71) 0.83 (0.74 to 0.94) 0.84 (0.74 to 0.95) 
Rectum 1.26 (0.73 to 2.19) 1.02 (0.89 to 1.18) 1.03 (0.89 to 1.2) 
T-stage 
0-2 1 1 1 
3 1.47 (0.66 to 3.29) 1.04 (0.87 to 1.25) 0.98 0(.82 to 1.19) 
4 1.75 (0.73 to 4.16) 1.29 (1.06 to 1.57) 1.24 (1.01 to 1.52) 
N-stage 
0 1 1 1 
1 1.41 (0.88 to 2.27) 1.45 (0.76 to 2.77) 1.34 (0.61 to 2.97) 
2 1.13 (0.63 to 2.03) 1.91 (1.67 to 2.18) 2.04 (1.78 to 2.35) 
Liver resection 
indication 
Metachronous  1 1 1 
Synchronous  1.07 (0.72 to 1.60) 1.1 (1.00 to 1.22) 1.14 (1.03 to 1.27) 
Liver resection 
type 
Minor resection 1 1 1 
Major resection 1.86 (1.25 to 2.76) 1.19 (1.07 to 1.31) 1.24 (1.11 to 1.37) 
Liver resection 
access 
Open 1 1 1 
Laparoscopic 0.28 (0.10 to 0.76) 0.87 (0.75 to 1.02) 0.81 (0.68 to 0.95) 
 
